• A de novo ERBB3 mutation resulted in Olaparib resistance after successful conversion therapy for a GBC patient bearing BRCA1 mutation.
    • Yang JX, Jia ZY, Liu FT, Wu WG, Li XC, Zou L, Li HF, Zhang F, Bao RF, Peng SY, Lau WY, Liu Y, Li ML, Liu YB.
    • Front Oncol. 2023 Feb 20;13:1078388. doi: 10.3389/fonc.2023.1078388.
    • Clinical Utility of Genomic Tests Evaluating Homologous Recombination Repair Deficiency (HRD) for Treatment Decisions in Early and Metastatic Breast Cancer.
    • Galland L, Roussot N, Desmoulins I, Mayeur D, Kaderbhai C, Ilie S, Hennequin A, Reda M, Albuisson J, Arnould L, Boidot R, Truntzer C, Ghiringhelli F, Ladoire S.
    • Cancers (Basel). 2023 Feb 17;15(4):1299. doi: 10.3390/cancers15041299.
    • PARP inhibitor-related hemorrhages:What does the real-world study say?
    • Wang S, Guo M, Fan P, Jin Z.
    • Front Oncol. 2023 Feb 14;13:1070343. doi: 10.3389/fonc.2023.1070343.
    • PARP inhibitors in the treatment of ARID1A mutant ovarian clear cell cancer: PI3K/Akt1-dependent mechanism of synthetic lethality.
    • Yakovlev V, Sullivan SA, Fields E, Temkin SM.
    • Front Oncol. 2023 Feb 13;13:1124147. doi: 10.3389/fonc.2023.1124147.
    • Radiotherapy, PARP Inhibition, and Immune-Checkpoint Blockade: A Triad to Overcome the Double-Edged Effects of Each Single Player.
    • Rosado MM, Pioli C.
    • Cancers (Basel). 2023 Feb 8;15(4):1093. doi: 10.3390/cancers15041093.
    • BRCA1/2 pathogenic variants are not common in Merkel cell carcinoma: Comprehensive molecular study of 30 cases and meta-analysis of the literature.
    • Gaubert A, Kervarrec T, Montaudié H, Burel-Vandenbos F, Cardot-Leccia N, Di Mauro I, Fabas T, Tallet A, Kubiniek V, Pedeutour F, Dadone-Montaudié B.
    • J Invest Dermatol. 2023 Feb 6:S0022-202X(23)00068-4. doi: 10.1016/j.jid.2023.01.014. Epub ahead of print.
    • Molecular-Guided Off-Label Targeted Therapy in a Large-Scale Precision Oncology Program.
    • Vashistha V, Katsoulakis E, Guo A, Price M, Ahmed S, Kelley MJ.
    • JCO Precis Oncol. 2023 Feb;7:e2200518. doi: 10.1200/PO.22.00518.
    • A phase 1 dose-escalation study of the poly(ADP-ribose) polymerase inhibitor senaparib in Australian patients with advanced solid tumors.
    • Gao B, Voskoboynik M, Cooper A, Wilkinson K, Hoon S, Hsieh CY, Cai S, Tian YE, Bao J, Ma N, Wang C, Zhang M, Li B, Guo M, Zhou R, Wang X, Xu C, de Souza P.
    • Cancer. 2023 Jan 31. doi: 10.1002/cncr.34662. Epub ahead of print.

    Related:

    •• Identifier: NCT03507543: The Safety and Pharmacokinetics of IMP4297 in Patients With Advanced Solid Tumors. (ClinicalTrials.gov . Accessed 2023 Jan 31.)

    • Poor response to sintilimab plus chemotherapy in a pulmonary epithelioid hemangioendothelioma patient: a case report.
    • Zeng H, Tang X, Tian X, Liu Y, Tian P.
    • Immunotherapy. 2023 Jan 25. doi: 10.2217/imt-2022-0073. Epub ahead of print.
    • Case report
    • Current status and future promise of next-generation poly (ADP-Ribose) polymerase 1-selective inhibitor AZD5305.
    • Zheng J, Li Z, Min W.
    • Front Pharmacol. 2023 Jan 23;13:979873. doi: 10.3389/fphar.2022.979873.
    • Case Report: Clinical benefit from multi-target tyrosine kinase inhibitor and PARP inhibitor in a patient with cancer of unknown primary with BRCA1 large genomic rearrangement.
    • Yu L, Lin J, Li H, Sun L, Wang S, Chen Y, Chen H, Lin L.
    • Front Pharmacol. 2023 Jan 23;14:997760. doi: 10.3389/fphar.2023.997760.
    • Genetic Testing Challenges in Oncology: Patient With Pending Bill Has BRCA1 Result Withheld.
    • Ray T.
    • Precision Oncology News. 2023 Jan 23.
    • PARP inhibition utilized in combination therapy with Olaparib-Temozolomide to achieve disease stabilization in a rare case of BRCA1-mutant, metastatic myxopapillary ependymoma.
    • Mahalingam P, Smith S, Lopez J, Sharma RK, Millard T, Thway K, Fisher C, Reardon DA, Jones R, Nicholson AG, Cunningham D, Welsh L, Sharma B.
    • Rare Tumors. 2023 Jan 19;15:20363613231152333. doi: 10.1177/20363613231152333.
    • Response to bipolar androgen therapy and PD-1 inhibition in a patient with metastatic castration-resistant prostate cancer and a germline CHEK2 mutation.
    • Berger BT, Labriola MK, Antonarakis ES, Armstrong AJ.
    • BMJ Case Rep. 2023 Jan 18;16(1):e251320. doi: 10.1136/bcr-2022-251320.
    • Case report
    • Thioparib inhibits homologous recombination repair, activates the type I IFN response, and overcomes olaparib resistance.
    • Wang LM, Wang P, Chen XM, Yang H, Song SS, Song Z, Jia L, Chen HD, Bao XB, Guo N, Huan XJ, Xi Y, Shen YY, Yang XY, Su Y, Sun YM, Gao YL, Chen Y, Ding J, Lang JY, Miao ZH, Zhang A, He JX.
    • EMBO Mol Med. 2023 Jan 18:e16235. doi: 10.15252/emmm.202216235. Epub ahead of print.
    • Positive response to Niraparib in chemo-refractory patient with metastatic appendiceal mucinous adenocarcinoma harboring ATM mutations: a case report.
    • Wang J, He H, Xu W, Chen J.
    • Front Oncol. 2023 Jan 17;12:1010871. doi: 10.3389/fonc.2023.1010871.
    • Combining targeted DNA repair inhibition and immune-oncology approaches for enhanced tumor control.
    • Concannon K, Morris BB, Gay CM, Byers LA.
    • Mol Cell. 2023 Jan 14:S1097-2765(22)01214-X. doi: 10.1016/j.molcel.2022.12.031. Epub ahead of print.
    • Review
    • Discovery of a potent olaparib-chlorambucil hybrid inhibitor of PARP1 for the treatment of cancer.
    • Qin H, Zhang J, Zhao Y, Zhang L, Feng J, Zhang L.
    • Front Pharmacol. 2023 Jan 9;13:1054616. doi: 10.3389/fphar.2022.1054616.
    • Clinical application of PARP inhibitors in ovarian cancer: from molecular mechanisms to the current status.
    • Wu Y, Xu S, Cheng S, Yang J, Wang Y.
    • J Ovarian Res. 2023 Jan 7;16(1):6. doi: 10.1186/s13048-023-01094-5.
    • Targeting the DNA damage response for cancer therapy.
    • Curtin NJ.
    • Biochem Soc Trans. 2023 Jan 6:BST20220681. doi: 10.1042/BST20220681. Epub ahead of print.
    • Testing for homologous recombination repair or homologous recombination deficiency for poly (ADP-ribose) polymerase inhibitors: A current perspective.
    • Herzog TJ, Vergote I, Gomella LG, Milenkova T, French T, Tonikian R, Poehlein C, Hussain M.
    • Eur J Cancer. 2022 Dec 21 [2023 Jan 1];179:136-146. doi: 10.1016/j.ejca.2022.10.021. Epub ahead of print.
    • How the Analysis of the Pathogenetic Variants of DDR Genes Will Change the Management of Prostate Cancer Patients.
    • Sciarra A, Frisenda M, Bevilacqua G, Gentilucci A, Cattarino S, Mariotti G, Del Giudice F, Di Pierro GB, Viscuso P, Casale P, I. Chung BI, Autorino R, Crivellaro S, Salciccia S.
    • Int J Mol Sci. 2022 Dec 30;24(1):674. doi: 10.3390/ijms24010674.
    • Pathologic complete response following FOLFIRINOX and olaparib treatment for hepatic metastasized pancreatic ductal adenocarcinoma with a germline BRCA mutation.
    • Okada K, Uemura K, Okamoto W, Sumiyoshi T, Shintakuya R, Otsuka H, Serikawa M, Ishii Y, Arihiro K, Takahashi S.
    • Clin J Gastroenterol. 2022 Dec 27. doi: 10.1007/s12328-022-01741-2. Epub ahead of print.
    • Case report
    • Mechanisms of PARP1 inhibitor resistance and their implications for cancer treatment.
    • Jackson LM, Moldovan GL.
    • NAR Cancer. 2022 Dec 22;4(4):zcac042. doi: 10.1093/narcan/zcac042.
    • Locally Performed HRD Testing for Ovarian Cancer? Yes, We Can!
    • Magliacane G, Brunetto E, Calzavara S, Bergamini A, Pipitone GB, Marra G, Redegallin M, Grassini G, Rabaiotti E, Taccagni G, Pecciarini L, Carrera P, Mangili G, Doglioni C, Cangi MG.
    • Cancers (Basel). 2022 Dec 21;15(1):43. doi: 10.3390/cancers15010043.
    • Mechanisms of Drug Resistance in Ovarian Cancer and Associated Gene Targets.
    • Alatise KL, Gardner S, Alexander-Bryant A.
    • Cancers (Basel). 2022 Dec 18;14(24):6246. doi: 10.3390/cancers14246246.
    • A Comparison of Patients’ and Physicians’ Knowledge and Expectations Regarding Precision Oncology Tests.
    • Dehar N, Abedin T, Tang P, Bebb G, Cheung WY.
    • Curr Oncol. 2022 Dec 16;29(12):9916-9927. doi: 10.3390/curroncol29120780.
    • 53BP1: Keeping It under Control, Even at a Distance from DNA Damage.
    • Rass E, Willaume S, Bertrand P.
    • Genes (Basel). 2022 Dec 16;13(12):2390. doi: 10.3390/genes13122390.
    • Ferroptosis synergistically sensitizes wee1 inhibitors: a bibliometric study.
    • Xu R, Wu X, Zhao Q, Yang Q.
    • Am J Transl Res. 2022 Dec 15;14(12):8473-8488.
    • Synthesis and in vitro biological evaluation of 3-ethyl-1,5-naphthyridin-2(1H)-one derivatives as potent PARP-1 selective inhibitors and PARP-1 DNA trappers.
    • Ren J, Quan X, Liu Y, Li J, Zhang X, Li Z, Zhang X.
    • Bioorg Med Chem Lett. 2022 Dec 15;78:129046. doi: 10.1016/j.bmcl.2022.129046. Epub 2022 Nov 4.
    • Cost-effectiveness of PARP inhibitors in malignancies: A systematic review.
    • Ding H, He C, Tong Y, Fang Q, Mi X, Chen L, Xin W, Fang L.
    • PLoS One. 2022 Dec 15;17(12):e0279286. doi: 10.1371/journal.pone.0279286.
    • BRCA1/2 Reversion Mutations in Patients Treated with Poly ADP-Ribose Polymerase (PARP) Inhibitors or Platinum Agents.
    • Darabi S, Braxton DR, Xiu J, Carneiro BA, Swensen J, Antonarakis ES, Liu SV, McKay RR, Spetzler D, El-Deiry WS, Demeure MJ.
    • Medicina (Kaunas). 2022 Dec 10;58(12):1818. doi: 10.3390/medicina58121818.
    • Targeting DNA damage response pathways in cancer.
    • Groelly FJ, Fawkes M, Dagg RA, Blackford AN, Tarsounas M.
    • Nat Rev Cancer. 2022 Dec 5. doi: 10.1038/s41568-022-00535-5. Epub ahead of print.
    • Review
    • Metastatic colorectal cancer as the primary phenotype in a hereditary breast and ovarian cancer patient with Germline BRCA1 mutation: a case report.
    • Liu Y, Zhu J, Wei X, Yang D, Li S, Qian X, Li L.
    • J Ovarian Res. 2022 Dec 3;15(1):127. doi: 10.1186/s13048-022-01069-y.
    • NGS-based targeted gene mutational profiles in Korean patients with pancreatic cancer.
    • Jung K, Lee S, Na HY, Kim JW, Lee JC, Hwang JH, Kim JW, Kim J.
    • Sci Rep. 2022 Dec 3;12(1):20937. doi: 10.1038/s41598-022-24732-2.
    • The BRCAness Landscape of Cancer.
    • Guo M, Wang SM.
    • Cells. 2022 Dec 1;11(23):3877. doi: 10.3390/cells11233877.
    • The potential of PARP inhibitors in targeted cancer therapy and immunotherapy.
    • Hunia J, Gawalski K, Szredzka A, Suskiewicz MJ, Nowis D.
    • Front Mol Biosci. 2022 Dec 1;9:1073797. doi: 10.3389/fmolb.2022.1073797.
    • Case report: olaparib use in metastatic lung adenocarcinoma with BRCA2 pathogenic variant.
    • Soon Jian Hao J, Hoai CS, Weng DTS, Ngeow J, Chiang J.
    • Cold Spring Harb Mol Case Stud. 2022 Dec 28 [Print 2022 Dec];8(7):a006223. doi: 10.1101/mcs.a006223.
    • Multiple-low-dose therapy: effective killing of high-grade serous ovarian cancer cells with ATR and CHK1 inhibitors.
    • Golder A, Nelson L, Tighe A, Barnes B, Coulson-Gilmer C, Morgan RD, McGrail JC, Taylor SS.
    • NAR Cancer. 2022 Nov 12 [eCollection 2022 Dec];4(4):zcac036. doi: 10.1093/narcan/zcac036.
    • Clinical Application of Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Prostate Cancer.
    • Inderjeeth AJ, Topp M, Sanij E, Castro E, Sandhu S.
    • Cancers (Basel). 2022 Nov 30;14(23):5922. doi: 10.3390/cancers14235922.
    • Pre-Existing and Acquired Resistance to PARP Inhibitor-Induced Synthetic Lethality.
    • Viet Le B, Podszywalow-Bartnicka P, Piwocka K, Skorski T.
    • Cancers (Basel). 2022 Nov 24;14(23):5795. doi: 10.3390/cancers14235795.
    • Long-term response to olaparib in a patient with metastatic pancreatic cancer associated with hereditary breast and ovarian cancer syndrome.
    • Tsuneizumi M, Terada S, Usui T, Yamaguchi K, Hayami R, Matsunuma R.
    • Oxf Med Case Reports. 2022 Nov 24;2022(11):omac124. doi: 10.1093/omcr/omac124.
    • Poly-ADP-ribose polymerase (PARP) inhibitors and ovarian function.
    • Li J, Li Q, Zhang L, Zhang S, Dai Y.
    • Biomed Pharmacother. 2022 Nov 18;157:114028. doi: 10.1016/j.biopha.2022.114028. Epub ahead of print.
    • Olaparib as an Experimental Therapy in a BRCA2-mutated Patient with Metastatic Ovarian Adenocarcinoma Originated from Liver Cancer.
    • Li C, Ye W, Zhou W, Ye Z, Yang W, Cheng Z.
    • Front Oncol. 2022 Nov 18;12:1010158. doi: 10.3389/fonc.2022.1010158.
    • Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled Trial.
    • Yap TA, Bardia A, Dvorkin M, Galsky MD, Beck JT, Wise DR, Karyakin O, Rubovszky G, Kislov N, Rohrberg K, Joy AA, Telli ML, Schram AM, Conte U, Chappey C, Stewart R, Stypinski D, Michelon E, Cesari R, Konstantinopoulos PA.
    • JAMA Oncol. 2022 Nov 17. doi: 10.1001/jamaoncol.2022.5228. Epub ahead of print.

    •• Identifier: NCT03330405: Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors. (ClinicalTrials.gov . Accessed 2022 Nov 19.)

    •• Commentary:

    Combining PARP Inhibitor With Immunotherapy-Does the Promise of Preclinical Data Translate to Clinic?

    • Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors: Results From JAVELIN BRCA/ATM, an Open-Label, Multicenter, Phase 2b, Tumor-Agnostic Trial.
    • Schram AM, Colombo N, Arrowsmith E, Narayan V, Yonemori K, Scambia G, Zelnak A, Bauer TM, Jin N, Ulahannan SV, Colleoni M, Aftimos P, Donoghue MTA, Rosen E, Rudneva VA, Telli ML, Domchek SM, Galsky MD, Hoyle M, Chappey C, Stewart R, Blake-Haskins JA, Yap TA.
    • JAMA Oncol. 2022 Nov 17. doi: 10.1001/jamaoncol.2022.5218. Epub ahead of print.

    Related:

    •• Identifier: NCT03565991: Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors. (ClinicalTrials.gov . Accessed 2022 Nov 19.)

    •• Commentary:

    Combining PARP Inhibitor With Immunotherapy-Does the Promise of Preclinical Data Translate to Clinic?

    • Role of PARP Inhibitors in Cancer Immunotherapy: Potential Friends to Immune Activating Molecules and Foes to Immune Checkpoints.
    • Franzese O, Graziani G.
    • Cancers (Basel). 2022 Nov 16;14(22):5633. doi: 10.3390/cancers14225633.
    • BMN673 Is a PARP Inhibitor with Unique Radiosensitizing Properties: Mechanisms and Potential in Radiation Therapy.
    • Soni A, Lin X, Mladenov E, Mladenova V, Stuschke M, Iliakis G.
    • Cancers (Basel). 2022 Nov 16;14(22):5619. doi: 10.3390/cancers14225619.
    • Potential value of the homologous recombination deficiency signature we developed in the prognosis and drug sensitivity of gastric cancer.
    • Wu X, Wang Q, Liu P, Sun L, Wang Y.
    • Front Genet. 2022 Nov 16;13:1026871. doi: 10.3389/fgene.2022.1026871.
    • Differential responses to taxanes and PARP inhibitors in ATM- versus BRCA2-mutated metastatic castrate-resistant prostate cancer.
    • Su CT, Nizialek E, Berchuck JE, Vlachostergios PJ, Ashkar R, Sokolova A, Barata PC, Aggarwal RR, McKay RR, Agarwal N, McClure HM, Nafissi N, Bryce AH, Sartor O, Sayegh N, Cheng HH, Adra N, Sternberg CN, Taplin ME, Cieslik M, Alva AS, Antonarakis ES.
    • Prostate. 2022 Nov 16. doi: 10.1002/pros.24454. Epub ahead of print.
    • Are targeted therapies or immunotherapies effective in metastatic pancreatic adenocarcinoma?
    • Rémond MS, Pellat A, Brezault C, Dhooge M, Coriat R.
    • ESMO Open. 2022 Nov 15;7(6):100638. doi: 10.1016/j.esmoop.2022.100638. Epub ahead of print.
    • Human metastatic cholangiocarcinoma patient-derived xenografts and tumoroids for preclinical drug evaluation.
    • Serra-Camprubí Q, Verdaguer H, Oliveros W, Lupión-Garcia N, Llop-Guevara A, Molina C, Vila-Casadesús M, Turpin A, Neuzillet C, Frigola J, Querol J, Yáñez-Bartolomé M, Castet F, Fabregat-Franco C, Escudero-Iriarte C, Escorihuela M, Arenas EJ, Bernado-Morales C, Haro N, Giles FJ, Pozo OJ, Miquel JM, Nuciforo PG, Vivancos A, Melé M, Serra V, Arribas J, Tabernero J, Peiró S, Macarulla T, Tian TV.
    • Clin Cancer Res. 2022 Nov 14:CCR-22-2551. doi: 10.1158/1078-0432.CCR-22-2551. Epub ahead of print.
    • Dose Adjustment of Poly (ADP-Ribose) Polymerase Inhibitors in Patients with Hepatic or Renal Impairment.
    • Zhao D, Long X, Wang J.
    • Drug Des Devel Ther. 2022 Nov 14;16:3947-3955. doi: 10.2147/DDDT.S387920.
    • Differences in Durability of PARP Inhibition by Clinically Approved PARP Inhibitors: Implications for Combinations and Scheduling.
    • Smith HL, Willmore E, Mukhopadhyay A, Drew Y, Curtin NJ.
    • Cancers (Basel). 2022 Nov 12;14(22):5559. doi: 10.3390/cancers14225559.
    • BRCA2 gene mutation in cancer.
    • Xie C, Luo J, He Y, Jiang L, Zhong L, Shi Y.
    • Medicine (Baltimore). 2022 Nov 11;101(45):e31705. doi: 10.1097/MD.0000000000031705.
    • Study Suggests a PARP Inhibitors Has Wider Cancer Applications.
    • [No author given]
    • Inside Precision Medicine. Topics. Oncology. 2022 Nov 9.

    Related:

    •• Original research:

    A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes.

    • Sequential Olaparib, Adavosertib Administration Overcomes Concurrent Use Toxicity Problems.
    • [No author given]
    • Inside Precision Medicine. Topics. Oncology. 2022 Nov 2.
    • Emerging strategies: PARP inhibitors in combination with immune checkpoint blockade in BRCA1 and BRCA2 mutation-associated and triple-negative breast cancer.
    • Gupta T, Vinayak S, Telli M.
    • Breast Cancer Res Treat. 2022 Nov 1. doi: 10.1007/s10549-022-06780-4. Epub ahead of print.
    • Review
    • Characterization of Oncology Clinical Trials Using Germline Genetic Data.
    • Kammula AV, Schäffer AA, Rajagopal PS.
    • JAMA Netw Open. 2022 Nov 1;5(11):e2242370. doi: 10.1001/jamanetworkopen.2022.42370.
    • DNA Repair Mechanisms, Protein Interactions and Therapeutic Targeting of the MRN Complex.
    • McCarthy-Leo C, Darwiche F, Tainsky MA.
    • Cancers (Basel). 2022 Oct 27;14(21):5278. doi: 10.3390/cancers14215278.
    • Recurrent Cervical Cancer Treated Successfully with Single-Agent PARP-Inhibitor, Olaparib.
    • Gross M, Spencer RJ.
    • Case Rep Obstet Gynecol. 2022 Oct 25;2022:6579715. doi: 10.1155/2022/6579715.
    • Biomarkers beyond BRCA: promising combinatorial treatment strategies in overcoming resistance to PARP inhibitors.
    • Chu YY, Yam C, Yamaguchi H, Hung MC.
    • J Biomed Sci. 2022 Oct 25;29(1):86. doi: 10.1186/s12929-022-00870-7.
    • The synthetic lethality of targeting cell cycle checkpoints and PARPs in cancer treatment.
    • Li S, Wang L, Wang Y, Zhang C, Hong Z, Han Z.
    • J Hematol Oncol. 2022 Oct 17;15(1):147. doi: 10.1186/s13045-022-01360-x.
    • SN-38 Sensitizes BRCA-Proficient Ovarian Cancers to PARP Inhibitors through Inhibiting Homologous Recombination Repair.
    • Lin S, Tian J, He Q, Yang M, Chen Z, Belogurov AA Jr, Li X, Zhang F, Liu Y, Chen G.
    • Dis Markers. 2022 Oct 11;2022:7243146. doi: 10.1155/2022/7243146.
    • Anti-cancer immune responses to DNA damage response inhibitors: Molecular mechanisms and progress toward clinical translation.
    • Carlsen L, El-Deiry WS.
    • Front Oncol. 2022 Oct 6;12:998388. doi: 10.3389/fonc.2022.998388.
    • Patient-associated risk factors for severe anemia in patients with advanced ovarian or breast cancer receiving olaparib monotherapy: A multicenter retrospective study.
    • Tashiro R, Kawazoe H, Mamishin K, Seto K, Udagawa R, Saito Y, Hashimoto H, Shimoi T, Yonemori K, Yonemura M, Terakado H, Kawasaki T, Furukawa T, Nakamura T.
    • Front Oncol. 2022 Oct 4;12:898150. doi: 10.3389/fonc.2022.898150.
    • Combined inhibition of PARP and EZH2 for cancer treatment: Current status, opportunities, and challenges.
    • Zhang X, Huo X, Guo H, Xue L.
    • Front Pharmacol. 2022 Oct 3;13:965244. doi: 10.3389/fphar.2022.965244.
    • NF-κB Signaling in Tumor Pathways Focusing on Breast and Ovarian Cancer.
    • Devanaboyina M, Kaur J, Whiteley E, Lin L, Einloth K, Morand S, Stanbery L, Hamouda D, Nemunaitis J.
    • Oncol Rev. 2022 Oct 3;16:10568. doi: 10.3389/or.2022.10568.
    • A First-in-Class Clinical G-Quadruplex-Targeting Drug. The Bench-to-Bedside Translation of the Fluoroquinolone QQ58 to CX-5461 (Pidnarulex).
    • Xu H, Hurley LH.
    • Bioorg Med Chem Lett. 2022 Oct 1:129016. doi: 10.1016/j.bmcl.2022.129016. Epub ahead of print.
    • Review

    Related:

    Original research:

    Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies.

    Identifier: NCT04890613: Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation. (ClinicalTrials.gov)

    • Unpaved roads: How the DNA damage response navigates endogenous genotoxins.
    • Thada V, Greenberg RA.
    • DNA Repair (Amst). 2022 Oct;118:103383. doi: 10.1016/j.dnarep.2022.103383. Epub 2022 Aug 2.
    • Review
    • A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes.
    • Gruber JJ, Afghahi A, Timms K, DeWees A, Gross W, Aushev VN, Wu HT, Balcioglu M, Sethi H, Scott D, Foran J, McMillan A, Ford JM, Telli ML.
    • Nat Cancer. 2022 Oct;3(10):1181-1191. doi: 10.1038/s43018-022-00439-1. Epub 2022 Oct 17.

    Related:

    •• Identifier: NCT02401347: Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors. (ClinicalTrials.gov . Accessed 2022 Oct 18.)

    •• Identifier: NCT04756765: Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer. (ClinicalTrials.gov . Accessed 2022 Oct 18.)

    •• Research news: Study Suggests a PARP Inhibitors Has Wider Cancer Applications. (Inside Precision Medicine)

    • Clinicogenomic characteristics and synthetic lethal implications of germline homologous recombination-deficient HCC.
    • An J, Oh JH, Oh B, Oh YJ, Ju JS, Kim W, Kang HJ, Sung CO, Shim JH.
    • Hepatology. 2022 Sep 30. doi: 10.1002/hep.32812. Epub ahead of print.
    • Durable response to olaparib combined low-dose cisplatin in advanced hepatocellular carcinoma with FANCA mutation: A case report.
    • Lai YH, Tung KC, Chen SC.
    • Medicine (Baltimore). 2022 Sep 30;101(39):e30719. doi: 10.1097/MD.0000000000030719.
    • Recent advances in cancer therapy using PARP inhibitors.
    • Kaur SD, Chellappan DK, Aljabali AA, Tambuwala M, Dua K, Kapoor DN.
    • Med Oncol. 2022 Sep 30;39(12):241. doi: 10.1007/s12032-022-01840-7.
    • Review
    • Targeting Homologous Recombination Deficiency in Ovarian Cancer with PARP Inhibitors: Synthetic Lethal Strategies That Impact Overall Survival.
    • Xie T, Dickson KA, Yee C, Ma Y, Ford CE, Bowden NA, Marsh DJ.
    • Cancers (Basel). 2022 Sep 23;14(19):4621. doi: 10.3390/cancers14194621.
    • Preclinical and clinical trial results using Talazoparib and Low-Dose Chemotherapy.
    • Wainberg ZA, Singh AS, Konecny GE, McCann KE, Hecht JR, Goldman J, Chmielowski B, Finn RS, O'Brien N, von Euw E, Price MM, Martinez D, Yonemoto L, Brennan M, Glaspy JA, Slamon DJ.
    • Clin Cancer Res. 2022 Sep 22:CCR-22-1553. doi: 10.1158/1078-0432.CCR-22-1553. Epub ahead of print.
    • Niraparib-induced STAT3 inhibition increases its antitumor effects.
    • Yu HE, Rodriguez-Rodriguez L, Zhao Q, Kohut A, Li YJ, Martincuks A, Austria T, Zhang C, Santiago NL, Borrero RM, Phan XT, Melstrom L.
    • Front Oncol. 2022 Sep 21;12:966492. doi: 10.3389/fonc.2022.966492.
    • Novel approach of desensitization in allergic reaction to Olaparib.
    • Beurer BM, Sprenger LM, Graneß K, Feldmann F, Warnke U, Biersack MG, Fischer D.
    • J Oncol Pharm Pract. 2022 Sep 21:10781552221124041. doi: 10.1177/10781552221124041. Epub ahead of print.
    • Case report
    • Merck KGaA, Nerviano Enter License Agreement for PARP1 Inhibitor NMS-293.
    • [No author given]
    • Precision Oncology News. 2022 Sep 21.

    Related:

    Identifier: NCT04182516: Study of NMS-03305293 in Pts With Selected Advanced/Metastatic Solid Tumors. (ClinicalTrials.gov)

    • TSG101 associates with PARP1 and is essential for PARylation and DNA damage-induced NF-?B activation.
    • Tufan AB, Lazarow K, Kolesnichenko M, Sporbert A, von Kries JP, Scheidereit C.
    • EMBO J. 2022 Sep 20:e110372. doi: 10.15252/embj.2021110372. Epub ahead of print.
    • KP372-1-Induced AKT Hyperactivation Blocks DNA Repair to Synergize With PARP Inhibitor Rucaparib via Inhibiting FOXO3a/GADD45a Pathway.
    • Jiang L, Liu Y, Su X, Wang J, Zhao Y, Tumbath S, Kilgore JA, Williams NS, Chen Y, Wang X, Mendonca MS, Lu T, Fu YX, Huang X.
    • Front Oncol. 2022 Sep 20;12:976292. doi: 10.3389/fonc.2022.976292.
    • Clinical Pharmacokinetics and Pharmacodynamics of Rucaparib.
    • Liao M, Beltman J, Giordano H, Harding TC, Maloney L, Simmons AD, Xiao JJ.
    • Clin Pharmacokinet. 2022 Sep 15. doi: 10.1007/s40262-022-01157-8. Epub ahead of print.
    • Imaging Agent May Have Potential as Noninvasive Test to Predict PARP Inhibitor Response.
    • Hopkins C.
    • Precision Oncology News. 2022 Sep 13.
    • Study: PARP inhibitor treatment for metastatic prostate cancer shows most benefit in men with inherited BRCA mutations.
    • [No author given]
    • FORCE. XRAY. 2022 Sep 6.

    Related:

    Original research:

    Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial.

    • Tumor Immune Microenvironment Changes by Multiplex Immunofluorescence Staining in a Pilot Study of Neoadjuvant Talazoparib for Early-Stage Breast Cancer Patients with a Hereditary BRCA Mutation.
    • Kumar T, Hobbs E, Yang F, Chang JT, Contreras A, Cuentas ERP, Garber H, Lee S, Lu Y, Scoggins ME, Adrada BE, Whitman GJ, Arun BK, Mittendorf EA, Litton JK.
    • Clin Cancer Res. 2022 Sep 1;28(17):3669-3676. doi: 10.1158/1078-0432.CCR-21-1278.
    • BAP1-defficient breast cancer in a patient with BAP1 cancer syndrome.
    • Blatnik A, Ribnikar D, Šetrajcic Dragoš V, Novakovic S, Stegel V, Grcar Kuzmanov B, Boc N, Peric B, Škerl P, Klancar G, Krajc M.
    • Breast Cancer. 2022 Sep;29(5):921-927. doi: 10.1007/s12282-022-01354-0. Epub 2022 Apr 5.
    • Upregulation of CXCL1 and LY9 contributes to BRCAness in ovarian cancer and mediates response to PARPi and immune checkpoint blockade.
    • Chen T, Yu T, Zhuang S, Geng Y, Xue J, Wang J, Ai L, Chen B, Zhao Z, Li Y, Wang J, Liang H, Xu Y, Gu Y.
    • Br J Cancer. 2022 Sep;127(5):916-926. doi: 10.1038/s41416-022-01836-0. Epub 2022 May 26.
    • Reconsidering the mechanisms of action of PARP inhibitors based on clinical outcomes.
    • Onji H, Murai J.
    • Cancer Sci. 2022 Sep;113(9):2943-2951. doi: 10.1111/cas.15477. Epub 2022 Jul 16.
    • Catastrophic chemotherapy toxicity leading to diagnosis of Fanconi anaemia due to FANCD1/BRCA2 during adulthood: description of an emerging phenotype.
    • Ip E, McNeil C, Grimison P, Scheinberg T, Tudini E, Ho G, Scott RJ, Brown C, Sandroussi C, Guitera P, Spurdle AB, Goodwin A.
    • J Med Genet. 2022 Sep;59(9):912-915. doi: 10.1136/jmedgenet-2021-108072. Epub 2021 Oct 25.
    • Case report
    • Comprehensive Analysis of Adverse Events Induced by PARP Inhibitors Using JADER and Time to Onset.
    • Yamaoka K, Fujiwara M, Uchida M, Uesawa Y, Muroi N, Shimizu T.
    • Life (Basel). 2022 Aug 31;12(9):1355. doi: 10.3390/life12091355.
    • Homologous Recombination Deficiency Scar: Mutations and Beyond—Implications for Precision Oncology.
    • van der Wiel AMA, Schuitmaker L, Cong Y, Theys J, Van Hoeck A, Vens C, Lambin P, Yaromina A, Dubois LJ.
    • Cancers (Basel). 2022 Aug 27;14(17):4157. doi: 10.3390/cancers14174157.
    • PARP inhibitor resistance in breast and gynecological cancer: Resistance mechanisms and combination therapy strategies.
    • Wang N, Yang Y, Jin D, Zhang Z, Shen K, Yang J, Chen H, Zhao X, Yang L, Lu H.
    • Front Pharmacol. 2022 Aug 25;13:967633. doi: 10.3389/fphar.2022.967633.
    • PLX038: a long-acting topoisomerase I inhibitor with robust anti-tumor activity in ATM deficient tumors and potent synergy with PARP inhibitors.
    • Thomas A, Fontaine SD, Diolaiti ME, Desai P, Kumar R, Takahashi N, Sciuto L, Nichols S, Ashworth A, Feng FY, Ashley GW, Nguyen M, Pommier Y, Santi DV.
    • Mol Cancer Ther. 2022 Aug 23:MCT-22-0217. doi: 10.1158/1535-7163.MCT-22-0217. Epub ahead of print.
    • Case Report: Fluzoparib for multiple lines of chemotherapy refractory in metastatic cutaneous squamous cell carcinoma with BRCA2 pathogenic mutation.
    • Sun X, Chen W, Qu X, Chen Y.
    • Front Pharmacol. 2022 Aug 12;13:968060. doi: 10.3389/fphar.2022.968060.
    • A Randomized, Double-Blind, Biomarker-Selected, Phase II Clinical Trial of Maintenance Poly ADP-Ribose Polymerase Inhibition With Rucaparib Following Chemotherapy for Metastatic Urothelial Carcinoma.
    • Crabb SJ, Hussain S, Soulis E, Hinsley S, Dempsey L, Trevethan A, Song Y, Barber J, Frew J, Gale J, Faust G, Brock S, McGovern U, Parikh O, Enting D, Sundar S, Ratnayake G, Lees K, Birtle AJ, Powles T, Jones RJ.
    • J Clin Oncol. 2022 Aug 12:JCO2200405. doi: 10.1200/JCO.22.00405. Epub ahead of print.
    • DNA damage repair genes alterations in genito-urinary malignancies.
    • Dariane C, Timsit MO.
    • Eur Surg Res. 2022 Aug 9. doi: 10.1159/000526415. Epub ahead of print.
    • Review
    • Preclinical characterization of AZD5305, a next generation, highly selective PARP1 inhibitor and trapper.
    • Illuzzi G, Staniszewska AD, Gill SJ, Pike A, McWilliams L, Critchlow SE, Cronin A, Fawell S, Hawthorne G, Jamal K, Johannes J, Leonard E, Macdonald R, Maglennon G, Nikkil J, O'Connor MJ, Smith A, Southgate H, Wilson J, Yates J, Cosulich S, Leo E.
    • Clin Cancer Res. 2022 Aug 5:CCR-22-0301. doi: 10.1158/1078-0432.CCR-22-0301. Epub ahead of print.

    Related:

    Identifier: NCT04644068: Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (PETRA). (ClinicalTrials.gov)

    • Rapid and durable response to fifth-line lorlatinib plus olaparib in an ALK-rearranged, BRCA2-mutated metastatic lung adenocarcinoma patient with critical tracheal stenosis: a case report.
    • Jin C, He Z, Guo M, Liu S, Wang Y, Qiu J, Li C, Wu D.
    • Anticancer Drugs. 2022 Aug 1;33(7):696-700. doi: 10.1097/CAD.0000000000001303. Epub 2022 Mar 23.
    • Case report
    • Further refining 2020 ESGO/ESTRO/ESP molecular risk classes in patients with early-stage endometrial cancer: A propensity score-matched analysis.
    • Nero C, Pasciuto T, Cappuccio S, Corrado G, Pelligra S, Zannoni GF, Santoro A, Piermattei A, Minucci A, Lorusso D, Fanfani F, Scambia G.
    • Cancer. 2022 Aug 1;128(15):2898-2907. doi: 10.1002/cncr.34331. Epub 2022 May 26.

    Related:

    Commentary:

    Molecular classification in endometrial cancer: Opportunities for precision oncology in a changing landscape.

    • A commentary on the discrepancy between blood and tumour BRCA testing: An open question.
    • De Paolis E, Marchetti C, Concolino P, Scambia G, Urbani A, Fagotti A, Minucci A.
    • BJOG. 2022 Aug;129(9):1422-1426. doi: 10.1111/1471-0528.17158. Epub 2022 Apr 5.

    Related:

    Commentary:

    Gene sequencing in ovarian cancer: continually moving targets.

    • Gene mutational profile of BRCAness and clinical implication in predicting response to platinum-based chemotherapy in patients with intrahepatic cholangiocarcinoma.
    • Rimini M, Macarulla T, Burgio V, Lonardi S, Niger M, Scartozzi M, Rapposelli IG, Aprile G, Ratti F, Pedica F, Verdaguer H, Nappo F, Nichetti F, Lai E, Valgiusti M, Cappetta A, Febregat C, Fassan M, De Braud F, Puzzoni M, Frassineti GL, Simionato F, De Cobelli F, Aldrighetti L, Fornaro L, Cascinu S, Casadei-Gardini A.
    • Eur J Cancer. 2022 Aug;171:232-241. doi: 10.1016/j.ejca.2022.05.004. Epub 2022 Jun 21.
    • PARP Inhibitors: Clinical Limitations and Recent Attempts to Overcome Them.
    • Kim D, Nam HJ.
    • Int J Mol Sci. 2022 Jul 29;23(15):8412. doi: 10.3390/ijms23158412.
    • The Mechanistic Understanding of RAD51 Defibrillation: A Critical Step in BRCA2-Mediated DNA Repair by Homologous Recombination.
    • Schipani F, Manerba M, Marotta R, Poppi L, Gennari A, Rinaldi F, Armirotti A, Farabegoli F, Roberti M, Di Stefano G, Rocchia W, Girotto S, Tirelli N, Cavalli A.
    • Int J Mol Sci. 2022 Jul 28;23(15):8338. doi: 10.3390/ijms23158338.
    • Editorial: Insight in cancer genetics: 2022.
    • Naro C, Cunliffe H, Sette C.
    • Front Oncol. 2022 Jul 26;12:988310. doi: 10.3389/fonc.2022.988310.
    • Case Report: Sustained complete remission on combination therapy with olaparib and pembrolizumab in BRCA2-mutated and PD-L1-positive metastatic cholangiocarcinoma after platinum derivate.
    • Zhou T, Mahn R, Möhring C, Sadeghlar F, Meyer C, Toma M, Kreppel B, Essler M, Glowka T, Matthaei H, Kalff JC, Strassburg CP, Gonzalez-Carmona MA.
    • Front Oncol. 2022 Jul 25;12:933943. doi: 10.3389/fonc.2022.933943.
    • Clinical use of PARP inhibitor in recurrent uterine leiomyosarcoma with presence of a somatic BRCA2 mutation.
    • Shammas N, Yang T, Abidi A, Amneus M, Hodeib M.
    • Gynecol Oncol Rep. 2022 Jul 14;42:101044. doi: 10.1016/j.gore.2022.101044.
    • A Novel PARP Inhibitor YHP-836 For the Treatment of BRCA-Deficiency Cancers.
    • Du T, Zhang Z, Zhou J, Sheng L, Yao H, Ji M, Xu B, Chen X.
    • Front Pharmacol. 2022 Jul 13;13:865085. doi: 10.3389/fphar.2022.865085.
    • Oncologists Seeing Lack of PARP Inhibitor Response in MSI-High, BRCA-Mutant Prostate Cancer Patients.
    • Kanski A.
    • Precision Oncology News. Biomarkers. BRCA. 2022 Jul 13.
    • Research news

    Related:

    Original research:

    PARP Inhibitor Insensitivity to BRCA1/2 Monoallelic Mutations in Microsatellite Instability-High Cancers.

    • Cost-Effectiveness of Poly ADP-Ribose Polymerase Inhibitors in Cancer Treatment: A Systematic Review.
    • Chan VKY, Yang R, Wong ICK, Li X.
    • Front Pharmacol. 2022 Jul 11;13:891149. doi: 10.3389/fphar.2022.891149.
    • Triple therapy in biliary tract cancers: GemOX plus immune checkpoint inhibitor in combination with lenvatinib or NGS-guided targeted therapy.
    • Dong X, Zhang Z, Zhang Q, Chen L, Cao G, Liu C, Song T, Lu W, Zhang W.
    • Cancer Res Clin Oncol. 2022 Jul 8. doi: 10.1007/s00432-022-04166-z. Epub ahead of print.
    • Do Not Forget Poly (Adenosine Diphosphate-Ribose) Polymerase Inhibitors in Ovarian Carcinosarcoma.
    • Magalhães D, Bartosch C, Abreu MH.
    • Cureus. 2022 Jul 8;14(7):e26662. doi: 10.7759/cureus.26662.
    • Exploiting replication gaps for cancer therapy.
    • Cong K, Cantor SB.
    • Mol Cell. 2022 Jul 7;82(13):2363-2369. doi: 10.1016/j.molcel.2022.04.023. Epub 2022 May 13.
    • AZD5305 More Tolerable than Earlier PARP Agents.
    • [No author given]
    • Cancer Discov. 2022 Jul 6;12(7):1602. doi: 10.1158/2159-8290.CD-NB2022-0039.
    • News
    • Genomic and epigenomic BRCA alterations predict adaptive resistance and response to platinum-based therapy in patients with triple-negative breast and ovarian carcinomas.
    • Menghi F, Banda K, Kumar P, Straub R, Dobrolecki L, Rodriguez IV, Yost SE, Chandok H, Radke MR, Somlo G, Yuan Y, Lewis MT, Swisher EM, Liu ET.
    • Sci Transl Med. 2022 Jul 6;14(652):eabn1926. doi: 10.1126/scitranslmed.abn1926. Epub 2022 Jul 6.

    Related:

    Research news: Breast, Ovarian Cancer Study Finds Ties Between Types of BRCA Alterations, Treatment Response. (Precision Oncology News)

    • Rational design, synthesis and biological evaluation of dual PARP-1/2 and TNKS1/2 inhibitors for cancer therapy.
    • Xu Y, Wu H, Huang L, Zhai B, Li X, Xu S, Wu X, Zhu Q, Xu Q.
    • Eur J Med Chem. 2022 Jul 5;237:114417. doi: 10.1016/j.ejmech.2022.114417. Epub 2022 Apr 27.
    • Evaluating Mismatch Repair Status to Screen Clinical Advanced Breast Carcinomas for Immunotherapy: Experience From a Large Academic Institution.
    • Arole V, Shafi S, Challa B, Parwani AV, Tozbikian G, Li Z.
    • Clin Breast Cancer. 2022 Jul;22(5):e680-e684. doi: 10.1016/j.clbc.2022.01.010. Epub 2022 Jan 22.
    • Exposure to escalating olaparib does not induce acquired resistance to PARPi and to other chemotherapeutic compounds in ovarian cancer cell lines.
    • Fedier A, Maggi N, Tozzi A, Disler M, Coelho R, Jacob F, Heinzelmann-Schwarz V.
    • Int J Oncol. 2022 Jul;61(1):89. doi: 10.3892/ijo.2022.5379. Epub 2022 Jun 1.
    • Phase II study of niraparib in recurrent or persistent rare fraction of gynecologic malignancies with homologous recombination deficiency (JGOG2052).
    • Asano H, Oda K, Yoshihara K, Ito YM, Matsumura N, Shimada M, Watari H, Enomoto T.
    • J Gynecol Oncol. 2022 Jul;33(4):e55. doi: 10.3802/jgo.2022.33.e55. Epub 2022 May 3.

    Related:

    Trial ID: jRCT2031210264: Phase 2 Study to Evaluate the Efficacy and Safety of Niraparib in Recurrent or Persistent Rare Gynecologic Malignancies with Homologous Recombination Deficiency (JGOG2052). (Japanese Registry of Clinical Trials)

    • Proteomic Analysis Identifies p62/SQSTM1 as a Critical Player in PARP Inhibitor Resistance.
    • Uddin MH, Zhou JY, Pimentel J, Patrick SM, Kim S, Shekhar MP, Wu GS.
    • Front Oncol. 2022 Jun 29;12:908603. doi: 10.3389/fonc.2022.908603.
    • Analysis of the Clinical Advancements for BRCA-Related Malignancies Highlights the Lack of Treatment Evidence for BRCA-Positive Male Breast Cancer.
    • McClurg DP, Urquhart G, McGoldrick T, Chatterji S, Miedzybrodzka Z, Speirs V, Elsberger B.
    • Cancers (Basel). 2022 Jun 28;14(13):3175. doi: 10.3390/cancers14133175.
    • A DNA damage nanoamplifier for the chemotherapy of triple-negative breast cancer via DNA damage induction and repair blocking.
    • Huang Y, Dai X, Guan Z, Liu D, Ren L, Chen M, Zeng Z, Jiang J, Luo Y, He Y, Huang M, Zhao C.
    • Int J Pharm. 2022 Jun 25;622:121897. doi: 10.1016/j.ijpharm.2022.121897. Epub 2022 Jun 8.
    • Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies.
    • Hilton J, Gelmon K, Bedard PL, Tu D, Xu H, Tinker AV, Goodwin R, Laurie SA, Jonker D, Hansen AR, Veitch ZW, Renouf DJ, Hagerman L, Lui H, Chen B, Kellar D, Li I, Lee SE, Kono T, Cheng BYC, Yap D, Lai D, Beatty S, Soong J, Pritchard KI, Soria-Bretones I, Chen E, Feilotter H, Rushton M, Seymour L, Aparicio S, Cescon DW.
    • Nat Commun. 2022 Jun 24;13(1):3607. doi: 10.1038/s41467-022-31199-2.

    Related:

    Identifier: NCT02719977: A Phase I Study of CX5461. (ClinicalTrials.gov)

    • Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU).
    • Rosenberg JE, Park SH, Kozlov V, Dao TV, Castellano D, Li JR, Mukherjee SD, Howells K, Dry H, Lanasa MC, Stewart R, Bajorin DF.
    • J Clin Oncol. 2022 Jun 23:JCO2200205. doi: 10.1200/JCO.22.00205. Epub ahead of print.
    • Homologous Recombination Deficiency in Ovarian, Breast, Colorectal, Pancreatic, Non-Small Cell Lung and Prostate Cancers, and the Mechanisms of Resistance to PARP Inhibitors.
    • Mekonnen N, Yang H, Shin YK.
    • Front Oncol. 2022 Jun 17;12:880643. doi: 10.3389/fonc.2022.880643.
    • The Homologous Recombination Deficiency Scar in Advanced Cancer: Agnostic Targeting of Damaged DNA Repair.
    • Pacheco-Barcia V, Muñoz A, Castro E, Ballesteros AI, Marquina G, González-Díaz I, Colomer R, Romero-Laorden N.
    • Cancers (Basel). 2022 Jun 15;14(12):2950. doi: 10.3390/cancers14122950.
    • Leptomeningeal disease in BRIP1-mutated pancreatic adenocarcinoma.
    • Yim E, Leung D.
    • BMJ Case Rep. 2022 Jun 8;15(6):e249837. doi: 10.1136/bcr-2022-249837.
    • Case report
    • Insights into the Possible Molecular Mechanisms of Resistance to PARP Inhibitors.
    • Piombino C, Cortesi L.
    • Cancers (Basel). 2022 Jun 5;14(11):2804. doi: 10.3390/cancers14112804.
    • Selective degradation of PARP2 by PROTACs via recruiting DCAF16 for triple-negative breast cancer.
    • Pu C, Tong Y, Liu Y, Lan S, Wang S, Yan G, Zhang H, Luo D, Ma X, Yu S, Huang Q, Deng R, Li R.
    • Eur J Med Chem. 2022 Jun 5;236:114321. doi: 10.1016/j.ejmech.2022.114321. Epub 2022 Apr 3.
    • PARPs: All for One and One for All? Enhancing Diversity in Clinical Trials.
    • Nicum S, Blagden SP.
    • Clin Cancer Res. 2022 Jun 1;28(11):2201-2203. doi: 10.1158/1078-0432.CCR-22-0442.
    • Commentary

    Related:

    Original research:

    Olaparib Maintenance Monotherapy in Asian Patients with Platinum-Sensitive Relapsed Ovarian Cancer: Phase III Trial (L-MOCA).

    • SIK2 inhibition enhances PARP inhibitor activity synergistically in ovarian and triple-negative breast cancers.
    • Lu Z, Mao W, Yang H, Santiago-O'Farrill JM, Rask PJ, Mondal J, Chen H, Ivan C, Liu X, Liu CG, Xi Y, Masuda K, Carrami EM, Chen M, Tang Y, Pang L, Lakomy DS, Calin GA, Liang H, Ahmed AA, Vankayalapati H, Bast RC Jr.
    • J Clin Invest. 2022 Jun 1;132(11):e146471. doi: 10.1172/JCI146471.
    • ASO Author Reflections: Broaden the Targeted Population of Synthetic Lethality for Taiwanese Breast Cancer.
    • Huang CC, Tseng LM.
    • Ann Surg Oncol. 2022 Jun;29(6):3591-3592. doi: 10.1245/s10434-022-11407-5. Epub 2022 Apr 7.
    • Commentary
    • Olaparib Use in Patients With Metastatic Breast Cancer Harboring Somatic BRCA1/2 Mutations or Mutations in Non-BRCA1/2, DNA Damage Repair Genes.
    • Walsh EM, Mangini N, Fetting J, Armstrong D, Chan IS, Connolly RM, Fiallos K, Lehman J, Nunes R, Petry D, Reynolds J, Shah M, Smith KL, Visvanathan K, Lauring J, Park BH, Stearns V, Wolff AC.
    • Clin Breast Cancer. 2022 Jun;22(4):319-325. doi: 10.1016/j.clbc.2021.12.007. Epub 2021 Dec 30.
    • PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers.
    • Luo L, Keyomarsi K.
    • Expert Opin Investig Drugs. 2022 Jun;31(6):607-631. doi: 10.1080/13543784.2022.2067527. Epub 2022 May 3.
    • Review
    • PARP Inhibitor Insensitivity to BRCA1/2 Monoallelic Mutations in Microsatellite Instability-High Cancers.
    • Sokol ES, Jin DX, Fine A, Trabucco SE, Maund S, Frampton G, Molinero L, Antonarakis ES.
    • JCO Precis Oncol. 2022 Jun;6:e2100531. doi: 10.1200/PO.21.00531.

    Related:

    Research news: Oncologists Seeing Lack of PARP Inhibitor Response in MSI-High, BRCA-Mutant Prostate Cancer Patients. (Precision Oncology News)

    • Veliparib for the treatment of solid malignancies.
    • George RR, Thomas R, Davice A, Mathew MS.
    • J Oncol Pharm Pract. 2022 Jun;28(4):924-934. doi: 10.1177/10781552221073990. Epub 2022 Jan 17.
    • Review
    • Functional RECAP (REpair CAPacity) assay identifies homologous recombination deficiency undetected by DNA-based BRCAness tests.
    • Meijer TG, Nguyen L, Van Hoeck A, Sieuwerts AM, Verkaik NS, Ladan MM, Ruigrok-Ritstier K, van Deurzen CHM, van de Werken HJG, Lips EH, Linn SC, Memari Y, Davies H, Nik-Zainal S, Kanaar R, Martens JWM, Cuppen E, Jager A, van Gent DC.
    • Oncogene. 2022 Jun;41(26):3498-3506. doi: 10.1038/s41388-022-02363-1. Epub 2022 Jun 3.
    • Validation of genomic and transcriptomic models of homologous recombination deficiency in a real-world pan-cancer cohort.
    • Leibowitz BD, Dougherty BV, Bell JSK, Kapilivsky J, Michuda J, Sedgewick AJ, Munson WA, Chandra TA, Dry JR, Beaubier N, Igartua C, Taxter T.
    • BMC Cancer. 2022 May 28;22(1):587. doi: 10.1186/s12885-022-09669-z.
    • Pharmacologic Induction of BRCAness in BRCA-Proficient Cancers: Expanding PARP Inhibitor Use.
    • Abbotts R, Dellomo AJ, Rassool FV.
    • Cancers (Basel). 2022 May 26;14(11):2640. doi: 10.3390/cancers14112640.
    • Complete response to pembrolizumab in a patient with dermatomyositis and MMR deficient ovarian cancer: A case report.
    • Valls ML, Kase AM, Patel R, Wang B, Aggarwal R, Colon-Otero G.
    • Gynecol Oncol Rep. 2022 May 25;41:101010. doi: 10.1016/j.gore.2022.101010.
    • Homologous Recombination Repair in Biliary Tract Cancers: A Prime Target for PARP Inhibition?
    • Yin C, Kulasekaran M, Roy T, Decker B, Alexander S, Margolis M, Jha RC, Kupfer GM, He AR.
    • Cancers (Basel). 2022 May 23;14(10):2561. doi: 10.3390/cancers14102561.
    • Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitor.
    • Tymon-Rosario JR, Manara P, Manavella DD, Bellone S, Hartwich TMP, Harold J, Yang-Hartwich Y, Zipponi M, Choi J, Jeong K, Mutlu L, Yang K, Altwerger G, Menderes G, Ratner E, Huang GS, Clark M, Andikyan V, Azodi M, Schwartz PE, Alexandrov LB, Santin AD.
    • Gynecol Oncol. 2022 May 19:S0090-8258(22)00305-5. doi: 10.1016/j.ygyno.2022.05.005. Epub ahead of print.
    • The effect of PARP inhibitors in homologous recombination proficient ovarian cancer: meta-analysis.
    • Skelin M, Šarcevic D, Lešin Gacina D, Mucalo I, Dilber I, Javor E.
    • J Chemother. 2022 May 13:1-8. doi: 10.1080/1120009X.2022.2073161. Epub ahead of print.
    • Meta-Analysis
    • Discovery of 4-Hydroxyquinazoline Derivatives as Small Molecular BET/PARP1 Inhibitors That Induce Defective Homologous Recombination and Lead to Synthetic Lethality for Triple-Negative Breast Cancer Therapy.
    • Zhang J, Yang C, Tang P, Chen J, Zhang D, Li Y, Yang G, Liu Y, Zhang Y, Wang Y, Liu J, Ouyang L.
    • J Med Chem. 2022 May 12;65(9):6803-6825. doi: 10.1021/acs.jmedchem.2c00135. Epub 2022 Apr 20.
    • OGG1 Inhibition Triggers Synthetic Lethality and Enhances The Effect of PARP Inhibitor Olaparib in BRCA1-Deficient TNBC Cells.
    • Baquero JM, Marchena-Perea E, Mirabet R, Torres-Ruiz R, Blanco-Aparicio C, Rodríguez-Perales S, Helleday T, Benítez-Buelga C, Benítez J, Osorio A.
    • Front Oncol. 2022 May 10;12:888810. doi: 10.3389/fonc.2022.888810.
    • DNA damage and metabolic mechanisms of cancer drug resistance.
    • Tiek D, Cheng SY.
    • Cancer Drug Resist. 2022 May 5;5:368-379. doi: 10.20517/cdr.2021.148.
    • Resveratrol sensitizes breast cancer to PARP inhibitor, talazoparib through dual inhibition of AKT and autophagy flux.
    • Pai Bellare G, Sankar Patro B.
    • Biochem Pharmacol. 2022 May;199:115024. doi: 10.1016/j.bcp.2022.115024. Epub 2022 Mar 31.
    • PARP Inhibition, a New Therapeutic Avenue in Patients with Prostate Cancer.
    • Flippot R, Patrikidou A, Aldea M, Colomba E, Lavaud P, Albigès L, Naoun N, Blanchard P, Terlizzi M, Garcia C, Bernard-Tessier A, Fuerea A, Di Palma M, Escudier B, Loriot Y, Baciarello G, Fizazi K.
    • Drugs. 2022 May;82(7):719-733. doi: 10.1007/s40265-022-01703-5. Epub 2022 May 5.
    • Review
    • Cracking the homologous recombination deficiency code: how to identify responders to PARP inhibitors.
    • Paulet L, Trecourt A, Leary A, Peron J, Descotes F, Devouassoux-Shisheboran M, Leroy K, You B, Lopez J.
    • Eur J Cancer. 2022 May;166:87-99. doi: 10.1016/j.ejca.2022.01.037. Epub 2022 Mar 10.
    • Review
    • Utility of Homologous Recombination Deficiency Biomarkers Across Cancer Types.
    • Takamatsu S, Brown JB, Yamaguchi K, Hamanishi J, Yamanoi K, Takaya H, Kaneyasu T, Mori S, Mandai M, Matsumura N.
    • JCO Precis Oncol. 2022 May;6:e2200085. doi: 10.1200/PO.22.00085.
    • Optimizing Chemotherapy of Pancreatic Acinar Cell Carcinoma: Our Experiences and Pooled Analysis of Literature.
    • Xu JY, Guan WL, Lu SX, Wei XL, Shi WJ, Ren C, Li YH, Li SP, Qiu MZ, Wang FH.
    • Clin Med Insights Oncol. 2022 Apr 30;16:11795549221090186. doi: 10.1177/11795549221090186.
    • Successful Treatment of a Patient With Brain Metastasis From Ovarian Cancer With BRCA Wild Type Using Niraparib: A Case Report and Review of the Literature.
    • Zhang Z, Xu M, Sakandar A, Du X, He H, He W, Li D, Wen Q.
    • Front Oncol. 2022 Apr 29;12:873198. doi: 10.3389/fonc.2022.873198.
    • Whole-genome and transcriptome analysis of advanced adrenocortical cancer highlights multiple alterations affecting epigenome and DNA repair pathways.
    • Lavoie JM, Csizmok V, Williamson LM, Culibrk L, Wang G, Marra MA, Laskin J, Jones SJM, Renouf DJ, Kollmannsberger CK.
    • Cold Spring Harb Mol Case Stud. 2022 Apr 28;8(3):a006148. doi: 10.1101/mcs.a006148.
    • Janssen Seeking European Union Approval for Zejula in HRR-Positive Prostate Cancer.
    • [No author given]
    • Precision Oncology News. Biomarkers. BRCA. 2022 Apr 28.
    • Minimally invasive secondary cytoreductive surgery for hepato-renal recess isolated recurrence of serous endometrial cancer in BRCA1 mutated patient.
    • Iacobelli V, Taliente F, Scambia G, Fanfani F, Giuliante F, Gallotta V.
    • Int J Gynecol Cancer. 2022 Apr 27:ijgc-2021-003271. doi: 10.1136/ijgc-2021-003271. Epub ahead of print.
    • Circulating tumor DNA genomic profiling reveals the complicated olaparib-resistance mechanism in prostate cancer salvage therapy: A case report.
    • Yuan F, Liu N, Yang MZ, Zhang XT, Luo H, Zhou H.
    • World J Clin Cases. 2022 Apr 16;10(11):3461-3471. doi: 10.12998/wjcc.v10.i11.3461.
    • Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification.
    • Pellegrino B, Herencia-Ropero A, Llop-Guevara A, Pedretti F, Moles-Fernández A, Viaplana C, Villacampa G, Guzmán M, Rodríguez O, Grueso J, Jiménez J, Arenas EJ, Degasperi A, Dias JML, Forment JV, O'Connor MJ, Déas O, Cairo S, Zhou Y, Musolino A, Caldas C, Nik-Zainal S, Clarke RB, Nuciforo P, Díez O, Serres-Créixams X, Peg V, Espinosa-Bravo M, Macarulla T, Oaknin A, Mateo J, Arribas J, Dienstmann R, Bellet M, Oliveira M, Saura C, Gutiérrez-Enríquez S, Balmaña J, Serra V.
    • Cancer Res. 2022 Apr 15;82(8):1646-1657. doi: 10.1158/0008-5472.CAN-21-2409.
    • Next-Generation AstraZeneca PARP1 Inhibitor Shows Activity in Multiple Cancers at Variety of Doses.
    • Kanski A.
    • Precision Oncology News. Biomarkers. BRCA. 2022 Apr 12.

    Related:

    Identifier: NCT04644068: Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (PETRA). (ClinicalTrials.gov)

    • UPenn Researchers Enrolling BRCA1/2 Carriers Into Inovio hTERT Cancer Vaccine study.
    • Hopkins C.
    • Precision Oncology News. Cancer Specialties. 2022 Apr 11.

    Related:

    Identifier: NCT04367675: INO 5401 Vaccination in BRCA1/2 Mutation Carriers. (ClinicalTrials.gov)

    • Current Systemic Treatments for the Hereditary Cancer Syndromes: Drug Development in Light of Genomic Defects.
    • Hasanov E, Pimentel I, Cruellas M, Lewis MA, Jonasch E, Balmaña J.
    • Am Soc Clin Oncol Educ Book. 2022 Apr;42:1-17. doi: 10.1200/EDBK_350232.
    • Racial and ethnic enrollment disparities in clinical trials of poly(ADP-ribose) polymerase inhibitors for gynecologic cancers.
    • Wagar MK, Mojdehbakhsh RP, Godecker A, Rice LW, Barroilhet L.
    • Gynecol Oncol. 2022 Apr;165(1):49-52. doi: 10.1016/j.ygyno.2022.01.032. Epub 2022 Feb 8.
    • Deubiquitination of FBP1 by USP7 blocks FBP1-DNMT1 interaction and decreases the sensitivity of pancreatic cancer cells to PARP inhibitors.
    • Cheng X, Zhang B, Guo F, Wu H, Jin X.
    • Mol Oncol. 2022 Apr;16(7):1591-1607. doi: 10.1002/1878-0261.13149. Epub 2021 Dec 17.
    • Cell cycle checkpoints and beyond: Exploiting the ATR/CHK1/WEE1 pathway for the treatment of PARP inhibitor-resistant cancer.
    • Gupta N, Huang TT, Horibata S, Lee JM.
    • Pharmacol Res. 2022 Apr;178:106162. doi: 10.1016/j.phrs.2022.106162. Epub 2022 Mar 5.
    • Review
    • Combining Carbon-Ion Irradiation and PARP Inhibitor, Olaparib Efficiently Kills BRCA1-Mutated Triple-Negative Breast Cancer Cells.
    • Kawanishi M, Fujita M, Karasawa K.
    • Breast Cancer (Auckl). 2022 Mar 23;16:11782234221080553. doi: 10.1177/11782234221080553.
    • Inhibitors of PARP: Number crunching and structure gazing.
    • Rudolph J, Jung K, Luger K.
    • Proc Natl Acad Sci U S A. 2022 Mar 15;119(11):e2121979119. doi: 10.1073/pnas.2121979119. Epub 2022 Mar 8.
    • Homologous Recombination Deficiency: Concepts, Definitions, and Assays.
    • Stewart MD, Merino Vega D, Arend RC, Baden JF, Barbash O, Beaubier N, Collins G, French T, Ghahramani N, Hinson P, Jelinic P, Marton MJ, McGregor K, Parsons J, Ramamurthy L, Sausen M, Sokol ES, Stenzinger A, Stires H, Timms KM, Turco D, Wang I, Williams JA, Wong-Ho E, Allen J.
    • Oncologist. 2022 Mar 11;27(3):167-174. doi: 10.1093/oncolo/oyab053.
    • PARP Inhibitors Resistance: Mechanisms and Perspectives.
    • Giudice E, Gentile M, Salutari V, Ricci C, Musacchio L, Carbone MV, Ghizzoni V, Camarda F, Tronconi F, Nero C, Ciccarone F, Scambia G, Lorusso D.
    • Cancers (Basel). 2022 Mar 10;14(6):1420. doi: 10.3390/cancers14061420.
    • Importance of Early Next-Generation Sequencing in Microsatellite Unstable Colon Cancer With a High Tumor Mutation Burden.
    • Ashish S, Raj M.
    • Cureus. 2022 Mar 6;14(3):e22894. doi: 10.7759/cureus.22894.
    • Molecular analysis of endometrial serous carcinoma reveals distinct clinicopathologic and genomic subgroups.
    • Lin DI, Fine A, Danziger NA, Huang RSP, Mata DA, Decker B, Killian JK, Ramkissoon SH, Lechpammer M, Janovitz T, Ross JS, Sokol ES, Elvin JA.
    • Gynecol Oncol. 2022 Mar;164(3):558-565. doi: 10.1016/j.ygyno.2021.12.030. Epub 2022 Jan 5.
    • DNA repair defects in cancer and therapeutic opportunities.
    • Hopkins JL, Lan L, Zou L.
    • Genes Dev. 2022 Mar 1;36(5-6):278-293. doi: 10.1101/gad.349431.122.
    • Review
    • Therapeutic implications of germline vulnerabilities in DNA repair for precision oncology.
    • Shah SM, Demidova EV, Lesh RW, Hall MJ, Daly MB, Meyer JE, Edelman MJ, Arora S.
    • Cancer Treat Rev. 2022 Mar;104:102337. doi: 10.1016/j.ctrv.2021.102337. Epub 2022 Jan 5.
    • PARP inhibitors for metastatic castration-resistant prostate cancer: Biological rationale and current evidence.
    • Bienkowski M, Tomasik B, Braun M, Jassem J.
    • Cancer Treat Rev. 2022 Mar;104:102359. doi: 10.1016/j.ctrv.2022.102359.Epub 2022 Feb 11.
    • Review
    • The role of PARP inhibitors in gastrointestinal cancers.
    • Hanna D, Chopra N, Hochhauser D, Khan K.
    • Crit Rev Oncol Hematol. 2022 Mar;171:103621. doi: 10.1016/j.critrevonc.2022.103621. Epub 2022 Feb 3.
    • Review
    • Safety, Feasibility, and Merits of Longitudinal Molecular Testing of Multiple Metastatic Sites to Inform mTNBC Patient Treatment in the Intensive Trial of Omics in Cancer.
    • Burton KA, Mahen E, Konnick EQ, Blau S, Dorschner MO, Ramirez AB, Schmechel SC, Song C, Parulkar R, Parker S, Senecal FM, Pritchard CC, Mecham BH, Szeto C, Spilman P, Zhu J, Gadi VK, Ronen R, Stilwell J, Kaldjian E, Dutkowski J, Benz SC, Rabizadeh S, Soon-Shiong P, Blau CA.
    • JCO Precis Oncol. 2022 Mar;6:e2100280. doi: 10.1200/PO.21.00280.
    • Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial.
    • Smith MR, Scher HI, Sandhu S, Efstathiou E, Lara PN Jr, Yu EY, George DJ, Chi KN, Saad F, Ståhl O, Olmos D, Danila DC, Mason GE, Espina BM, Zhao X, Urtishak KA, Francis P, Lopez-Gitlitz A, Fizazi K; GALAHAD investigators.
    • Lancet Oncol. 2022 Mar;23(3):362-373. doi: 10.1016/S1470-2045(21)00757-9. Epub 2022 Feb 4.

    Related:

    Identifier: NCT02854436: An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies (Galahad). (ClinicalTrials.gov)

    Research news: Study: PARP inhibitor treatment for metastatic prostate cancer shows most benefit in men with inherited BRCA mutations. (FORCE. XRAY)

    • PARP Inhibitor Applicability: Detailed Assays for Homologous Recombination Repair Pathway Components.
    • O'Sullivan Coyne G, Karlovich C, Wilsker D, Voth AR, Parchment RE, Chen AP, Doroshow JH.
    • Onco Targets Ther. 2022 Feb 24;15:165-180. doi: 10.2147/OTT.S278092.
    • DNA Repair Enzyme Poly(ADP-Ribose) Polymerase 1/2 (PARP1/2)-Targeted Nuclear Imaging and Radiotherapy.
    • Nguyen NT, Pacelli A, Nader M, Kossatz S.
    • Cancers (Basel). 2022 Feb 23;14(5):1129. doi: 10.3390/cancers14051129.
    • VPA and TSA Interrupt the Interplay between mutp53 and HSP70, Leading to CHK1 and RAD51 Down-Regulation and Sensitizing Pancreatic Cancer Cells to AZD2461 PARP Inhibitor.
    • Romeo MA, Gilardini Montani MS, Benedetti R, Arena A, D'Orazi G, Cirone M.
    • Int J Mol Sci. 2022 Feb 18;23(4):2268. doi: 10.3390/ijms23042268.
    • RB1 loss overrides PARP inhibitor sensitivity driven by RNASEH2B loss in prostate cancer.
    • Miao C, Tsujino T, Takai T, Gui F, Tsutsumi T, Sztupinszki Z, Wang Z, Azuma H, Szallasi Z, Mouw KW, Zou L, Kibel AS, Jia L.
    • Sci Adv. 2022 Feb 18;8(7):eabl9794. doi: 10.1126/sciadv.abl9794. Epub 2022 Feb 18.
    • Dual-target inhibitors of poly (ADP-ribose) polymerase-1 for cancer therapy: Advances, challenges, and opportunities.
    • Hu X, Zhang J, Zhang Y, Jiao F, Wang J, Chen H, Ouyang L, Wang Y.
    • Eur J Med Chem. 2022 Feb 15;230:114094. doi: 10.1016/j.ejmech.2021.114094. Epub 2021 Dec 30.
    • Review
    • Recent advances in DDR (DNA damage response) inhibitors for cancer therapy.
    • Cheng B, Pan W, Xing Y, Xiao Y, Chen J, Xu Z.
    • Eur J Med Chem. 2022 Feb 15;230:114109. doi: 10.1016/j.ejmech.2022.114109. Epub 2022 Jan 12.
    • Review
    • Everything Comes with a Price: The Toxicity Profile of DNA-Damage Response Targeting Agents.
    • Martorana F, Da Silva LA, Sessa C, Colombo I.
    • Cancers (Basel). 2022 Feb 14;14(4):953. doi: 10.3390/cancers14040953.
    • Phase 2 Trial (POLA Study) of Lurbinectedin plus Olaparib in Patients with Advanced Solid Tumors: Results of Efficacy, Tolerability, and the Translational Study.
    • Poveda A, Lopez-Reig R, Oaknin A, Redondo A, Rubio MJ, Guerra E, Fariñas-Madrid L, Gallego A, Rodriguez-Freixinos V, Fernandez-Serra A, Juan O, Romero I, Lopez-Guerrero JA.
    • Cancers (Basel). 2022 Feb 12;14(4):915. doi: 10.3390/cancers14040915.
    • Precision Medicine for BRCA/PALB2-Mutated Pancreatic Cancer and Emerging Strategies to Improve Therapeutic Responses to PARP Inhibition.
    • Principe DR.
    • Cancers (Basel). 2022 Feb 11;14(4):897. doi: 10.3390/cancers14040897.
    • Phase Ib SEASTAR Study: Combining Rucaparib and Sacituzumab Govitecan in Patients With Cancer With or Without Mutations in Homologous Recombination Repair Genes.
    • Yap TA, Hamilton E, Bauer T, Dumbrava EE, Jeselsohn R, Enke A, Hurley S, Lin KK, Habeck J, Giordano H, Shapiro GI.
    • JCO Precis Oncol. [2022 Feb 9];6:e2100456. doi: 10.1200/PO.21.00456.
    • Varsity Pharmaceuticals Licenses Pol-Theta Inhibitor From Dana-Farber Cancer Institute.
    • [No author given]
    • Precision Oncology News. Biomarkers. BRCA. 2022 Feb 7.

    Related:

    Original research:

    A first-in-class Polymerase Theta Inhibitor selectively targets Homologous-Recombination-Deficient Tumors.

    • Inibidores da PARP: do mecanismo de ação à prática clínica [PARP Inhibitors: From the Mechanism of Action to Clinical Practice].
    • Branco C, Paredes J.
    • Acta Med Port. 2022 Feb 1;35(2):135-143. Portuguese. doi: 10.20344/amp.13870. Epub 2022 Feb 1.
    • Molecular tests for prediction of tumor sensitivity to cytotoxic drugs.
    • Imyanitov EN, Iyevleva AG.
    • Cancer Lett. 2022 Feb 1;526:41-52. doi: 10.1016/j.canlet.2021.11.021. Epub 2021 Nov 20.
    • Review
    • Clinicopathological Significance of BRCAness in Resectable Pancreatic Ductal Adenocarcinoma and Its Association With Anticancer Drug Sensitivity in Pancreatic Cancer Cells.
    • Tadehara M, Kato T, Adachi K, Tamaki A, Kesen Y, Sakurai Y, Ichinoe M, Koizumi W, Murakumo Y.
    • Pancreas. 2022 Feb 1;51(2):183-189. doi: 10.1097/MPA.0000000000001975.
    • Therapeutic Targeting of DNA Damage Response in Cancer.
    • Choi W, Lee ES.
    • Int J Mol Sci. 2022 Feb 1;23(3):1701. doi: 10.3390/ijms23031701.
    • Identifying Transcripts with Tandem Duplications from RNA-Sequencing Data to Predict BRCA1-Type Primary Breast Cancer.
    • Qu S, Martens JWM, Hollestelle A, Smid M.
    • Cancers (Basel). 2022 Jan 31;14(3):753. doi: 10.3390/cancers14030753.
    • Overview of Immune Checkpoint Inhibitors in Gynecological Cancer Treatment.
    • Pirš B, Škof E, Smrkolj V, Smrkolj Š.
    • Cancers (Basel). 2022 Jan 27;14(3):631. doi: 10.3390/cancers14030631.
    • FDA Grants Fast Track Status to CX-5461 for Breast and Ovarian Cancers With BRCA1/2, PALB2, or Other HRD Mutations.
    • Rosa K.
    • OncLive. 2022 Jan 25.

    Related:

    News release: Senhwa’s Pidnarulex Receives US FDA Fast Track Designation for the Treatment of Solid Tumors with BRCA1/2, PALB2 and other HR Gene Mutations. (Senhwa Biosciences. Accessed 2022 Oct 5.)

    Identifier: NCT04890613: Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation. (ClinicalTrials.gov . Accessed 2022 Oct 5.)

    • What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review (Part 6): Correlation of PD-L1 Expression with the Status of Mismatch Repair System, BRCA, PTEN, and Other Genes.
    • Palicelli A, Croci S, Bisagni A, Zanetti E, De Biase D, Melli B, Sanguedolce F, Ragazzi M, Zanelli M, Chaux A, Cañete-Portillo S, Bonasoni MP, Ascani S, De Leo A, Giordano G, Landriscina M, Carrieri G, Cormio L, Gandhi J, Nicoli D, Farnetti E, Piana S, Tafuni A, Bonacini M.
    • Biomedicines. 2022 Jan 22;10(2):236. doi: 10.3390/biomedicines10020236.
    • Tempus, GSK Initiate Phase II Trial of Niraparib in PALB2-Mutated Tumors.
    • [No author given]
    • Precision Oncology News. Diagnostics. 2022 Jan 14.
    • Case Report: Effectiveness of Targeted Treatment in a Patient With Pancreatic Cancer Harboring PALB2 Germline Mutation and KRAS Somatic Mutation.
    • Wu W, Liu Y, Jin Y, Liu L, Guo Y, Xu M, Hao Q, Li D, Fang W, Zhang A, Zhao P.
    • Front Med (Lausanne). 2022 Jan 13;8:746637. doi: 10.3389/fmed.2021.746637.
    • Harnessing Synthetic Lethal Interactions for Personalized Medicine.
    • Shieh GS.
    • J Pers Med. 2022 Jan 12;12(1):98. doi: 10.3390/jpm12010098.
    • Comprehensive Analysis of Somatic Reversion Mutations in Homologous Recombination Repair (HRR) Genes in A Large Cohort of Chinese Pan-cancer Patients.
    • Zong H, Zhang J, Xu Z, Pan JN, Wang R, Han J, Jiang M, Ren R, Zang L, Wang H, Cao WM.
    • J Cancer. 2022 Jan 9;13(4):1119-1129. doi: 10.7150/jca.65650.
    • Structure-based design, synthesis, and evaluation of inhibitors with high selectivity for PARP-1 over PARP-2.
    • Yu J, Luo L, Hu T, Cui Y, Sun X, Gou W, Hou W, Li Y, Sun T.
    • Eur J Med Chem. 2022 Jan 5;227:113898. doi: 10.1016/j.ejmech.2021.113898. Epub 2021 Oct 9.
    • Platinum-Based Neoadjuvant Chemotherapy Before Radical Prostatectomy for Locally Advanced Prostate Cancer With Homologous Recombination Deficiency: A Case Report.
    • Zhuang J, Zhang S, Qiu X, Fu Y, Ai S, Zhao T, Yang Y, Guo H.
    • Front Oncol. 2022 Jan 5;11:777318. doi: 10.3389/fonc.2021.777318.
    • Auger Emitter Conjugated PARP Inhibitor for Therapy in Triple Negative Breast Cancers: A Comparative In-Vitro Study.
    • Sankaranarayanan RA, Peil J, Vogg ATJ, Bolm C, Terhorst S, Classen A, Bauwens M, Maurer J, Mottaghy F, Morgenroth A.
    • Cancers (Basel). 2022 Jan 4;14(1):230. doi: 10.3390/cancers14010230.
    • ATM: Functions of ATM Kinase and Its Relevance to Hereditary Tumors.
    • Ueno S, Sudo T, Hirasawa A.
    • Int J Mol Sci. 2022 Jan 4;23(1):523. doi: 10.3390/ijms23010523.
    • Landscape of homologous recombination deficiencies in solid tumours: analyses of two independent genomic datasets.
    • Lai Z, Brosnan M, Sokol ES, Xie M, Dry JR, Harrington EA, Barrett JC, Hodgson D.
    • BMC Cancer. 2022 Jan 3;22(1):13. doi: 10.1186/s12885-021-09082-y.
    • A phase IA dose-escalation study of PHI-101, a new checkpoint kinase 2 inhibitor, for platinum-resistant recurrent ovarian cancer.
    • Park SJ, Chang SJ, Suh DH, Kong TW, Song H, Kim TH, Kim JW, Kim HS, Lee SJ.
    • BMC Cancer. 2022 Jan 3;22(1):28. doi: 10.1186/s12885-021-09138-z.
    • Complete Response of a Mutated BRCA2 Metastatic Clear Cell Endometrial Adenocarcinoma to the Poly (ADP ribose) Polymerase (PARP) Inhibitor Olaparib.
    • Anzellini D, Arcangeli G, Del Bianco S.
    • Cancer Diagn Progn. 2022 Jan 3;2(1):84-86. doi: 10.21873/cdp.10080.
    • Response to olaparib in metastatic lung adenocarcinoma with germline BRCA2 mutation: a case report.
    • Wu C, Fan M, Hu Y.
    • Anticancer Drugs. 2022 Jan 1;33(1):e734-e737. doi: 10.1097/CAD.0000000000001160.
    • Case report
    • Aberrant Transcript Usage Is Associated with Homologous Recombination Deficiency and Predicts Therapeutic Response.
    • Kang HG, Hwangbo H, Kim MJ, Kim S, Lee EJ, Park MJ, Kim JW, Kim BG, Cho EH, Chang S, Lee JY, Choi JK.
    • Cancer Res. 2022 Jan 1;82(1):142-154. doi: 10.1158/0008-5472.CAN-21-2023. Epub 2021 Oct 28.
    • Germline Variants in DNA Damage Repair Genes: An Emerging Role in the Era of Precision Medicine in Pancreatic Adenocarcinoma.
    • Shoucair S, Baker AR, Yu J.
    • Ann Gastroenterol Surg. 2021 Sep 29 [2022 Jan];6(1):7-16. doi: 10.1002/ags3.12514. eCollection 2022 Jan.
    • Molecular targeted drugs resistance impairs double-strand break repair and sensitizes ER-positive breast cancer to PARP inhibitors.
    • Suzuki Y, Wenwen W, Ohta T, Hayashi SI.
    • Breast Cancer. 2022 Jan;29(1):77-91. doi: 10.1007/s12282-021-01282-5. Epub 2021 Aug 3.
    • Défauts de la recombinaison homologue et inhibiteurs de PARP en thérapeutique [Homologous recombination deficiency and PARP inhibitors in therapeutics].
    • Salaün H, Saint-Ghislain M, Bellesoeur A, Beuzeboc P, Neuzillet C, Diéras V, Stern MH, Rodrigues M.
    • Bull Cancer. 2022 Jan;109(1):76-82. French. doi: 10.1016/j.bulcan.2021.09.015. Epub 2021 Nov 17.
    • Review, [Article in French]
    • Metabolism-related pharmacokinetic drug-drug interactions with poly (ADP-ribose) polymerase inhibitors (Review).
    • Zhao D, Long X, Wang J.
    • Oncol Rep. 2022 Jan;47(1):20. doi: 10.3892/or.2021.8231. Epub 2021 Nov 23.
    • Review
    • FDI-6 and olaparib synergistically inhibit the growth of pancreatic cancer by repressing BUB1, BRCA1 and CDC25A signaling pathways.
    • Wu SQ, Huang SH, Lin QW, Tang YX, Huang L, Xu YG, Wang SP.
    • Pharmacol Res. 2022 Jan;175:106040. doi: 10.1016/j.phrs.2021.106040. Epub 2021 Dec 22.
    • Human iPSC-derived fallopian tube organoids with BRCA1 mutation recapitulate early-stage carcinogenesis.
    • Yucer N, Ahdoot R, Workman MJ, Laperle AH, Recouvreux MS, Kurowski K, Naboulsi DJ, Liang V, Qu Y, Plummer JT, Gayther SA, Orsulic S, Karlan BY, Svendsen CN.
    • Cell Rep. 2021 Dec 28;37(13):110146. doi: 10.1016/j.celrep.2021.110146.

    Related:

    Research news: Researchers Create Organoids that Model BRCA-Positive Ovarian Cancer. (Clinical OMICs)

    • Preventing and Overcoming Resistance to PARP Inhibitors: A Focus on the Clinical Landscape.
    • Prados-Carvajal R, Irving E, Lukashchuk N, Forment JV.
    • Cancers (Basel). 2021 Dec 23;14(1):44. doi: 10.3390/cancers14010044.
    • Inferring Homologous Recombination Deficiency of Ovarian Cancer From the Landscape of Copy Number Variation at Subchromosomal and Genetic Resolutions.
    • Zhang M, Ma SC, Tan JL, Wang J, Bai X, Dong ZY, Zhang QX.
    • Front Oncol. 2021 Dec 16;11:772604. doi: 10.3389/fonc.2021.772604.
    • Research Advances in the Role of the Poly ADP Ribose Polymerase Family in Cancer.
    • Sha H, Gan Y, Zou R, Wu J, Feng J.
    • Front Oncol. 2021 Dec 16;11:790967. doi: 10.3389/fonc.2021.790967.
    • Perspectives on PARP Inhibitor Combinations for Ovarian Cancer.
    • Bonadio RC, Estevez-Diz MDP.
    • Front Oncol. 2021 Dec 15;11:754524. doi: 10.3389/fonc.2021.754524.
    • Discovery of Potent and Novel Dual PARP/BRD4 Inhibitors for Efficient Treatment of Pancreatic Cancer.
    • Wang SP, Li Y, Huang SH, Wu SQ, Gao LL, Sun Q, Lin QW, Huang L, Meng LQ, Zou Y, Zhu QH, Xu YG.
    • J Med Chem. 2021 Dec 9;64(23):17413-17435. doi: 10.1021/acs.jmedchem.1c01535. Epub 2021 Nov 23.
    • Genomic attributes of homology-directed DNA repair deficiency in metastatic prostate cancer.
    • De Sarkar N, Dasgupta S, Chatterjee P, Coleman I, Ha G, Ang LS, Kohlbrenner EA, Frank SB, Nunez TA, Salipante SJ, Corey E, Morrissey C, Van Allen E, Schweizer MT, Haffner MC, Patel R, Hanratty B, Lucas JM, Dumpit RF, Pritchard CC, Montgomery RB, Nelson PS.
    • JCI Insight. 2021 Dec 8;6(23):e152789. doi: 10.1172/jci.insight.152789.
    • Case Report: Niraparib as Maintenance Therapy in A Patient With Ovarian Carcinosarcoma.
    • Zhang JQ, Zhao BB, Wang MM, Li L.
    • Front Oncol. 2021 Dec 6;11:603591. doi: 10.3389/fonc.2021.603591.
    • Filling in the gaps in PARP inhibitor-induced synthetic lethality.
    • Paes Dias M, Jonkers J.
    • Mol Cell Oncol. 2021 Dec 6;8(6):2010512. doi: 10.1080/23723556.2021.2010512.
    • Genomic Features and Clinical Implications of Intraductal Carcinoma of the Prostate.
    • Kang M, Lee H, Byeon SJ, Kwon GY, Jeon SS.
    • Int J Mol Sci. 2021 Dec 4;22(23):13125. doi: 10.3390/ijms222313125.
    • Multimodality therapy in metastatic pancreas cancer with a BRCA mutation and durable long-term outcome: biology, intervention, or both?
    • Sutton TL, Grossberg A, Ey F, O'Reilly EM, Sheppard BC.
    • Cancer Biol Ther. 2021 Dec 2;22(10-12):532-536. doi: 10.1080/15384047.2021.1991739. Epub 2021 Oct 25.
    • Pancreas cancer and BRCA: A critical subset of patients with improving therapeutic outcomes.
    • Momtaz P, O'Connor CA, Chou JF, Capanu M, Park W, Bandlamudi C, Berger MF, Kelsen DP, Suehnholz SP, Chakravarty D, Yu KH, Varghese AM, Zervoudakis A, Li J, Ku GY, Park JS, Shcherba M, Harding JJ, Goldberg Z, Abou-Alfa GK, Salo-Mullen EE, Stadler ZK, Iacobuzio-Donahue CA, O'Reilly EM.
    • Cancer. 2021 Dec 1;127(23):4393-4402. doi: 10.1002/cncr.33812. Epub 2021 Aug 5.
    • Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513.
    • Chiorean EG, Guthrie KA, Philip PA, Swisher EM, Jalikis F, Pishvaian MJ, Berlin J, Noel MS, Suga JM, Garrido-Laguna I, Cardin DB, Radke MR, Duong M, Bellasea S, Lowy AM, Hochster HS.
    • Clin Cancer Res. 2021 Dec 1;27(23):6314-6322. doi: 10.1158/1078-0432.CCR-21-1789. Epub 2021 Sep 27.
    • Durable clinical benefit from PARP inhibition in a platinum-sensitive, BRCA2-mutated pancreatic cancer patient after earlier progression on placebo treatment on the POLO trial: a case report.
    • Rubinson D, Wolpin BM, Warsofsky IS, Ryan DP, Perez K, Rahma O, Singh H, Yurgelun MB, Shapiro GI, Aguirre AJ, D'Andrea AD, Cleary JM.
    • J Gastrointest Oncol. 2021 Dec;12(6):3133-3140. doi: 10.21037/jgo-21-197.
    • Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy.
    • Samstein RM, Krishna C, Ma X, Pei X, Lee KW, Makarov V, Kuo F, Chung J, Srivastava RM, Purohit TA, Hoen DR, Mandal R, Setton J, Wu W, Shah R, Qeriqi B, Chang Q, Kendall S, Braunstein L, Weigelt B, Carrillo Albornoz PB, Morris LGT, Mandelker DL, Reis-Filho JS, de Stanchina E, Powell SN, Chan TA, Riaz N.
    • Nat Cancer. 2021 Dec;1(12):1188-1203. doi: 10.1038/s43018-020-00139-8. Epub 2020 Nov 16.

    Related:

    Research news: Cancer Patients With BRCA1/2 Mutations Respond Differently to Immunotherapy, Study Shows. (Precision Oncology News; subscription required)

    • Understanding and overcoming resistance to PARP inhibitors in cancer therapy.
    • Dias MP, Moser SC, Ganesan S, Jonkers J.
    • Nat Rev Clin Oncol. 2021 Dec;18(12):773-791. doi: 10.1038/s41571-021-00532-x. Epub 2021 Jul 20.
    • Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutations.
    • Sokolova AO, Marshall CH, Lozano R, Gulati R, Ledet EM, De Sarkar N, Grivas P, Higano CS, Montgomery B, Nelson PS, Olmos D, Sokolov V, Schweizer MT, Yezefski TA, Yu EY, Paller CJ, Sartor O, Castro E, Antonarakis ES, Cheng HH.
    • Prostate. 2021 Dec;81(16):1382-1389. doi: 10.1002/pros.24236. Epub 2021 Sep 13.
    • Tackling PARP inhibitor resistance.
    • Fugger K, Hewitt G, West SC, Boulton SJ.
    • Trends Cancer. 2021 Dec;7(12):1102-1118. doi: 10.1016/j.trecan.2021.08.007. Epub 2021 Sep 22.
    • AstraZeneca, Merck File Adjuvant Lynparza sNDA for Early-Stage Breast Cancer.
    • [No author given]
    • Precision Oncology News. Biomarkers. BRCA. 2021 Nov 30.
    • Favorable Response to Olaparib in a Patient with Cancer of Unknown Primary Carrying a Germline BRCA1 R71K Mutation.
    • Jia X, Zhao S, Li X, Lv L, Chen X, Pan E, Ou Q, Song C, Sun S, Zhao J, Xu L, Li M.
    • Onco Targets Ther. 2021 Nov 27;14:5353-5360. doi: 10.2147/OTT.S334847.
    • Discovery of Potent and Novel Dual PARP/BRD4 Inhibitors for Efficient Treatment of Pancreatic Cancer.
    • Wang SP, Li Y, Huang SH, Wu SQ, Gao LL, Sun Q, Lin QW, Huang L, Meng LQ, Zou Y, Zhu QH, Xu YG.
    • J Med Chem. 2021 Nov 23. doi: 10.1021/acs.jmedchem.1c01535. Epub ahead of print.
    • Inhibition of poly (ADP-Ribose) polymerase: A promising strategy targeting pancreatic cancer with BRCAness phenotype.
    • Jeong KY, Lee H.
    • World J Gastrointest Oncol. 2021 Nov 15;13(11):1544-1550. doi: 10.4251/wjgo.v13.i11.1544.
    • Functional pre-therapeutic evaluation by genome editing of variants of uncertain significance of essential tumor suppressor genes.
    • Billaud A, Chevalier LM, Augereau P, Frenel JS, Passot C, Campone M, Morel A.
    • Genome Med. 2021 Nov 9;13(1):174. doi: 10.1186/s13073-021-00976-x.
    • Quantitative Analysis of the Efficacy of PARP Inhibitors as Maintenance Therapy in Recurrent Ovarian Cancer.
    • Gao L, Chen R, Li T, Li L, Zheng Q.
    • Front Pharmacol. 2021 Nov 8;12:771836. doi: 10.3389/fphar.2021.771836.
    • Heightened Sensitivity of Germline BRCA Mutant Patients Treated With Concurrent or Adjuvant PARP Inhibition and Radiotherapy for Brain Metastases.
    • Santos P, Imber BS, Lapen K, Pike LRG, Moss N, Seidman AD, Beal K.
    • Int J Radiat Oncol Biol Phys. 2021 Nov 1;111(3S):e605. doi: 10.1016/j.ijrobp.2021.07.1614.
    • Integrated, Integral, and Exploratory Biomarkers in the Development of Poly(ADP-Ribose) Polymerase Inhibitors.
    • Konecny GE, Chander C, Zhang L.
    • Cancer J. 2021 Nov-Dec 01;27(6):482-490. doi: 10.1097/PPO.0000000000000564.
    • Review
    • The Clinical Challenges, Trials, and Errors of Combatting Poly(ADP-Ribose) Polymerase Inhibitors Resistance.
    • Pham MM, Hinchcliff E, Avila M, Westin SN.
    • Cancer J. 2021 Nov-Dec 01;27(6):491-500. doi: 10.1097/PPO.0000000000000562.
    • Review
    • DNA Damage Repair Inhibitors-Combination Therapies.
    • Smith G, Alholm Z, Coleman RL, Monk BJ.
    • Cancer J. 2021 Nov-Dec 01;27(6):501-505. doi: 10.1097/PPO.0000000000000561.
    • Review
    • Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy.
    • Miller RE.
    • Cancer J. 2021 Nov-Dec 01;27(6):506-510. doi: 10.1097/PPO.0000000000000565.
    • Review
    • BRCA-mutant pancreatic ductal adenocarcinoma.
    • Lai E, Ziranu P, Spanu D, Dubois M, Pretta A, Tolu S, Camera S, Liscia N, Mariani S, Persano M, Migliari M, Donisi C, Demurtas L, Pusceddu V, Puzzoni M, Scartozzi M.
    • Br J Cancer. 2021 Nov;125(10):1321-1332. doi: 10.1038/s41416-021-01469-9. Epub 2021 Jul 14.
    • Review
    • Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial.
    • Carreira S, Porta N, Arce-Gallego S, Seed G, Llop-Guevara A, Bianchini D, Rescigno P, Paschalis A, Bertan C, Baker C, Goodall J, Miranda S, Riisnaes R, Figueiredo I, Ferreira A, Pereira R, Crespo M, Gurel B, Nava Rodrigues D, Pettitt SJ, Yuan W, Serra V, Rekowski J, Lord CJ, Hall E, Mateo J, de Bono JS.
    • Cancer Discov. 2021 Nov;11(11):2812-2827. doi: 10.1158/2159-8290.CD-21-0007. Epub 2021 May 27.
    • Unusual metastasis in BRCA mutated pancreatic cancer while on maintenance Olaparib: Two case reports and review of the literature.
    • Assaf I, Mans L, Sakr R, Verset G, Van Laethem JL.
    • Eur J Cancer. 2021 Nov;157:63-67. doi: 10.1016/j.ejca.2021.07.042. Epub 2021 Sep 4.
    • Case report
    • Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer.
    • Shah PD, Wethington SL, Pagan C, Latif N, Tanyi J, Martin LP, Morgan M, Burger RA, Haggerty A, Zarrin H, Rodriguez D, Domchek S, Drapkin R, Shih IM, Smith SA, Dean E, Gaillard S, Armstrong D, Torigian DA, Hwang WT, Giuntoli R, Simpkins F.
    • Gynecol Oncol. 2021 Nov;163(2):246-253. doi: 10.1016/j.ygyno.2021.08.024. Epub 2021 Oct 5.
    • Adherence to PARP inhibitor therapy among women with ovarian cancer.
    • Moss HA, Chen L, Hershman DL, Davidson B, Wright JD.
    • Gynecol Oncol. 2021 Nov;163(2):262-268. doi: 10.1016/j.ygyno.2021.08.025. Epub 2021 Sep 9.
    • Discordant Reporting of a Previously Undescribed Pathogenic Germline BRCA2 Variant in Blood and Tumor Tissue in a Patient With Pancreatic Adenocarcinoma.
    • Kordes M, Tamborero D, Lagerstedt-Robinson K, Yachnin J, Rosenquist R, Löhr JM, Gustafsson Liljefors M.
    • JCO Precis Oncol. 2021 Nov;5:974-980. doi: 10.1200/PO.21.00024.
    • Germline PALB2 Variants and PARP Inhibitors in Endometrial Cancer.
    • Cilento MA, Poplawski NK, Paramasivam S, Thomas DM, Kichenadasse G.
    • J Natl Compr Canc Netw. 2021 Nov;19(11):1212-1217. doi: 10.6004/jnccn.2021.7067.
    • Synthetic Lethality in Ovarian Cancer.
    • Chandrasekaran A, Elias KM.
    • Mol Cancer Ther. 2021 Nov;20(11):2117-2128. doi: 10.1158/1535-7163.MCT-21-0500. Epub 2021 Sep 13.
    • Homologous recombination proficiency in ovarian and breast cancer patients.
    • Creeden JF, Nanavaty NS, Einloth KR, Gillman CE, Stanbery L, Hamouda DM, Dworkin L, Nemunaitis J.
    • BMC Cancer. 2021 Oct 28;21(1):1154. doi: 10.1186/s12885-021-08863-9.
    • BRCA1 Versus BRCA2 and PARP Inhibitors Efficacy in Solid Tumors:A Meta-Analysis of Randomized Controlled Trials.
    • Li S, Tao L, Dai H, Gong X, Zhuo Y, Xiang H, Zhao Y, Gao Q, Deng L.
    • Front Oncol. 2021 Oct 28;11:718871. doi: 10.3389/fonc.2021.718871.
    • Targeted Therapeutic Strategies for Triple-Negative Breast Cancer.
    • Li Y, Zhan Z, Yin X, Fu S, Deng X.
    • Front Oncol. 2021 Oct 28;11:731535. doi: 10.3389/fonc.2021.731535.
    • PARP Inhibitors in Combination with Radiotherapy: To Do or Not to Do?
    • Barcellini A, Loap P, Murata K, Villa R, Kirova Y, Okonogi N, Orlandi E.
    • Cancers (Basel). 2021 Oct 27;13(21):5380. doi: 10.3390/cancers13215380.
    • The role of patient-derived ovarian cancer organoids in the study of PARP inhibitors sensitivity and resistance: from genomic analysis to functional testing.
    • Tao M, Wu X.
    • J Exp Clin Cancer Res. 2021 Oct 26;40(1):338. doi: 10.1186/s13046-021-02139-7.
    • PARP Inhibition in Prostate Cancer With Homologous Recombination Repair Alterations.
    • von Werdt A, Brandt L, Schärer OD, Rubin MA.
    • JCO Precis Oncol. 2021 Oct 22;5:PO.21.00152. doi: 10.1200/PO.21.00152.
    • Role of PARP in TNBC: Mechanism of Inhibition, Clinical Applications, and Resistance.
    • Singh DD, Parveen A, Yadav DK.
    • Biomedicines. 2021 Oct 21;9(11):1512. doi: 10.3390/biomedicines9111512.
    • Emergence of polyclonal BRCA2 reversions following PARP inhibitor treatment: An illustrative case report.
    • McFarland TR, Tandar CE, Agarwal N, Swami U.
    • Cancer Treat Res Commun. 2021;29:100480. doi: 10.1016/j.ctarc.2021.100480. Epub 2021 Oct 20.
    • First successful case of platinum-based chemotherapy for neuroendocrine prostate cancer with BRCA2 and PTEN alterations.
    • Omura M, Kosaka T, Aimono E, Nakamura K, Hongo H, Mikami S, Nishihara H, Oya M.
    • IJU Case Rep. 2021 Oct 20;5(1):41-44. doi: 10.1002/iju5.12383.
    • Replication catastrophe is responsible for intrinsic PAR glycohydrolase inhibitor-sensitivity in patient-derived ovarian cancer models.
    • Coulson-Gilmer C, Morgan RD, Nelson L, Barnes BM, Tighe A, Wardenaar R, Spierings DCJ, Schlecht H, Burghel GJ, Foijer F, Desai S, McGrail JC, Taylor SS.
    • J Exp Clin Cancer Res. 2021 Oct 16;40(1):323. doi: 10.1186/s13046-021-02124-0.
    • Comparative Assessment of Diagnostic Homologous Recombination Deficiency-Associated Mutational Signatures in Ovarian Cancer.
    • Sztupinszki Z, Diossy M, Börcsök J, Prosz A, Cornelius N, Kjeldsen MK, Mirza MR, Szallasi Z.
    • Clin Cancer Res. 2021 Oct 15;27(20):5681-5687. doi: 10.1158/1078-0432.CCR-21-0981. Epub 2021 Aug 11.
    • Homologous Recombination Deficiency Assays in Epithelial Ovarian Cancer: Current Status and Future Direction.
    • Chiang YC, Lin PH, Cheng WF.
    • Front Oncol. 2021 Oct 14;11:675972. doi: 10.3389/fonc.2021.675972.
    • CRISPR screens guide the way for PARP and ATR inhibitors biomarker discovery.
    • Schleicher EM, Moldovan GL.
    • FEBS J. 2021 Oct 3. doi: 10.1111/febs.16217. Epub ahead of print.
    • Prognostic Significance of Disease Control at 12 Weeks in Patients With Advanced Pancreatic Cancer Receiving FOLFIRINOX as First-line Chemotherapy.
    • Batra A, Tang PA, Cheung WY.
    • Am J Clin Oncol. 2021 Oct 1;44(10):519-525. doi: 10.1097/COC.0000000000000856.
    • Alterations of DNA damage response pathway: Biomarker and therapeutic strategy for cancer immunotherapy.
    • Jiang M, Jia K, Wang L, Li W, Chen B, Liu Y, Wang H, Zhao S, He Y, Zhou C.
    • Acta Pharm Sin B. 2021 Oct;11(10):2983-2994. doi: 10.1016/j.apsb.2021.01.003. Epub 2021 Jan 6.
    • Treatment of Metastatic Castration-resistant Prostate Cancer: Are PARP Inhibitors Shifting the Paradigm?
    • Fujimoto N, Harada K, Shiota M, Tomisaki I, Minato A, Nagata Y, Kimuro R, Harada M, Fujisawa M.
    • Anticancer Res. 2021 Oct;41(10):4687-4695. doi: 10.21873/anticanres.15282.
    • Efficacy and safety of anti-PD-1-based therapy in combination with PARP inhibitors for patients with advanced solid tumors in a real-world setting.
    • Wu Z, Tao H, Zhang S, Wang X, Ma J, Li R, Liu Z, Wang J, Cui P, Chen S, Di H, Huang Z, Zheng X, Hu Y.
    • Cancer Immunol Immunother. 2021 Oct;70(10):2971-2980. doi: 10.1007/s00262-021-02852-4. Epub 2021 Mar 19.
    • Immune checkpoint inhibitor sensitivity of DNA repair deficient tumors.
    • Rochefort P, Desseigne F, Bonadona V, Dussart S, Coutzac C, Sarabi M, la Fouchardiere C.
    • Immunotherapy. 2021 Oct;13(14):1205-1213. doi: 10.2217/imt-2021-0024. Epub 2021 Sep 8.
    • Review
    • Discovery of MTR-106 as a highly potent G-quadruplex stabilizer for treating BRCA-deficient cancers.
    • Li MZ, Meng T, Song SS, Bao XB, Ma LP, Zhang N, Yu T, Zhang YL, Xiong B, Shen JK, Miao ZH, He JX.
    • Invest New Drugs. 2021 Oct;39(5):1213-1221. doi: 10.1007/s10637-021-01096-4. Epub 2021 Mar 12.
    • Pancreatic Acinar Cell Carcinoma with Germline BRCA2 Mutation and Severe Pancreatic Panniculitis: A Case Report.
    • Dreikhausen L, Schulte N, Belle S, Weidner P, Moersdorf J, Reissfelder C, Ebert MP, Zhan T.
    • Visc Med. 2021 Oct;37(5):447-450. doi: 10.1159/000515267. Epub 2021 Mar 29.
    • Case report
    • Study: Genetic testing for inherited mutations may be helpful for all people with advanced or metastatic cancer.
    • [No author given]
    • FORCE. XRAY. 2021 Sep 30.

    Related:

    Original research:

    Therapeutic Implications of Germline Testing in Patients With Advanced Cancers.

    • Poly(ADP-Ribose) Polymerase-1 Inhibitors Drug Discovery, Design, and Development as Anticancer Agents from Past to Present: A Mini-Review.
    • AlGhamdi A, AlMubayedh H.
    • Mini Rev Med Chem. 2021 Sep 29. doi: 10.2174/1389557521666210929144045. Epub ahead of print.
    • Review
    • Towards a CRISPeR understanding of homologous recombination with high-throughput functional genomics.
    • Hayward SB, Ciccia A.
    • Curr Opin Genet Dev. 2021 Sep 25;71:171-181. doi: 10.1016/j.gde.2021.08.006. Epub ahead of print.
    • Review
    • Active Targeted Nanoparticles for Delivery of Poly(ADP-ribose) Polymerase (PARP) Inhibitors: A Preliminary Review.
    • Sargazi S, Mukhtar M, Rahdar A, Barani M, Pandey S, Díez-Pascual AM.
    • Int J Mol Sci. 2021 Sep 25;22(19):10319. doi: 10.3390/ijms221910319.
    • Harnessing DNA Repair Defects to Augment Immune-Based Therapies in Triple-Negative Breast Cancer.
    • Clark CA, Yang ES.
    • Front Oncol. 2021 Sep 24;11:703802. doi: 10.3389/fonc.2021.703802.
    • Let-7i Reduces Aggressive Phenotype and Induces BRCAness in Ovarian Cancer Cells.
    • Chirshev E, Suzuki T, Wang H, Nguyen A, Hojo N, Sanderman L, Mirshahidi S, Ioffe YJ, Unternaehrer JJ.
    • Cancers (Basel). 2021 Sep 15;13(18):4617. doi: 10.3390/cancers13184617.
    • Phase 1b dose expansion and translational analyses of olaparib in combination with capivasertib in recurrent endometrial, triple negative breast, and ovarian cancer.
    • Westin SN, Labrie M, Litton JK, Blucher A, Fang Y, Vellano CP, Marszalek JR, Feng N, Ma X, Creason A, Fellman B, Yuan Y, Lee S, Kim T, Liu J, Chelariu-Raicu A, Chen TH, Kabil N, Soliman PT, Frumovitz M, Schmeler KM, Jazaeri A, Lu KH, Murthy R, Meyer L, Sun C, Sood AK, Coleman RL, Mills GB.
    • Clin Cancer Res. 2021 Sep 13:clincanres.1656.2021. doi: 10.1158/1078-0432.CCR-21-1656. Epub ahead of print.
    • Genomic Determinants of Homologous Recombination Deficiency across Human Cancers.
    • Qing T, Wang X, Jun T, Ding L, Pusztai L, Huang KL.
    • Cancers (Basel). 2021 Sep 12;13(18):4572. doi: 10.3390/cancers13184572.
    • The prevalence of homologous recombination deficiency (HRD) in various solid tumors and the role of HRD as a single biomarker to immune checkpoint inhibitors.
    • Kim H, Ahn S, Kim H, Hong JY, Lee J, Park SH, Park JO, Park YS, Lim HY, Kang WK, Kim KM, Kim ST.
    • J Cancer Res Clin Oncol. 2021 Sep 12. doi: 10.1007/s00432-021-03781-6. Epub ahead of print.
    • REV1-Polζ maintains the viability of homologous recombination-deficient cancer cells through mutagenic repair of PRIMPOL-dependent ssDNA gaps.
    • Taglialatela A, Leuzzi G, Sannino V, Cuella-Martin R, Huang JW, Wu-Baer F, Baer R, Costanzo V, Ciccia A.
    • Mol Cell. 2021 Sep 7:S1097-2765(21)00683-3. doi: 10.1016/j.molcel.2021.08.016. Epub ahead of print.
    • Successful treatment of refractory lung adenocarcinoma harboring a germline BRCA2 mutation with olaparib: A case report.
    • Zhang L, Wang J, Cui LZ, Wang K, Yuan MM, Chen RR, Zhang LJ.
    • World J Clin Cases. 2021 Sep 6;9(25):7498-7503. doi: 10.12998/wjcc.v9.i25.7498.
    • Patients with bi-allelic BRCA1/2 inactivation respond to olaparib treatment across histologic tumor types.
    • van der Wijngaart H, Hoes LR, van Berge Henegouwen JM, van der Velden DL, Zeverijn LJ, Roepman P, van Werkhoven E, de Leng WWJ, Jansen AML, Mehra N, Robbrecht DGJ, Labots M, de Groot DJA, Hoeben A, Hamberg P, Gelderblom H, Voest EE, Verheul HMW.
    • Clin Cancer Res. 2021 Sep 2:clincanres.1104.2021. doi: 10.1158/1078-0432.CCR-21-1104. Epub ahead of print.
    • The trans cell cycle effects of PARP inhibitors underlie their selectivity toward BRCA1/2-deficient cells.
    • Simoneau A, Xiong R, Zou L.
    • Genes Dev. 2021 Sep 1;35(17-18):1271-1289. doi: 10.1101/gad.348479.121. Epub 2021 Aug 12.
    • Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic Implications.
    • Moretto R, Elliott A, Zhang J, Arai H, Germani MM, Conca V, Xiu J, Stafford P, Oberley M, Abraham J, Spetzler D, Rossini D, Antoniotti C, Marshall J, Shields A, Lopes G, Lonardi S, Pietrantonio F, Tomasello G, Passardi A, Tamburini E, Santini D, Aprile G, Masi G, Falcone A, Lenz HJ, Korn M, Cremolini C.
    • J Natl Cancer Inst. 2021 Sep 1:djab169. doi: 10.1093/jnci/djab169. Epub ahead of print.

    Related:

    Research news:

    Are Homologous Recombination Deficiency Mutations Relevant in Colorectal Cancer?

    • Olaparib effectively treats local recurrence of extrahepatic cholangiocarcinoma in a patient harboring a BRCA2-inactivating mutation: a case report.
    • Li W, Ma Z, Fu X, Hao Z, Shang H, Shi J, Lei M, Xu M, Ning S, Hua X.
    • Ann Transl Med. 2021 Sep;9(18):1487. doi: 10.21037/atm-21-3681.
    • Hedgehog/GLI1 Transcriptionally Regulates FANCD2 in Ovarian Tumor Cells: Its Inhibition Induces HR-Deficiency and Synergistic Lethality with PARP Inhibition.
    • Mani C, Tripathi K, Chaudhary S, Somasagara RR, Rocconi RP, Crasto C, Reedy M, Athar M, Palle K.
    • Neoplasia. 2021 Sep;23(9):1002-1015. doi: 10.1016/j.neo.2021.06.010. Epub 2021 Aug 8.
    • Selinexor, a selective inhibitor of nuclear export, enhances the anti-tumor activity of olaparib in triple negative breast cancer regardless of BRCA1 mutation status.
    • Marijon H, Gery S, Chang H, Landesman Y, Shacham S, Lee DH, de Gramont A, Koeffler HP.
    • Oncotarget. 2021 Aug 31;12(18):1749-1762. doi: 10.18632/oncotarget.28047.
    • G-quadruplex DNA: a novel target for drug design.
    • Teng FY, Jiang ZZ, Guo M, Tan XZ, Chen F, Xi XG, Xu Y.
    • Cell Mol Life Sci. 2021 Aug 30. doi: 10.1007/s00018-021-03921-8. Epub ahead of print.
    • Review
    • Copper-Mediated Radiosynthesis of [18F]Rucaparib.
    • Chen Z, Destro G, Guibbal F, Chan CY, Cornelissen B, Gouverneur V.
    • Org Lett. 2021 Aug 30. doi: 10.1021/acs.orglett.1c02770. Epub ahead of print.
    • Discovery of First-in-Class Dual PARP and EZH2 Inhibitors for Triple-Negative Breast Cancer with Wild-Type BRCA.
    • Wang C, Qu L, Li S, Yin F, Ji L, Peng W, Luo H, Lu D, Liu X, Chen X, Kong L, Wang X.
    • J Med Chem. 2021 Aug 29. doi: 10.1021/acs.jmedchem.1c00567. Epub ahead of print.
    • Cytotoxic and targeted therapy for BRCA1/2-driven cancers.
    • Imyanitov EN.
    • Hered Cancer Clin Pract. 2021 Aug 28;19(1):36. doi: 10.1186/s13053-021-00193-y.
    • Uncovering cancer vulnerabilities by machine learning prediction of synthetic lethality.
    • Benfatto S, Serçin Ö, Dejure FR, Abdollahi A, Zenke FT, Mardin BR.
    • Mol Cancer. 2021 Aug 28;20(1):111. doi: 10.1186/s12943-021-01405-8.
    • Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity.
    • Cindy Yang SY, Lien SC, Wang BX, Clouthier DL, Hanna Y, Cirlan I, Zhu K, Bruce JP, El Ghamrasni S, Iafolla MAJ, Oliva M, Hansen AR, Spreafico A, Bedard PL, Lheureux S, Razak A, Speers V, Berman HK, Aleshin A, Haibe-Kains B, Brooks DG, McGaha TL, Butler MO, Bratman SV, Ohashi PS, Siu LL, Pugh TJ.
    • Nat Commun. 2021 Aug 26;12(1):5137. doi: 10.1038/s41467-021-25432-7.
    • Targeting DNA Damage Repair Mechanisms in Pancreas Cancer.
    • Perkhofer L, Golan T, Cuyle PJ, Matysiak-Budnik T, Van Laethem JL, Macarulla T, Cauchin E, Kleger A, Beutel AK, Gout J, Stenzinger A, Van Cutsem E, Bellmunt J, Hammel P, O'Reilly EM, Seufferlein T.
    • Cancers (Basel). 2021 Aug 24;13(17):4259. doi: 10.3390/cancers13174259.
    • Multitumor Case Series of Germline BRCA1, BRCA2 and CHEK2-Mutated Patients Responding Favorably on Immune Checkpoint Inhibitors.
    • Kinget L, Bechter O, Punie K, Debruyne PR, Brems H, Clement P, Roussel E, Van Herck Y, Albersen M, Baldewijns M, Schöffski P, Beuselinck B.
    • Curr Oncol. 2021 Aug 24;28(5):3227-3239. doi: 10.3390/curroncol28050280.
    • A novel germline BRCA2 mutation in a Chinese patient with prostate cancer sensitive to platinum chemotherapy: a case report.
    • Jiang L, Bai Z, Zhu S, Zhao T, Yang Y, Li Z, Chen D, Wu Z, Wang Y, Zhou F, Li Y.
    • BMC Urol. 2021 Aug 23;21(1):114. doi: 10.1186/s12894-021-00879-4.
    • RE: Endometrial Cancer Risk in Women with Germline BRCA1 or BRCA2 Mutations: Multicenter Cohort Study.
    • Nahshon C, Lavie O.
    • J Natl Cancer Inst. 2021 Aug 23:djab154. doi: 10.1093/jnci/djab154. Epub ahead of print.

    Related:

    Letter, Reply:

    Response to Nahshon and Lavie.

    Original research:

    Endometrial Cancer Risk in Women with Germline BRCA1 or BRCA2 Mutations: Multicenter Cohort Study.

    • Genetic Variants and Tumor Immune Microenvironment: Clues for Targeted Therapies in Inflammatory Breast Cancer (IBC).
    • Gong Y, Nagarathinam R, Arisi MF, Gerratana L, Winn JS, Slifker M, Pei J, Cai KQ, Hasse Z, Obeid E, Noriega J, Sebastiano C, Ross E, Alpaugh K, Cristofanilli M, Fernandez SV.
    • Int J Mol Sci. 2021 Aug 19;22(16):8924. doi: 10.3390/ijms22168924.
    • Discovery of Novel Apigenin-Piperazine Hybrids as Potent and Selective Poly (ADP-Ribose) Polymerase-1 (PARP-1) Inhibitors for the Treatment of Cancer.
    • Long H, Hu X, Wang B, Wang Q, Wang R, Liu S, Xiong F, Jiang Z, Zhang XQ, Ye WC, Wang H.
    • J Med Chem. 2021 Aug 18. doi: 10.1021/acs.jmedchem.1c00735. Epub ahead of print.
    • Targeting DNA damage repair pathways in pancreas cancer.
    • Crowley F, Park W, O'Reilly EM.
    • Cancer Metastasis Rev. 2021 Aug 17. doi: 10.1007/s10555-021-09983-1. Epub ahead of print.
    • Review
    • Recent Advances in Enhancing the Therapeutic Index of PARP Inhibitors in Breast Cancer.
    • Franchet C, Hoffmann JS, Dalenc F.
    • Cancers (Basel). 2021 Aug 17;13(16):4132. doi: 10.3390/cancers13164132.
    • Therapeutic Potential of PARP Inhibitors in the Treatment of Gastrointestinal Cancers.
    • Alhusaini A, Cannon A, Maher SG, Reynolds JV, Lynam-Lennon N.
    • Biomedicines. 2021 Aug 16;9(8):1024. doi: 10.3390/biomedicines9081024.
    • BRCAness as a Biomarker of Susceptibility to PARP Inhibitors in Glioblastoma Multiforme.
    • Xavier MA, Rezende F, Titze-de-Almeida R, Cornelissen B.
    • Biomolecules. 2021 Aug 11;11(8):1188. doi: 10.3390/biom11081188.
    • Utility of Homologous Recombination Deficiency Biomarkers Across Cancer Types.
    • Takamatsu S, Brown JB, Yamaguchi K, Hamanishi J, Yamanoi K, Takaya H, Kaneyasu T, Mori S, Mandai M, Matsumura N.
    • JCO Precis Oncol. 2021 Aug 11;5:PO.21.00141. doi: 10.1200/PO.21.00141.
    • The Fanconi anemia pathway and Breast Cancer: A comprehensive review of clinical data.
    • Gianni P, Matenoglou E, Geropoulos G, Agrawal N, Adnani H, Zafeiropoulos S, Miyara SJ, Guevara S, Mumford JM, Molmenti EP, Giannis D.
    • Clin Breast Cancer. 2021 Aug 10:S1526-8209(21)00238-X. doi: 10.1016/j.clbc.2021.08.001. Epub ahead of print.
    • Review
    • Revealing biomarkers associated with PARP inhibitors based on genetic interactions in cancer genome.
    • Dong Q, Liu M, Chen B, Zhao Z, Chen T, Wang C, Zhuang S, Li Y, Wang Y, Ai L, Liu Y, Liang H, Qi L, Gu Y.
    • Comput Struct Biotechnol J. 2021 Aug 10;19:4435-4446. doi: 10.1016/j.csbj.2021.08.007.
    • Guardians of the Genome: BRCA2 and Its Partners.
    • Le HP, Heyer WD, Liu J.
    • Genes (Basel). 2021 Aug 10;12(8):1229. doi: 10.3390/genes12081229.
    • Anticancer activity of RAPTA-EA1 in triple-negative BRCA1 proficient breast cancer cells: single and combined treatment with the PARP inhibitor olaparib.
    • Hongthong K, Nhukeaw T, Temboot P, Dyson PJ, Ratanaphan A.
    • Heliyon. 2021 Aug 10;7(8):e07749. doi: 10.1016/j.heliyon.2021.e07749.
    • Subclone eradication analysis identifies targets for enhanced cancer therapy and reveals L1 retrotransposition as a dynamic source of cancer heterogeneity.
    • Ketola K, Kaljunen H, Taavitsainen S, Kaarijärvi R, Järvelä E, Rodriguez Martin B, Haase K, Woodcock DJ, Tubio J, Wedge DC, Nykter M, Bova GS.
    • Cancer Res. 2021 Aug 4:canres.0371.2021. doi: 10.1158/0008-5472.CAN-21-0371. Epub ahead of print.
    • Burning Rock Biotech, Impact Therapeutics Partner on CDx for PARP Inhibitor Senaparib.
    • [No author given]
    • GenomeWeb. Disease Areas. Cancer. 2021 Aug 3.
    • Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in BRCA1, BRCA2, or PALB2.
    • Reiss KA, Mick R, O'Hara MH, Teitelbaum U, Karasic TB, Schneider C, Cowden S, Southwell T, Romeo J, Izgur N, Hannan ZM, Tondon R, Nathanson K, Vonderheide RH, Wattenberg MM, Beatty G, Domchek SM.
    • J Clin Oncol. 2021 Aug 1;39(22):2497-2505. doi: 10.1200/JCO.21.00003. Epub 2021 May 10.

    Related:

    Research news: Clovis' Rubraca Benefits BRCA1/2, PALB2-Mutated Pancreatic Cancer Patients as Maintenance Therapy. (Precision Oncology News)

    • PARP inhibitor olaparib has a potential to increase the effectiveness of electrochemotherapy in BRCA1 mutated breast cancer in mice.
    • Bosnjak M, Jesenko T, Markelc B, Janzic L, Cemazar M, Sersa G.
    • Bioelectrochemistry. 2021 Aug;140:107832. doi: 10.1016/j.bioelechem.2021.107832. Epub 2021 May 1. Erratum in: Bioelectrochemistry. 2021 Oct;141:107865.
    • Risk of pneumonitis in cancer patients treated with PARP inhibitors: A meta-analysis of randomized controlled trials and a pharmacovigilance study of the FAERS database.
    • Ma Z, Sun X, Zhao Z, Lu W, Guo Q, Wang S, You J, Zhang Y, Liu L.
    • Gynecol Oncol. 2021 Aug;162(2):496-505. doi: 10.1016/j.ygyno.2021.05.012. Epub 2021 May 19.
    • Meta-Analysis
    • Increased chemosensitivity via BRCA2-independent DNA damage in DSS1- and PCID2-depleted breast carcinomas.
    • Gondo N, Sakai Y, Zhang Z, Hato Y, Kuzushima K, Phimsen S, Kawashima Y, Kuroda M, Suzuki M, Okada S, Iwata H, Toyama T, Rezano A, Kuwahara K.
    • Lab Invest. 2021 Aug;101(8):1048-1059. doi: 10.1038/s41374-021-00613-6. Epub 2021 May 24.

    Related:

    •• Original research:

    Increased chemosensitivity via BRCA2-independent DNA damage in DSS1- and PCID2-depleted breast carcinomas.

    • Genetic Contribution to Metastatic Prostate Cancer.
    • Sokolova AO, Obeid EI, Cheng HH.
    • Urol Clin North Am. 2021 Aug;48(3):349-363. doi: 10.1016/j.ucl.2021.03.005. Epub 2021 Jun 10.
    • Review
    • Genetically Informed Prostate Cancer Treatment for Metastatic Disease.
    • Siebert AL, Szymaniak BM, Numan Y, Morgans AK.
    • Urol Clin North Am. 2021 Aug;48(3):365-371. doi: 10.1016/j.ucl.2021.03.006. Epub 2021 Jun 10.
    • Review
    • Olaparib in combination with pegylated liposomal doxorubicin for platinum-resistant ovarian cancer regardless of BRCA status: a GEICO phase II trial (ROLANDO study).
    • Perez-Fidalgo JA, Cortés A, Guerra E, García Y, Iglesias M, Bohn Sarmiento U, Calvo García E, Manso Sánchez L, Santaballa A, Oaknin A, Redondo A, Rubio MJ, González-Martín A.
    • ESMO Open. 2021 Jul 27;6(4):100212. doi: 10.1016/j.esmoop.2021.100212. Epub ahead of print.
    • Untangling Triple-Negative Breast Cancer Molecular Peculiarity and Chemo-Resistance: Trailing Towards Marker-Based Targeted Therapies.
    • Kanwal B.
    • Cureus. 2021 Jul 26;13(7):e16636. doi: 10.7759/cureus.16636.
    • Mechanisms of acquired resistance of BRCA1/2-driven tumors to platinum compounds and PARP inhibitors.
    • Imyanitov E, Sokolenko A.
    • World J Clin Oncol. 2021 Jul 24;12(7):544-556. doi: 10.5306/wjco.v12.i7.544.
    • BRCA mutations and gastrointestinal cancers: When to expect the unexpected?
    • Maccaroni E, Giampieri R, Lenci E, Scortichini L, Bianchi F, Belvederesi L, Brugiati C, Pagliaretta S, Ambrosini E, Berardi R.
    • World J Clin Oncol. 2021 Jul 24;12(7):565-580. doi: 10.5306/wjco.v12.i7.565.
    • Analysis of Adaptive Olaparib Resistance Effects on Cisplatin Sensitivity in Triple Negative Breast Cancer Cells.
    • Gajan A, Sarma A, Kim S, Gurdziel K, Wu GS, Shekhar MP.
    • Front Oncol. 2021 Jul 22;11:694793. doi: 10.3389/fonc.2021.694793.
    • Opportunities for Utilization of DNA Repair Inhibitors in Homologous Recombination Repair-Deficient and Proficient Pancreatic Adenocarcinoma.
    • Cleary JM, Wolpin BM, Dougan SK, Raghavan S, Singh H, Huffman B, Sethi NS, Nowak JA, Shapiro GI, Aguirre AJ, D'Andrea AD.
    • Clin Cancer Res. 2021 Jul 20:clincanres.1367.2021. doi: 10.1158/1078-0432.CCR-21-1367. Epub ahead of print.
    • Review
    • Development of PARP inhibitor combinations for castration resistant prostate cancer unselected for homologous recombination repair mutations.
    • McFarland TR, Kessel A, Swami U, Agarwal N.
    • Am J Transl Res. 2021 Jul 15;13(7):7427-7439.
    • PARP inhibitors in advanced prostate cancer: when to use them?
    • Díaz-Mejía N, García-Illescas D, Morales-Barrera R, Suarez C, Planas J, Maldonado X, Carles J, Mateo J.
    • Endocr Relat Cancer. 2021 Jul 15;28(8):T79-T93. doi: 10.1530/ERC-21-0133.
    • Investigational Drug Treatments for Triple-Negative Breast Cancer.
    • Damaskos C, Garmpis N, Garmpi A, Nikolettos K, Sarantis P, Georgakopoulou VE, Nonni A, Schizas D, Antoniou EA, Karamouzis MV, Nikolettos N, Kontzoglou K, Patsouras A, Voutyritsa E, Syllaios A, Koustas E, Trakas N, Dimitroulis D.
    • J Pers Med. 2021 Jul 10;11(7):652. doi: 10.3390/jpm11070652.
    • Suppression of DNA Polymerase ß Activity Is Synthetically Lethal in BRCA1-Deficient Cells.
    • Yuhas SC, Mishra A, DeWeese TL, Greenberg MM.
    • ACS Chem Biol. 2021 Jul 9. doi: 10.1021/acschembio.1c00385. Epub ahead of print.
    • Exploiting DNA Damage Repair in Precision Cancer Therapy: BRCA1 as a Prime Therapeutic Target.
    • Raimundo L, Calheiros J, Saraiva L.
    • Cancers (Basel). 2021 Jul 9;13(14):3438. doi: 10.3390/cancers13143438.
    • Cost-effectiveness analysis of olaparib and niraparib as maintenance therapy for women with recurrent platinum-sensitive ovarian cancer.
    • Leung JH, Lang HC, Wang SY, Lo HF, Chan AL.
    • Expert Rev Pharmacoecon Outcomes Res. 2021 Jul 9. doi: 10.1080/14737167.2021.1954506. Epub ahead of print.
    • Drug Desensitizations for Chemotherapy: Safety and Efficacy in Preventing Anaphylaxis.
    • Caiado J, Castells MC.
    • Curr Allergy Asthma Rep. 2021 Jul 7;21(6):37. doi: 10.1007/s11882-021-01014-x.
    • Review
    • Dual PARP and RAD51 Inhibitory Drug Conjugates Show Synergistic and Selective Effects on Breast Cancer Cells.
    • Malka MM, Eberle J, Niedermayer K, Zlotos DP, Wiesmüller L.
    • Biomolecules. 2021 Jul 3;11(7):981. doi: 10.3390/biom11070981.
    • Design, Synthesis and Activity Evaluation of New Phthalazinone PARP Inhibitors.
    • Huang M, Ren J, Wang Y, Chen X, Yang J, Tang T, Yang Z, Li X, Ji M, Cai J.
    • Chem Pharm Bull (Tokyo). 2021 [Jul 1];69(7):620-629. doi: 10.1248/cpb.c20-01018.
    • Identifying patients eligible for PARP inhibitor treatment: from NGS-based tests to 3D functional assays.
    • Morice PM, Coquan E, Weiswald LB, Lambert B, Vaur D, Poulain L.
    • Br J Cancer. 2021 Jul;125(1):7-14. doi: 10.1038/s41416-021-01295-z. Epub 2021 Mar 25.
    • Commentary, Review
    • Precision medicine in breast cancer: From clinical trials to clinical practice.
    • Crimini E, Repetto M, Aftimos P, Botticelli A, Marchetti P, Curigliano G.
    • Cancer Treat Rev. 2021 Jul;98:102223. doi: 10.1016/j.ctrv.2021.102223. Epub 2021 May 12.
    • Review
    • Pamiparib: First Approval.
    • Markham A.
    • Drugs. 2021 Jul;81(11):1343-1348. doi: 10.1007/s40265-021-01552-8.
    • Review
    • Entinostat, a selective HDAC1/2 inhibitor, potentiates the effects of olaparib in homologous recombination proficient ovarian cancer.
    • Gupta VG, Hirst J, Petersen S, Roby KF, Kusch M, Zhou H, Clive ML, Jewell A, Pathak HB, Godwin AK, Wilson AJ, Crispens MA, Cybulla E, Vindigni A, Fuh KC, Khabele D.
    • Gynecol Oncol. 2021 Jul;162(1):163-172. doi: 10.1016/j.ygyno.2021.04.015. Epub 2021 Apr 16.
    • Defizienz der homologen Rekombinationsreparatur als prädiktiver Marker : Grundlagen und Nachweis [Homologous recombination repair deficiency as a predictive biomarker : Basic mechanisms and detection methods].
    • Pfarr N, Merkelbach-Bruse S.
    • Pathologe. 2021 Jul;42(4):391-398. German. doi: 10.1007/s00292-021-00950-9. Epub 2021 Jun 21.
    • Review, Article in German
    • Remarkable Response to Olaparib in a Patient with Combined Hepatocellular-Cholangiocarcinoma Harboring a Biallelic BRCA2 Mutation.
    • Su YL, Ng CT, Jan YH, Hsieh YL, Wu CL, Tan KT.
    • Onco Targets Ther. 2021 Jun 29;14:3895-3901. doi: 10.2147/OTT.S317514.
    • Biomarkers for Homologous Recombination Deficiency in Cancer.
    • Wagener-Ryczek S, Merkelbach-Bruse S, Siemanowski J.
    • J Pers Med. 2021 Jun 28;11(7):612. doi: 10.3390/jpm11070612.
    • Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency.
    • Cong K, Peng M, Kousholt AN, Lee WTC, Lee S, Nayak S, Krais J, VanderVere-Carozza PS, Pawelczak KS, Calvo J, Panzarino NJ, Jonkers J, Johnson N, Turchi JJ, Rothenberg E, Cantor SB.
    • Mol Cell. 2021 Jun 26:S1097-2765(21)00458-5. doi: 10.1016/j.molcel.2021.06.011. Epub ahead of print.
    • Chinese Regulators Approve Lynparza for BRCA1/2-Mutated mCRPC.
    • [No author given]
    • Precision Oncology News. Biomarkers. BRCA. 2021 Jun 24.
    • Pfizer Studying Talzenna in Advanced Prostate Cancer Patients With DNA Damage Response Gene Defects.
    • [No author given]
    • Precision Oncology News. Cancer Specialties. Prostate Cancer. 2021 Jun 23.
    • An Algorithm Combining Patient Performance Status, Second Hit Analysis, PROVEAN and Dann Prediction Tools Could Foretell Sensitization to PARP Inhibitors in Digestive, Skin, Ovarian and Breast Cancers.
    • Chevrier S, Richard C, Collot T, Mananet H, Arnould L, Boidot R.
    • Cancers (Basel). 2021 Jun 22;13(13):3113. doi: 10.3390/cancers13133113.
    • The evolving role of germline genetic testing and management in prostate cancer: Report from the Princess Margaret Cancer Centre International Retreat.
    • Clark R, Kenk M, McAlpine K, Thain E, Farncombe KM, Pritchard CC, Nussbaum R, Wyatt AW, de Bono J, Vesprini D, Bombard Y, Lorentz J, Narod S, Kim R, Fleshner N.
    • Can Urol Assoc J. 2021 Jun 22. doi: 10.5489/cuaj.7383. Epub ahead of print.
    • Synthesis and evaluation of 2-(4-[4-acetylpiperazine-1-carbonyl] phenyl)-1H-benzo[d]imidazole-4-carboxamide derivatives as potential PARP-1 inhibitors and preliminary study on structure-activity relationship.
    • Chen M, Huang H, Wu K, Liu Y, Jiang L, Li Y, Tang G, Peng J, Cao X.
    • Drug Dev Res. 2021 Jun 21. doi: 10.1002/ddr.21843. Epub ahead of print.
    • A karboplatin-kemoterápia hatékonysága egy áttétes, kasztrációrezisztens, BRCA2-mutáció-pozitív prosztatarákos betegben. [Efficacy of carboplatin chemotherapy in a metastatic, castration-resistant, BRCA2 mutation positive prostate cancer patient.]
    • Nagy ND, Fazekas T, Baghy K, Papp G, Csizmarik A, Szucs M, Nyirády P, Szarvas T.
    • Orv Hetil. 2021 Jun 20;162(25):1004-1008. doi: 10.1556/650.2021.32112.
    • A subset of lung cancer cases shows robust signs of homologous recombination deficiency associated genomic mutational signatures.
    • Diossy M, Sztupinszki Z, Borcsok J, Krzystanek M, Tisza V, Spisak S, Rusz O, Timar J, Csabai I, Fillinger J, Moldvay J, Pedersen AG, Szuts D, Szallasi Z.
    • NPJ Precis Oncol. 2021 Jun 18;5(1):55. doi: 10.1038/s41698-021-00199-8.
    • Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance.
    • Zatreanu D, Robinson HMR, Alkhatib O, Boursier M, Finch H, Geo L, Grande D, Grinkevich V, Heald RA, Langdon S, Majithiya J, McWhirter C, Martin NMB, Moore S, Neves J, Rajendra E, Ranzani M, Schaedler T, Stockley M, Wiggins K, Brough R, Sridhar S, Gulati A, Shao N, Badder LM, Novo D, Knight EG, Marlow R, Haider S, Callen E, Hewitt G, Schimmel J, Prevo R, Alli C, Ferdinand A, Bell C, Blencowe P, Bot C, Calder M, Charles M, Curry J, Ekwuru T, Ewings K, Krajewski W, MacDonald E, McCarron H, Pang L, Pedder C, Rigoreau L, Swarbrick M, Wheatley E, Willis S, Wong AC, Nussenzweig A, Tijsterman M, Tutt A, Boulton SJ, Higgins GS, Pettitt SJ, Smith GCM, Lord CJ.
    • Nat Commun. 2021 Jun 17;12(1):3636. doi: 10.1038/s41467-021-23463-8.
    • New RAD51 Inhibitors to Target Homologous Recombination in Human Cells.
    • Shkundina IS, Gall AA, Dick A, Cocklin S, Mazin AV.
    • Genes (Basel). 2021 Jun 16;12(6):920. doi: 10.3390/genes12060920.
    • Therapeutic Implications of Germline Testing in Patients With Advanced Cancers.
    • Stadler ZK, Maio A, Chakravarty D, Kemel Y, Sheehan M, Salo-Mullen E, Tkachuk K, Fong CJ, Nguyen B, Erakky A, Cadoo K, Liu Y, Carlo MI, Latham A, Zhang H, Kundra R, Smith S, Galle J, Aghajanian C, Abu-Rustum N, Varghese A, O'Reilly EM, Morris M, Abida W, Walsh M, Drilon A, Jayakumaran G, Zehir A, Ladanyi M, Ceyhan-Birsoy O, Solit DB, Schultz N, Berger MF, Mandelker D, Diaz LA Jr, Offit K, Robson ME.
    • J Clin Oncol. 2021 Jun 16:JCO2003661. doi: 10.1200/JCO.20.03661. Epub ahead of print.
    • The RAD51-FFPE Test; Calibration of a Functional Homologous Recombination Deficiency Test on Diagnostic Endometrial and Ovarian Tumor Blocks.
    • van Wijk LM, Kramer CJH, Vermeulen S, Ter Haar NT, de Jonge MM, Kroep JR, de Kroon CD, Gaarenstroom KN, Vrieling H, Bosse T, Vreeswijk MPG.
    • Cancers (Basel). 2021 Jun 15;13(12):2994. doi: 10.3390/cancers13122994.
    • Phase 1 Combination Study of the CHK1 inhibitor prexasertib, and the PARP inhibitor olaparib, in high-grade serous ovarian cancer and other solid tumors.
    • Do K, Kochupurakkal BS, Kelland S, de Jonge A, Hedglin J, Powers A, Quinn N, Gannon C, Vuong L, Parmar K, Lazaro JB, D'Andrea AD, Shapiro GI.
    • Clin Cancer Res. 2021 Jun 15:clincanres.1279.2021. doi: 10.1158/1078-0432.CCR-21-1279. Epub ahead of print.
    • Fuzuloparib: First Approval.
    • Lee A.
    • Drugs. 2021 Jun 12. doi: 10.1007/s40265-021-01541-x. Epub ahead of print.
    • Review
    • Regulation of RAD51 at the Transcriptional and Functional Levels: What Prospects for Cancer Therapy?
    • Orhan E, Velazquez C, Tabet I, Sardet C, Theillet C.
    • Cancers (Basel). 2021 Jun 11;13(12):2930. doi: 10.3390/cancers13122930.
    • Feasibility of BRCA1/2 Testing of Formalin-Fixed and Paraffin-Embedded Pancreatic Tumor Samples: A Consecutive Clinical Series.
    • Bruno R, Sensi E, Lupi C, Giordano M, Bernardini L, Vivaldi C, Fornaro L, Vasile E, Campani D, Fontanini G.
    • Diagnostics (Basel). 2021 Jun 7;11(6):1046. doi: 10.3390/diagnostics11061046.
    • Progression-free survival by investigator versus blinded independent central review in newly diagnosed patients with high-grade serous ovarian cancer: Analysis of the VELIA/GOG-3005 trial.
    • Aghajanian C, Bookman MA, Fleming GF, Swisher EM, Steffensen KD, Friedlander M, Okamoto A, Jackson CG, Sullivan D, Ratajczak CK, Coleman RL.
    • Gynecol Oncol. 2021 Jun 7:S0090-8258(21)00437-6. doi: 10.1016/j.ygyno.2021.05.031. Epub ahead of print.
    • Precision Medicine in Oncology: A Review of Multi-Tumor Actionable Molecular Targets with an Emphasis on Non-Small Cell Lung Cancer.
    • Stein MK, Oluoha O, Patel K, VanderWalde A.
    • J Pers Med. 2021 Jun 5;11(6):518. doi: 10.3390/jpm11060518.
    • Platform study of genotyping-guided precision medicine for rare solid tumours: a study protocol for a phase II, non-randomised, 18-month, open-label, multiarm, single-centre clinical trial testing the safety and efficacy of multiple Chinese-approved targeted drugs and PD-1 inhibitors in the treatment of metastatic rare tumours.
    • Wang S, Huang HY, Wu D, Fang H, Ying J, Bai Y, Yu Y, Fang Y, Jiang N, Sun C, Yu A, Fan Q, Xing S, Ni Y, Zhang W, Wu C, Ji X, Wang H, Guo Y, Tang Q, Wang Y, Tang Y, Li N.
    • BMJ Open. 2021 Jun 3;11(6):e044543. doi: 10.1136/bmjopen-2020-044543.
    • PARP inhibitor treatment of advanced breast cancer beyond the BRCA-mutated type: a meta-analysis.
    • Yan F, Jiang Q, He M, Shen P.
    • Future Oncol. 2021 Jun;17(18):2381-2393. doi: 10.2217/fon-2020-1175. Epub 2021 Mar 31.
    • Incidence of myelodysplastic syndrome and acute myeloid leukemia in patients receiving poly-ADP ribose polymerase inhibitors for the treatment of solid tumors: A meta-analysis of randomized trials.
    • Nitecki R, Melamed A, Gockley AA, Floyd J, Krause KJ, Coleman RL, Matulonis UA, Giordano SH, Lu KH, Rauh-Hain JA.
    • Gynecol Oncol. 2021 Jun;161(3):653-659. doi: 10.1016/j.ygyno.2021.03.011. Epub 2021 Mar 15.
    • Mutational spectrum in clinically aggressive low-grade serous carcinoma/serous borderline tumors of the ovary-Clinical significance of BRCA2 gene variants in genomically stable tumors.
    • Zhang X, Devins K, Ko EM, Reyes MC, Simpkins F, Drapkin R, Schwartz LE, Yoon JY.
    • Gynecol Oncol. 2021 Jun;161(3):762-768. doi: 10.1016/j.ygyno.2021.03.019. Epub 2021 Mar 24.
    • Combined modality therapy including cytoreductive surgery and heated intraperitoneal chemotherapy for synchronous low volume peritoneal carcinomatosis from adenocarcinoma of the tail of pancreas in a BRCA-2 carrier resulting in long-term disease-free survival: A case report.
    • Hoefer RA, Obiora C, Azab B, Harden EA, Kessler JF.
    • Int J Surg Case Rep. 2021 Jun;83:106047. doi: 10.1016/j.ijscr.2021.106047. Epub 2021 May 29.
    • A first-in-class Polymerase Theta Inhibitor selectively targets Homologous-Recombination-Deficient Tumors.
    • Zhou J, Gelot C, Pantelidou C, Li A, Yücel H, Davis RE, Färkkilä A, Kochupurakkal B, Syed A, Shapiro GI, Tainer JA, Blagg BSJ, Ceccaldi R, D'Andrea AD.
    • Nat Cancer. 2021 Jun;2(6):598-610. doi: 10.1038/s43018-021-00203-x. Epub 2021 Jun 17.

    Related:

    Press: Old Antibiotic Targets BRCA-Mutated, PARP Inhibitor-Resistant Tumors (Clinical OMICs)

    • PARP inhibition promotes ferroptosis via repressing SLC7A11 and synergizes with ferroptosis inducers in BRCA-proficient ovarian cancer.
    • Hong T, Lei G, Chen X, Li H, Zhang X, Wu N, Zhao Y, Zhang Y, Wang J.
    • Redox Biol. 2021 Jun;42:101928. doi: 10.1016/j.redox.2021.101928. Epub 2021 Mar 5.
    • A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions.
    • Marhold M, Heinzel A, Merchant A, Perco P, Krainer M.
    • J Vis Exp. 2021 May 27;(171). doi: 10.3791/60328.
    • Breast Cancer Predisposition Genes and Synthetic Lethality.
    • Neiger HE, Siegler EL, Shi Y.
    • Int J Mol Sci. 2021 May 25;22(11):5614. doi: 10.3390/ijms22115614.
    • Ex vivo analysis of DNA repair targeting in extreme rare cutaneous apocrine sweat gland carcinoma.
    • Mäkelä R, Härmä V, Fajardo NB, Wells G, Lygerou Z, Sangfelt O, Kononen J, Rantala JK.
    • Oncotarget. 2021 May 25;12(11):1100-1109. doi: 10.18632/oncotarget.27961.
    • Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS).
    • Grivas P, Loriot Y, Morales-Barrera R, Teo MY, Zakharia Y, Feyerabend S, Vogelzang NJ, Grande E, Adra N, Alva A, Necchi A, Rodriguez-Vida A, Gupta S, Josephs DH, Srinivas S, Wride K, Thomas D, Simmons A, Loehr A, Dusek RL, Nepert D, Chowdhury S.
    • BMC Cancer. 2021 May 24;21(1):593. doi: 10.1186/s12885-021-08085-z.
    • BRCA Genetic Test and Risk-Reducing Salpingo-Oophorectomy for Hereditary Breast and Ovarian Cancer: State-of-the-Art.
    • Sekine M, Nishino K, Enomoto T.
    • Cancers (Basel). 2021 May 23;13(11):2562. doi: 10.3390/cancers13112562.
    • Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial.
    • Bertucci F, Gonçalves A, Guille A, Adelaïde J, Garnier S, Carbuccia N, Billon E, Finetti P, Sfumato P, Monneur A, Pécheux C, Khran M, Brunelle S, Mescam L, Thomassin-Piana J, Poizat F, Charafe-Jauffret E, Turrini O, Lambaudie E, Provansal M, Extra JM, Madroszyk A, Gilabert M, Sabatier R, Vicier C, Mamessier E, Chabannon C, Pakradouni J, Viens P, André F, Gravis G, Popovici C, Birnbaum D, Chaffanet M.
    • Genome Med. 2021 May 18;13(1):87. doi: 10.1186/s13073-021-00897-9.
    • Effect of cisplatin on metastatic castration-resistant prostate cancer with BRCA2 mutation: A case report.
    • Koguchi D, Tabata KI, Tsumura H, Mori K, Koh H, Iwamura M.
    • Urol Case Rep. 2021 May 17;38:101712. doi: 10.1016/j.eucr.2021.101712.
    • Heterogeneity and Clonal Evolution of Acquired PARP Inhibitor Resistance in TP53- and BRCA1-Deficient Cells.
    • Färkkilä A, Rodríguez A, Oikkonen J, Gulhan DC, Nguyen H, Domínguez J, Ramos S, Mills CE, Perez-Villatoro F, Lazaro JB, Zhou J, Clairmont CS, Moreau LA, Park PJ, Sorger PK, Hautaniemi S, Frias S, D'Andrea AD.
    • Cancer Res. 2021 May 15;81(10):2774-2787. doi: 10.1158/0008-5472.CAN-20-2912. Epub 2021 Jan 29.
    • DNA Damage Repair Inhibitor for Breast Cancer Treatment.
    • Min A, Lee KH, Im SA.
    • Adv Exp Med Biol. 2021 [First Online: 14 May 2021];1187:159-179. doi: 10.1007/978-981-32-9620-6_8.
    • Review, eBook chapter
    • The Role of PARP Inhibitors in the Treatment of Prostate Cancer: Recent Advances in Clinical Trials.
    • Xia M, Guo Z, Hu Z.
    • Biomolecules. 2021 May 12;11(5):722. doi: 10.3390/biom11050722.
    • The role of PARP inhibitors in BRCA mutated pancreatic cancer.
    • Chi J, Chung SY, Parakrama R, Fayyaz F, Jose J, Saif MW.
    • Therap Adv Gastroenterol. 2021 May 10;14:17562848211014818. doi: 10.1177/17562848211014818.
    • C/EBPß promotes poly(ADP-ribose) polymerase inhibitor resistance by enhancing homologous recombination repair in high-grade serous ovarian cancer.
    • Tan J, Zheng X, Li M, Ye F, Song C, Xu C, Zhang X, Li W, Wang Y, Zeng S, Li H, Chen G, Huang X, Ma D, Liu D, Gao Q.
    • Oncogene. 2021 May 8. doi: 10.1038/s41388-021-01788-4. Epub ahead of print.
    • Homologous Recombination Repair Deficiency and Implications for Tumor Immunogenicity.
    • van Wilpe S, Tolmeijer SH, Koornstra RHT, de Vries IJM, Gerritsen WR, Ligtenberg M, Mehra N.
    • Cancers (Basel). 2021 May 7;13(9):2249. doi: 10.3390/cancers13092249.
    • Discovery of novel and potent PARP/PI3K dual inhibitors for the treatment of cancer.
    • Wu Z, Bai Y, Jin J, Jiang T, Shen H, Ju Q, Zhu Q, Xu Y.
    • Eur J Med Chem. 2021 May 5;217:113357. doi: 10.1016/j.ejmech.2021.113357. Epub 2021 Mar 10.
    • Integrated support vector machine and pharmacophore based virtual screening driven identification of thiophene carboxamide scaffold containing compound as potential PARP1 inhibitor.
    • Singh M, Rajawat J, Kuldeep J, Shukla N, Mishra DP, Siddiqi MI.
    • J Biomol Struct Dyn. 2021 May 5:1-14. doi: 10.1080/07391102.2021.1913229. Epub ahead of print.
    • Detection of Molecular Signatures of Homologous Recombination Deficiency in Bladder Cancer.
    • Börcsök J, Diossy M, Sztupinski Z, Prosz A, Tisza V, Spisak S, Rusz O, Stormoen DR, Pappot H, Csabai I, Brunak S, Mouw KW, Szallasi Z.
    • Clin Cancer Res. 2021 May 4:clincanres.5037.2020. doi: 10.1158/1078-0432.CCR-20-5037. Epub ahead of print.
    • Evaluation of BRCA1 and BRCA2 as Indicators of Response to Immune Checkpoint Inhibitors.
    • Zhou Z, Li M.
    • JAMA Netw Open. 2021 May 3;4(5):e217728. doi: 10.1001/jamanetworkopen.2021.7728.
    • Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2).
    • Swisher EM, Kwan TT, Oza AM, Tinker AV, Ray-Coquard I, Oaknin A, Coleman RL, Aghajanian C, Konecny GE, O'Malley DM, Leary A, Provencher D, Welch S, Chen LM, Wahner Hendrickson AE, Ma L, Ghatage P, Kristeleit RS, Dorigo O, Musafer A, Kaufmann SH, Elvin JA, Lin DI, Chambers SK, Dominy E, Vo LT, Goble S, Maloney L, Giordano H, Harding T, Dobrovic A, Scott CL, Lin KK, McNeish IA.
    • Nat Commun. 2021 May 3;12(1):2487. doi: 10.1038/s41467-021-22582-6.
    • Olaparib Monotherapy for Previously Treated Pancreatic Cancer With DNA Damage Repair Genetic Alterations Other Than Germline BRCA Variants: Findings From 2 Phase 2 Nonrandomized Clinical Trials.
    • Javle M, Shacham-Shmueli E, Xiao L, Varadhachary G, Halpern N, Fogelman D, Boursi B, Uruba S, Margalit O, Wolff RA, Golan T.
    • JAMA Oncol. 2021 May 1;7(5):693-699. doi: 10.1001/jamaoncol.2021.0006.
    • Synergistic Effect of Bazedoxifene and PARP Inhibitor in the Treatment of Ovarian Cancer Regardless of BRCA Mutation.
    • Zhang R, Wang T, Lin J.
    • Anticancer Res. 2021 May;41(5):2277-2286. doi: 10.21873/anticanres.15003.
    • Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis.
    • Schettini F, Giudici F, Bernocchi O, Sirico M, Corona SP, Giuliano M, Locci M, Paris I, Scambia G, De Placido S, Rescigno P, Prat A, Curigliano G, Generali D.
    • Eur J Cancer. 2021 May;149:134-152. doi: 10.1016/j.ejca.2021.02.035. Epub 2021 Apr 13. Erratum in: Eur J Cancer. 2021 Aug;153:274.
    • Meta-Analysis
    • Pancreas cancer: Therapeutic trials in metastatic disease.
    • Smithy JW, O'Reilly EM.
    • J Surg Oncol. 2021 May;123(6):1475-1488. doi: 10.1002/jso.26359.
    • Review
    • The safety, tolerability and pharmacokinetics of niraparib in Japanese patients with solid tumours: results of a phase I dose-escalation study.
    • Yonemori K, Shimizu T, Kondo S, Iwasa S, Koyama T, Kitano S, Sato J, Shimomura A, Shibaki R, Suri A, Kase Y, Sumino S, Tamura K, Yamamoto N.
    • Jpn J Clin Oncol. 2021 Apr 30;51(5):693-699. doi: 10.1093/jjco/hyab013.
    • Germline Genetics of Prostate Cancer: Prevalence of Risk Variants and Clinical Implications for Disease Management.
    • Doan DK, Schmidt KT, Chau CH, Figg WD.
    • Cancers (Basel). 2021 Apr 29;13(9):2154. doi: 10.3390/cancers13092154.
    • Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging.
    • O'Sullivan J, Mersaoui SY, Poirier G, Masson JY.
    • J Vis Exp. 2021 Apr 28;(170). doi: 10.3791/62553.
    • The PARP Enzyme Family and the Hallmarks of Cancer Part 2: Hallmarks Related to Cancer Host Interactions.
    • Demény MA, Virág L.
    • Cancers (Basel). 2021 Apr 24;13(9):2057. doi: 10.3390/cancers13092057.
    • A Population Pharmacokinetic Meta-analysis of Veliparib, a PARP Inhibitor, Across Phase I/II/III Trials in Cancer Patients.
    • Stodtmann S, Nuthalapati S, Eckert D, Kasichayanula S, Joshi R, Bach BA, Mensing S, Menon R, Xiong H.
    • J Clin Pharmacol. 2021 Apr 24. doi: 10.1002/jcph.1875. Epub ahead of print.
    • The PARP Enzyme Family and the Hallmarks of Cancer Part 1. Cell Intrinsic Hallmarks.
    • Demény MA, Virág L.
    • Cancers (Basel). 2021 Apr 23;13(9):2042. doi: 10.3390/cancers13092042.
    • Targeting HR Repair as a Synthetic Lethal Approach to Increase DNA Damage Sensitivity by a RAD52 Inhibitor in BRCA2-Deficient Cancer Cells.
    • Tseng WC, Chen CY, Chern CY, Wang CA, Lee WC, Chi YC, Cheng SF, Kuo YT, Chiu YC, Tseng ST, Lin PY, Liou SJ, Li YC, Chen CC.
    • Int J Mol Sci. 2021 Apr 23;22(9):4422. doi: 10.3390/ijms22094422.
    • Complete pathological response to olaparib and bevacizumab in advanced cervical cancer following chemoradiation in a BRCA1 mutation carrier: a case report.
    • Montero-Macias R, Koual M, Crespel C, Le Frére-Belda MA, Hélène HB, Nguyen-Xuan HT, Garinet S, Perkins G, Balay V, Durdux C, Florin M, Péré H, Bats AS.
    • J Med Case Rep. 2021 Apr 23;15(1):210. doi: 10.1186/s13256-021-02767-9.
    • Olaparib Treatment in a Patient with Advanced Gallbladder Cancer Harboring BRCA1 Mutation.
    • Li X, Gao L, Qiu M, Cao D.
    • Onco Targets Ther. 2021 Apr 22;14:2815-2819. doi: 10.2147/OTT.S303594.
    • Cost-Effectiveness Analysis of Olaparib Maintenance Treatment for Germline BRCA-Mutated Metastatic Pancreatic Cancer.
    • Li N, Zheng H, Huang Y, Zheng B, Cai H, Liu M.
    • Front Pharmacol. 2021 Apr 20;12:632818. doi: 10.3389/fphar.2021.632818.
    • Age-related activity of Poly (ADP-ribose) polymerase (PARP) in men with localized prostate cancer.
    • Deniz M, Zengerling F, Gundelach T, Moreno-Villanueva M, Bürkle A, Janni W, Bolenz C, Kostezka S, Marienfeld R, Benckendorff J, Friedl TWP, Wiesmüller L, Rall-Scharpf M.
    • Mech Ageing Dev. 2021 Apr 19:111494. doi: 10.1016/j.mad.2021.111494. Epub ahead of print.
    • CHK2 inhibition provides a strategy to suppress hematological toxicity from PARP inhibitors.
    • Xu Z, Vandenberg CJ, Lieschke E, Di Rago L, Scott CL, Majewski IJ.
    • Mol Cancer Res. 2021 Apr 16:molcanres.0791.2020. doi: 10.1158/1541-7786.MCR-20-0791. Epub ahead of print.
    • In silico screening identifies a novel small molecule inhibitor that counteracts PARP inhibitor resistance in ovarian cancer.
    • Lin ZP, Al Zouabi NN, Xu ML, Bowen NE, Wu TL, Lavi ES, Huang PH, Zhu YL, Kim B, Ratner ES.
    • Sci Rep. 2021 Apr 13;11(1):8042. doi: 10.1038/s41598-021-87325-5.
    • WNT inhibition creates a BRCA-like state in Wnt-addicted cancer.
    • Kaur A, Lim JYS, Sepramaniam S, Patnaik S, Harmston N, Lee MA, Petretto E, Virshup DM, Madan B.
    • EMBO Mol Med. 2021 Apr 9;13(4):e13349. doi: 10.15252/emmm.202013349. Epub 2021 Mar 4.
    • Drug and molecular radiotherapy combinations for metastatic castration resistant prostate cancer.
    • Staniszewska M, Iking J, Lückerath K, Hadaschik B, Herrmann K, Ferdinandus J, Fendler WP.
    • Nucl Med Biol. 2021 Apr 9;96-97:101-111. doi: 10.1016/j.nucmedbio.2021.03.009. Epub ahead of print.
    • Review
    • Targeting the nucleotide salvage factor DNPH1 sensitizes BRCA-deficient cells to PARP inhibitors.
    • Fugger K, Bajrami I, Silva Dos Santos M, Young SJ, Kunzelmann S, Kelly G, Hewitt G, Patel H, Goldstone R, Carell T, Boulton SJ, MacRae J, Taylor IA, West SC.
    • Science. 2021 Apr 9;372(6538):156-165. doi: 10.1126/science.abb4542.

    Related:

    Comment:

    Epigenetic nucleotides enhance therapy.

    • Treatment Strategies for ARID1A-Deficient Ovarian Clear Cell Carcinoma.
    • Takahashi K, Takenaka M, Okamoto A, Bowtell DDL, Kohno T.
    • Cancers (Basel). 2021 Apr 7;13(8):1769. doi: 10.3390/cancers13081769.
    • Olaparib and rucaparib for the treatment of DNA repair-deficient metastatic castration-resistant prostate cancer.
    • Maughan BL, Antonarakis ES.
    • Expert Opin Pharmacother. 2021 Apr 7:1-8. doi: 10.1080/14656566.2021.1912015. Epub ahead of print.
    • Review
    • Olaparib in hormone receptor-positive, HER2-negative metastatic breast cancer with a somatic BRCA2 mutation.
    • Schwartzberg LS, Kiedrowski LA.
    • Ther Adv Med Oncol. 2021 Apr 5;13:17588359211006962. doi: 10.1177/17588359211006962.
    • Hereditary Prostate Cancer: Genes Related, Target Therapy and Prevention.
    • Vietri MT, D'Elia G, Caliendo G, Resse M, Casamassimi A, Passariello L, Albanese L, Cioffi M, Molinari AM.
    • Int J Mol Sci. 2021 Apr 4;22(7):3753. doi: 10.3390/ijms22073753.
    • Synthetic Lethality in Cancer Therapeutics: The Next Generation.
    • Setton J, Zinda M, Riaz N, Durocher D, Zimmermann M, Koehler M, Reis-Filho JS, Powell SN.
    • Cancer Discov. 2021 Apr 1. doi: 10.1158/2159-8290.CD-20-1503. Epub ahead of print.
    • Review
    • Exploiting synthetic lethality to target BRCA1/2-deficient tumors: where we stand.
    • Patel PS, Algouneh A, Hakem R.
    • Oncogene. 2021 Apr;40(17):3001-3014. doi: 10.1038/s41388-021-01744-2. Epub 2021 Mar 14.
    • Review
    • Decreased expression of the translation factor eIF3e induces senescence in breast cancer cells via suppression of PARP1 and activation of mTORC1.
    • Morris C, Durand S, Jalinot P.
    • Oncotarget. 2021 Mar 30;12(7):649-664. doi: 10.18632/oncotarget.27923.
    • Selective killing of homologous recombination-deficient cancer cell lines by inhibitors of the RPA:RAD52 protein-protein interaction.
    • Al-Mugotir M, Lovelace JJ, George J, Bessho M, Pal D, Struble L, Kolar C, Rana S, Natarajan A, Bessho T, Borgstahl GEO.
    • PLoS One. 2021 Mar 30;16(3):e0248941. doi: 10.1371/journal.pone.0248941.
    • Shaping the BRCAness mutational landscape by alternative double-strand break repair, replication stress and mitotic aberrancies.
    • Stok C, Kok YP, van den Tempel N, van Vugt MATM.
    • Nucleic Acids Res. 2021 Mar 21:gkab151. doi: 10.1093/nar/gkab151. Epub ahead of print.
    • NICE Recommends Lynparza, Avastin Combination in Ovarian Cancer Through Cancer Drugs Fund.
    • [No author given]
    • Precision Oncology News. Business & Policy. 2021 Mar 19.
    • Candidate Markers of Olaparib Response from Genomic Data Analyses of Human Cancer Cell Lines.
    • Amuzu S, Carmona E, Mes-Masson AM, Greenwood CMT, Tonin PN, Ragoussis J.
    • Cancers (Basel). 2021 Mar 15;13(6):1296. doi: 10.3390/cancers13061296.
    • Integrating PARP Inhibitors Into Advanced Prostate Cancer Therapeutics.
    • Gong J, Posadas E, Bhowmick N, Kim H, Daskivich T, Gupta A, Sandler H, Kamrava M, Zumsteg Z, Freedland S, Figlin R.
    • Oncology (Williston Park). 2021 Mar 15;35(3):119-125. doi: 10.46883/ONC.2021.3503.0119.
    • An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer.
    • Stringer-Reasor EM, May JE, Olariu E, Caterinicchia V, Li Y, Chen D, Della Manna DL, Rocque GB, Vaklavas C, Falkson CI, Nabell LM, Acosta EP, Forero-Torres A, Yang ES.
    • Breast Cancer Res. 2021 Mar 4;23(1):30. doi: 10.1186/s13058-021-01408-9.
    • Replication Gaps Underlie BRCA Deficiency and Therapy Response.
    • Panzarino NJ, Krais JJ, Cong K, Peng M, Mosqueda M, Nayak SU, Bond SM, Calvo JA, Doshi MB, Bere M, Ou J, Deng B, Zhu LJ, Johnson N, Cantor SB.
    • Cancer Res. 2021 Mar 1;81(5):1388-1397. doi: 10.1158/0008-5472.CAN-20-1602. Epub 2020 Nov 12.

    Related:

    Commentary:

    Which Holds the Key to BRCAness: Inability to Repair the Break, Protect the Fork, or Prevent the Gap?

    • LRRK2 inhibition potentiates PARP inhibitor cytotoxicity through inhibiting homologous recombination-mediated DNA double strand break repair.
    • Chen L, Hou J, Zeng X, Guo Q, Deng M, Kloeber JA, Tu X, Zhao F, Wu Z, Huang J, Luo K, Kim W, Lou Z.
    • Clin Transl Med. 2021 Mar;11(3):e341. doi: 10.1002/ctm2.341.
    • Total and out-of-pocket costs for PARP inhibitors among insured ovarian cancer patients.
    • Liang MI, Chen L, Hershman DL, Hillyer GC, Huh WK, Guyton A, Wright JD.
    • Gynecol Oncol. 2021 Mar;160(3):793-799. doi: 10.1016/j.ygyno.2020.12.015. Epub 2020 Dec 27.
    • Narrative review: predicting future molecular and clinical profiles of prostate cancer in the United States.
    • Santoni M, Cimadamore A, Massari F, Sorgentoni G, Cheng L, Lopez-Beltran A, Battelli N, Montironi R.
    • Transl Androl Urol. 2021 Mar;10(3):1562-1568. doi: 10.21037/tau-20-1439.
    • Homologous Recombination Deficiency Testing for BRCA-Like Tumors: The Road to Clinical Validation.
    • Ladan MM, van Gent DC, Jager A.
    • Cancers (Basel). 2021 Feb 28;13(5):1004. doi: 10.3390/cancers13051004.
    • Blocking Fra-1 sensitizes triple-negative breast cancer to PARP inhibitor.
    • Song D, He H, Sinha I, Hases L, Yan F, Archer A, Haldosen LA, Zhao C, Williams C.
    • Cancer Lett. 2021 Feb 27:S0304-3835(21)00092-6. doi: 10.1016/j.canlet.2021.02.018. Epub ahead of print.
    • BKM120 sensitizes BRCA-proficient triple negative breast cancer cells to olaparib through regulating FOXM1 and Exo1 expression.
    • Li Y, Wang Y, Zhang W, Wang X, Chen L, Wang S.
    • Sci Rep. 2021 Feb 26;11(1):4774. doi: 10.1038/s41598-021-82990-y.
    • The Synergistic Effect of PARP Inhibitors and Immune Checkpoint Inhibitors.
    • Wu Z, Cui P, Tao H, Zhang S, Ma J, Liu Z, Wang J, Qian Y, Chen S, Huang Z, Zheng X, Huang D, Hu Y.
    • Clin Med Insights Oncol. 2021 Feb 25;15:1179554921996288. doi: 10.1177/1179554921996288.
    • Treatment-emergent neuroendocrine prostate cancer with a germline BRCA2 mutation: identification of a candidate reversion mutation associated with platinum/PARP-inhibitor resistance.
    • Pandya D, Shah M, Kaplan F, Martino C, Levy G, Kazanjian M, Batter S, Martignetti J, Frank RC.
    • Cold Spring Harb Mol Case Stud. 2021 Feb 19;7(1):a005801. doi: 10.1101/mcs.a005801.
    • Prevalence of Homologous Recombination Pathway Gene Mutations in Melanoma: Rationale for a New Targeted Therapeutic Approach.
    • Kim KB, Soroceanu L, de Semir D, Millis SZ, Ross J, Vosoughi E, Dar AA, Nosrati M, Desprez PY, Ice R, Chen M, Chetal K, Bhattacharjee A, Moretto J, Leong SP, Singer MI, Parrett BM, Minor DR, McAllister S, Miller JR 3rd, Salomonis N, Kashani-Sabet M.
    • J Invest Dermatol. 2021 Feb 18:S0022-202X(21)00155-X. doi: 10.1016/j.jid.2021.01.024. Epub ahead of print.
    • Benefit of AstraZeneca's Cediranib Plus Lynparza May Be Limited to HRR-Deficient Prostate Cancers.
    • Hopkins C.
    • Precision Oncology News. Cancer Specialties. 2021 Feb 12.
    • Conference news
    • Efficacy of PARP inhibition combined with EZH2 inhibition depends on BRCA mutation status and microenvironment in breast cancer.
    • Chen MK.
    • FEBS J. 2021 Feb 11. doi: 10.1111/febs.15730. Epub ahead of print.
    • Commentary
    • Clinical significance of homologous recombination deficiency score testing in endometrial Cancer.
    • Siedel JH, Ring KL, Hu W, Dood RL, Wang Y, Baggerly K, Darcy KM, Conrads TP, Gallagher S, Tshiaba P, Neff C, Timms KM, Mangala S, Westin SN, Broaddus R, Lopez-Berestein G, Lu KH, Coleman RL, Maxwell GL, Sood AK.
    • Gynecol Oncol. 2021 Feb 6:S0090-8258(20)34181-0. doi: 10.1016/j.ygyno.2020.12.010. Epub ahead of print.
    • Olaparib – cancer de prostate métastatique résistant à la castration muté BRCA [Drug approval: Olaparib - metastatic castration-resistant prostate cancer with BRCA mutation].
    • Saillant A, Flippot R.
    • Bull Cancer. 2021 Feb 2:S0007-4551(21)00015-1. French. doi: 10.1016/j.bulcan.2020.11.010. Epub ahead of print.
    • Letter, [Article in French]
    • Current and future landscape of poly (ADP-ribose) polymerase inhibition resistance.
    • Hinchcliff E, Chelariu-Raicu A, Westin SN.
    • Curr Opin Obstet Gynecol. 2021 Feb 1;33(1):19-25. doi: 10.1097/GCO.0000000000000678.
    • Review
    • Ongoing partial response at 6 months to olaparib for metastatic melanoma with somatic PALB2 mutation after failure of immunotherapy: a case report.
    • Lau B, Menzies AM, Joshua AM.
    • Ann Oncol. 2021 Feb;32(2):280-282. doi: 10.1016/j.annonc.2020.11.006. Epub 2020 Dec 9.
    • Case report
    • Preclinical evaluation of radiation therapy of BRCA1-associated mammary tumors using a mouse model.
    • Cho EJ, Kim JK, Baek HJ, Kim SE, Park EJ, Choi BK, Kim TH, Shin DH, Lim YK, Deng CX, Kim SS.
    • Int J Biol Sci. 2021 Jan 31;17(3):689-701. doi: 10.7150/ijbs.53667.
    • Heterogeneity and clonal evolution of acquired PARP inhibitor resistance in TP53- and BRCA1-deficient cells.
    • Färkkilä A, Rodríguez A, Oikkonen J, Gulhan DC, Nguyen H, Domínguez J, Ramos S, Mills CE, Perez-Villatoro F, Lazaro JB, Zhou J, Clairmont CS, Moreau LA, Park PJ, Sorger PK, Hautaniemi S, Frias S, D'Andrea AD.
    • Cancer Res. 2021 Jan 29:canres.2912.2020. doi: 10.1158/0008-5472.CAN-20-2912. Epub ahead of print.
    • DNA damage response alterations in gastric cancer: knocking down a new wall.
    • Ricci AD, Rizzo A, Brandi G.
    • Future Oncol. 2021 Jan 29. doi: 10.2217/fon-2020-0989. Epub ahead of print.
    • Editorial
    • Promoter methylation of DNA homologous recombination genes is predictive of the responsiveness to PARP inhibitor treatment in testicular germ cell tumors.
    • Lobo J, Constâncio V, Guimarães-Teixeira C, Leite-Silva P, Miranda-Gonçalves V, Sequeira JP, Pistoni L, Guimarães R, Cantante M, Braga I, Maurício J, Looijenga LH, Henrique R, Jerónimo C.
    • Mol Oncol. 2021 Jan 29. doi: 10.1002/1878-0261.12909. Epub ahead of print.
    • Therapeutic Potential of Olaparib in Combination With Pembrolizumab in a Young Patient With a Maternally Inherited BRCA2 Germline Variant: A Research Report.
    • Waddington T, Mambetsariev I, Pharaon R, Fricke J, Baroz AR, Romo H, Ghanem B, Gray S, Salgia R.
    • Clin Lung Cancer. 2021 Jan 27:S1525-7304(21)00012-7. doi: 10.1016/j.cllc.2021.01.009. Epub ahead of print.
    • Case report
    • A single-arm phase II study of olaparib maintenance with pembrolizumab and bevacizumab in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer (OPEB-01).
    • Lee YJ, Lim MC, Kim BG, Ngoi NY, Choi CH, Park SY, Tan DS, Go Y, Lee JY.
    • J Gynecol Oncol. 2021 Jan 27:e31. doi: 10.3802/jgo.2021.32.e31. Epub ahead of print.
    • Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial.
    • Fennell DA, King A, Mohammed S, Branson A, Brookes C, Darlison L, Dawson AG, Gaba A, Hutka M, Morgan B, Nicholson A, Richards C, Wells-Jordan P, Murphy GJ, Thomas A; MiST1 study group.
    • Lancet Respir Med. 2021 Jan 27:S2213-2600(20)30390-8. doi: 10.1016/S2213-2600(20)30390-8. Epub ahead of print.
    • Whole-exome sequencing reveals germline-mutated small cell lung cancer subtype with favorable response to DNA repair-targeted therapies.
    • Tlemsani C, Takahashi N, Pongor L, Rajapakse VN, Tyagi M, Wen X, Fasaye GA, Schmidt KT, Desai P, Kim C, Rajan A, Swift S, Sciuto L, Vilimas R, Webb S, Nichols S, Figg WD, Pommier Y, Calzone K, Steinberg SM, Wei JS, Guha U, Turner CE, Khan J, Thomas A.
    • Sci Transl Med. 2021 Jan 27;13(578):eabc7488. doi: 10.1126/scitranslmed.abc7488.

    Related:

    Research News: Small Cell Lung Cancer Study Uncovers Disease-Associated Germline Mutations. (GenomeWeb)

    • Clinical use and mechanisms of resistance for PARP inhibitors in homologous recombination-deficient cancers.
    • Janysek DC, Kim J, Duijf PHG, Dray E.
    • Transl Oncol. 2021 Jan 27;14(3):101012. doi: 10.1016/j.tranon.2021.101012. Epub ahead of print.
    • CHEK2 mutation in a patient with pancreatic adenocarcinoma-a rare case report.
    • Vittal A, Saha D, Samanta I, Kasi A.
    • AME Case Rep. 2021 Jan 25;5:5. doi: 10.21037/acr-20-83.
    • Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance.
    • Kim DS, Camacho CV, Kraus WL.
    • Exp Mol Med. 2021 Jan 25. doi: 10.1038/s12276-021-00557-3. Epub ahead of print.
    • Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer.
    • Lotan TL, Kaur HB, Salles DC, Murali S, Schaeffer EM, Lanchbury JS, Isaacs WB, Brown R, Richardson AL, Cussenot O, Cancel-Tassin G, Timms KM, Antonarakis ES.
    • Mod Pathol. 2021 Jan 18. doi: 10.1038/s41379-020-00731-4. Epub ahead of print.
    • Homologous Recombination Repair Mechanisms in Serous Endometrial Cancer.
    • Jönsson JM, Bååth M, Björnheden I, Sahin ID, Måsbäck A, Hedenfalk I.
    • Cancers (Basel). 2021 Jan 12;13(2):E254. doi: 10.3390/cancers13020254.
    • A novel somatic BRCA2 point mutation in a metastatic pancreatic cancer patient: a case report.
    • Wang D, Guan R, Tao Q, Liu S, Yu M, Li X.
    • BMC Med Genomics. 2021 Jan 6;14(1):6. doi: 10.1186/s12920-020-00850-6.
    • PARPi, immunothérapies et anticorps monoclonaux conjugués dans les cancers du sein triple-négatifs [Recent therapeutic trends in triple-negative metastatic breast cancers: PARP inhibitors, immunotherapies and antibody-drug conjugates].
    • Dalenc F, Sarradin V, Nicolaï V, Franchet C, Ung M.
    • Bull Cancer. 2021 Jan 6:S0007-4551(20)30504-X. French. doi: 10.1016/j.bulcan.2020.11.007. Epub ahead of print.
    • Review. [Article in French]
    • The financial burden of PARP inhibitors on patients, payors, and financial assistance programs: Who bears the cost?
    • Goldsberry WN, Summerlin SS, Guyton A, Caddell B, Huh WK, Kim KH, Liang MI.
    • Gynecol Oncol. 2021 Jan 4:S0090-8258(20)34254-2. doi: 10.1016/j.ygyno.2020.12.039. Epub ahead of print.
    • Tumor-Infiltrating Lymphocyctes in Triple-Negative Breast Cancer: Update for 2020.
    • Brown LC, Salgado R, Luen SJ, Savas P, Loi S.
    • Cancer J. 2021 Jan-Feb 01;27(1):25-31. doi: 10.1097/PPO.0000000000000501.
    • Review
    • PARP Inhibitors in Triple-Negative Breast Cancer Including Those With BRCA Mutations.
    • Layman RM, Arun B.
    • Cancer J. 2021 Jan-Feb 01;27(1):67-75. doi: 10.1097/PPO.0000000000000499.
    • Review
    • Design, synthesis, and biological evaluation of quinazolin-4(3H)-one derivatives co-targeting poly(ADP-ribose) polymerase-1 and bromodomain containing protein 4 for breast cancer therapy.
    • Chang X, Sun D, Shi D, Wang G, Chen Y, Zhang K, Tan H, Liu J, Liu B, Ouyang L.
    • Acta Pharm Sin B. 2021 Jan;11(1):156-180. doi: 10.1016/j.apsb.2020.06.003. Epub 2020 Jun 24.
    • Successful treatment of a patient with brain metastases from endometrial cancer using Niraparib: a case report.
    • Wang Q, Zhang F, Gao H, Xu Y.
    • Ann Palliat Med. 2021 Jan;10(1):818-827. doi: 10.21037/apm-21-113.
    • First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors.
    • Yap TA, Tan DSP, Terbuch A, Caldwell R, Guo C, Goh BC, Heong V, Haris NRM, Bashir S, Drew Y, Hong DS, Meric-Bernstam F, Wilkinson G, Hreiki J, Wengner AM, Bladt F, Schlicker A, Ludwig M, Zhou Y, Liu L, Bordia S, Plummer R, Lagkadinou E, de Bono JS.
    • Cancer Discov. 2021 Jan;11(1):80-91. doi: 10.1158/2159-8290.CD-20-0868. Epub 2020 Sep 28.

    Related:

    Commentary:

    ATR Inhibition as an Attractive Therapeutic Resource against Cancer.

    Press: Bayer's ATR Inhibitor May Benefit Cancers With ATM Aberrations, Early Data Suggest (Precision Oncology News)

    • A pathogenic germline BRCA2 variant in a patient with hypopharyngeal squamous cell carcinoma.
    • Correa T, Laux DE, Hoffman HT.
    • Clin Case Rep. 2020 Nov 25;9(1):429-432. doi: 10.1002/ccr3.3548. eCollection 2021 Jan.
    • Efficacy of cancer vaccines in selected gynaecological breast and ovarian cancers: A 20-year systematic review and meta-analysis.
    • Dafni U, Martín-Lluesma S, Balint K, Tsourti Z, Vervita K, Chenal J, Coukos G, Zaman K, Sarivalasis A, Kandalaft LE.
    • Eur J Cancer. 2021 Jan;142:63-82. doi: 10.1016/j.ejca.2020.10.014. Epub 2020 Nov 19.
    • Review
    • [Effects of Olaparib, a PARP-1 Inhibitor, on Triple Negative Breast Cancer Cells with a BRCA1 Mutation].
    • Tsunoda Y, Sasaki A, Sakamoto N, Haruyama Y, Nashimoto M, Koshida Y, Fukuma E.
    • Gan To Kagaku Ryoho. 2021 Jan;48(1):53-56.
    • [Article in Japanese]
    • PARP inhibitor resistance and TP53 mutations in patients treated with olaparib for BRCA-mutated cancer: Four case reports.
    • Collot T, Niogret J, Carnet M, Chevrier S, Humblin E, Favier L, Bengrine-Lefevre L, Desmoulins I, Arnould L, Boidot R.
    • Mol Med Rep. 2021 Jan;23(1):75. doi: 10.3892/mmr.2020.11713. Epub 2020 Nov 25.
    • Case report
    • Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer.
    • Mehta AK, Cheney EM, Hartl CA, Pantelidou C, Oliwa M, Castrillon JA, Lin JR, Hurst KE, de Oliveira Taveira M, Johnson NT, Oldham WM, Kalocsay M, Berberich MJ, Boswell SA, Kothari A, Johnson S, Dillon DA, Lipschitz M, Rodig S, Santagata S, Garber JE, Tung N, Yélamos J, Thaxton JE, Mittendorf EA, Sorger PK, Shapiro GI, Guerriero JL.
    • Nat Cancer. 2021 Jan;2(1):66-82. doi: 10.1038/s43018-020-00148-7. Epub 2020 Dec 14.

    Related:

    Research news: PARP Inhibitor Breast Cancer Treatments May Be Improved by Targeting Immunosuppressive Macrophages (Clinical OMICs)

    • Dissecting the molecular determinants of clinical PARP1 inhibitor selectivity for tankyrase1.
    • Ryan K, Bolaños B, Smith M, Palde P, Cuenca PD, VanArsdale TL, Niessen S, Zhang L, Behenna D, Ornelas MA, Tran KT, Kaiser S, Lum L, Stewart A, Gajiwala KS.
    • J Biol Chem. 2020 Dec 24:jbc.RA120.016573. doi: 10.1074/jbc.RA120.016573. Epub ahead of print.
    • XRCC1 deficient triple negative breast cancers are sensitive to ATR, ATM and Wee1 inhibitor either alone or in combination with olaparib.
    • Ali R, Alblihy A, Toss MS, Algethami M, Al Sunni R, Green AR, Rakha EA, Madhusudan S.
    • Ther Adv Med Oncol. 2020 Dec 21;12:1758835920974201. doi: 10.1177/1758835920974201.
    • Poly(ADP-ribose) polymerase inhibition in pancreatic cancer.
    • Singh HM, Bailey P, Hübschmann D, Berger AK, Neoptolemos J, Jäger D, Siveke J, Springfeld C.
    • Genes Chromosomes Cancer. 2020 Dec 20. doi: 10.1002/gcc.22932. Epub ahead of print.
    • Review
    • TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes.
    • Tung NM, Robson ME, Ventz S, Santa-Maria CA, Nanda R, Marcom PK, Shah PD, Ballinger TJ, Yang ES, Vinayak S, Melisko M, Brufsky A, DeMeo M, Jenkins C, Domchek S, D'Andrea A, Lin NU, Hughes ME, Carey LA, Wagle N, Wulf GM, Krop IE, Wolff AC, Winer EP, Garber JE.
    • J Clin Oncol. 2020 Dec 20;38(36):4274-4282. doi: 10.1200/JCO.20.02151. Epub 2020 Oct 29.

    Related:

    Commentary, Review:

    Germline Mutations in Other Homologous Recombination Repair-Related Genes Than BRCA1/2: Predictive or Prognostic Factors?

    • BRCA Methylation Testing Identifies a Subset of Ovarian Carcinomas without Germline Variants That Can Benefit from PARP Inhibitor.
    • Sahnane N, Carnevali I, Formenti G, Casarin J, Facchi S, Bombelli R, Di Lauro E, Memoli D, Salvati A, Rizzo F, Sessa F, Tibiletti MG.
    • Int J Mol Sci. 2020 Dec 19;21(24):E9708. doi: 10.3390/ijms21249708.
    • PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality-An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness.
    • Gralewska P, Gajek A, Marczak A, Mikula M, Ostrowski J, Sliwinska A, Rogalska A.
    • Int J Mol Sci. 2020 Dec 19;21(24):E9715. doi: 10.3390/ijms21249715.
    • PARP Theranostic Auger Emitters Are Cytotoxic in BRCA Mutant Ovarian Cancer and Viable Tumors from Ovarian Cancer Patients Enable Ex-Vivo Screening of Tumor Response.
    • Riad A, Gitto SB, Lee H, Winters HD, Martorano PM, Hsieh CJ, Xu K, Omran DK, Powell DJ Jr, Mach RH, Makvandi M.
    • Molecules. 2020 Dec 19;25(24):E6029. doi: 10.3390/molecules25246029.
    • DNA damage response and breast cancer development: Possible therapeutic applications of ATR, ATM, PARP, BRCA1 inhibition.
    • Mirza-Aghazadeh-Attari M, Recio MJ, Darband SG, Kaviani M, Safa A, Mihanfar A, Sadighparvar S, Karimian A, Alemi F, Majidinia M, Yousefi B.
    • DNA Repair (Amst). 2020 Dec 17;98:103032. doi: 10.1016/j.dnarep.2020.103032. Epub ahead of print.
    • Review
    • Lynparza Cost-Effectiveness Analysis IDs Pancreatic Cancer Subgroups That Derive Most Benefit.
    • Kanski A.
    • Precision Oncology News. 2020 Dec 17.
    • Research news

    Related:

    Original research:

    Cost-Effectiveness of Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.

    • Cost-Effectiveness Analysis of Maintenance Olaparib in Patients with Metastatic Pancreatic Cancer and a Germline BRCA1/2 Mutation Based on the POLO Trial.
    • Zhan M, Zheng H, Yang Y, He Z, Xu T, Li Q.
    • Cancer Manag Res. 2020 Dec 16;12:12919-12926. doi: 10.2147/CMAR.S283169.
    • Enhanced Efficacy of Combined Therapy with Checkpoint Kinase 1 Inhibitor and Rucaparib Via Regulation of Rad-51 Expression in BRCA Wild-Type Epithelial Ovarian Cancer Cells.
    • Cho HY, Kim YB, Park WH, No JH.
    • Cancer Res Treat. 2020 Dec 16. doi: 10.4143/crt.2020.1013. Epub ahead of print.
    • Discovery of isoquinolinone and naphthyridinone-based inhibitors of poly(ADP-ribose) polymerase-1 (PARP1) as anticancer agents: Structure activity relationship and preclinical characterization.
    • Karche NP, Bhonde M, Sinha N, Jana G, Kukreja G, Kurhade SP, Jagdale AR, Tilekar AR, Hajare AK, Jadhav GR, Gupta NR, Limaye R, Khedkar N, Thube BR, Shaikh JS, Rao Irlapati N, Phukan S, Gole G, Bommakanti A, Khanwalkar H, Pawar Y, Kale R, Kumar R, Gupta R, Praveen Kumar VR, Wahid S, Francis A, Bhat T, Kamble N, Patil V, Nigade PB, Modi D, Pawar S, Naidu S, Volam H, Pagdala V, Mallurwar S, Goyal H, Bora P, Ahirrao P, Singh M, Kamalakannan P, Naik KR, Kumar P, Powar RG, Shankar RB, Bernstein PR, Gundu J, Nemmani K, Narasimham L, George KS, Sharma S, Bakhle D, Kamboj RK, Palle VP.
    • Bioorg Med Chem. 2020 Dec 15;28(24):115819. doi: 10.1016/j.bmc.2020.115819. Epub 2020 Oct 14.
    • A very long-acting Poly(ADP-ribose) polymerase inhibitor suppresses cancer cell growth in DNA repair-deficient tumor models.
    • Fontaine SD, Ashley GW, Houghton PJ, Kurmasheva RT, Diolaiti M, Ashworth A, Peer CJ, Nguyen R, Figg WD, Beckford-Vera DR, Santi DV.
    • Cancer Res. 2020 Dec 15:canres.1741.2020. doi: 10.1158/0008-5472.CAN-20-1741. Epub ahead of print.
    • Clinical Outcome-Related Mutational Signatures Identified by Integrative Genomic Analysis in Nasopharyngeal Carcinoma.
    • Dai W, Chung DL, Chow LK, Yu VZ, Lei LC, Leong MM, Chan CK, Ko JM, Lung ML.
    • Clin Cancer Res. 2020 Dec 15;26(24):6494-6504. doi: 10.1158/1078-0432.CCR-20-2854. Epub 2020 Sep 28.
    • Pancreatic mucinous cystadenocarcinoma in a patient harbouring BRCA1 germline mutation effectively treated with olaparib: A case report.
    • Di Marco M, Carloni R, De Lorenzo S, Mosconi C, Palloni A, Grassi E, Filippini DM, Ricci AD, Rizzo A, Di Federico A, Santini D, Turchetti D, Ricci C, Ingaldi C, Alberici L, Minni F, Golfieri R, Brandi G, Casadei R.
    • World J Gastrointest Oncol. 2020 Dec 15;12(12):1456-1463. doi: 10.4251/wjgo.v12.i12.1456.
    • Breast metastasis from pelvic high-grade serous adenocarcinoma: a report of two cases.
    • Harada Y, Kubo M, Kai M, Yamada M, Zaguirre K, Ohgami T, Yahata H, Ohishi Y, Yamamoto H, Oda Y, Nakamura M.
    • Surg Case Rep. 2020 Dec 9;6(1):317. doi: 10.1186/s40792-020-01090-7.
    • Differential immunomodulatory Effect of PARP Inhibition in BRCA1 deficient and competent tumor cells.
    • Alvarado-Cruz I, Mahmoud M, Khan M, Zhao S, Oeck S, Meas R, Clairmont K, Quintana V, Zhu Y, Porciuncula A, Wyatt H, Ma S, Shyr Y, Kong Y, LoRusso PM, Laverty D, Nagel ZD, Schalper KA, Krauthammer M, Sweasy JB.
    • Biochem Pharmacol. 2020 Dec 4:114359. doi: 10.1016/j.bcp.2020.114359. Epub ahead of print.
    • Update on the Role of Poly (ADP-Ribose) Polymerase Inhibitors in the DNA Repair-Deficient Pancreatic Cancers: A Narrative Review.
    • Kasi A, Al-Jumayli M, Park R, Baranda J, Sun W.
    • J Pancreat Cancer. 2020 Dec 4;6(1):107-115. doi: 10.1089/pancan.2020.0010.
    • Combinatorial efficacy of olaparib with radiation and ATR inhibitor requires PARP1 protein in homologous recombination proficient pancreatic cancer.
    • Parsels LA, Engelke CG, Parsels J, Flanagan SA, Zhang Q, Tanska D, Wahl DR, Canman CE, Lawrence TS, Morgan MA.
    • Mol Cancer Ther. 2020 Dec 2:molcanther.0365.2020. doi: 10.1158/1535-7163.MCT-20-0365. Epub ahead of print.
    • Patient selection biomarker strategies for PARP inhibitor therapy.
    • Pilié PG, George A, Yap TA.
    • Ann Oncol. 2020 Dec;31(12):1603-1605. doi: 10.1016/j.annonc.2020.09.017. Epub 2020 Oct 1.
    • Editorial
    • Alterations of DNA damage repair in cancer: from mechanisms to applications.
    • Jiang M, Jia K, Wang L, Li W, Chen B, Liu Y, Wang H, Zhao S, He Y, Zhou C.
    • Ann Transl Med. 2020 Dec;8(24):1685. doi: 10.21037/atm-20-2920.
    • Development of new poly(ADP-ribose) polymerase (PARP) inhibitors in ovarian cancer: Quo Vadis?
    • Boussios S, Moschetta M, Karihtala P, Samartzis EP, Sheriff M, Pappas-Gogos G, Ozturk MA, Uccello M, Karathanasi A, Tringos M, Rassy E, Pavlidis N.
    • Ann Transl Med. 2020 Dec;8(24):1706. doi: 10.21037/atm.2020.03.156.
    • The effect of the triazene compound CT913 on ovarian cancer cells in vitro and its synergistic interaction with the PARP-inhibitor olaparib.
    • Wichmann C, Klotz DM, Zeiler HJ, Hilger RA, Grützmann K, Krüger A, Aust D, Wimberger P, Kuhlmann JD.
    • Gynecol Oncol. 2020 Dec;159(3):850-859. doi: 10.1016/j.ygyno.2020.09.018. Epub 2020 Sep 23.
    • Inhibition of poly(ADP-ribose) polymerase induces synthetic lethality in BRIP1 deficient ovarian epithelial cells.
    • Ciccone MA, Adams CL, Bowen C, Thakur T, Ricker C, Culver JO, Maoz A, Melas M, Idos GE, Jeyasekharan AD, Matsuo K, Roman LD, Gruber SB, McDonnell KJ.
    • Gynecol Oncol. 2020 Dec;159(3):869-876. doi: 10.1016/j.ygyno.2020.09.040. Epub 2020 Oct 5.
    • Identification of probe-quality degraders for Poly(ADP-ribose) polymerase-1 (PARP-1).
    • Zhang Z, Chang X, Zhang C, Zeng S, Liang M, Ma Z, Wang Z, Huang W, Shen Z.
    • J Enzyme Inhib Med Chem. 2020 Dec;35(1):1606-1615. doi: 10.1080/14756366.2020.1804382.
    • Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial.
    • Rocconi RP, Grosen EA, Ghamande SA, Chan JK, Barve MA, Oh J, Tewari D, Morris PC, Stevens EE, Bottsford-Miller JN, Tang M, Aaron P, Stanbery L, Horvath S, Wallraven G, Bognar E, Manning L, Nemunaitis J, Shanahan D, Slomovitz BM, Herzog TJ, Monk BJ, Coleman RL.
    • Lancet Oncol. 2020 Dec;21(12):1661-1672. doi: 10.1016/S1470-2045(20)30533-7.
    • Novel poly (ADP-ribose) polymerases inhibitor DHC-1 exhibits in vitro and in vivo anticancer activity on BRCA-deficient pancreatic cancer cells.
    • Wu X, Li Q, Zhang F, Wang L, Wang J, Fan J, Di G, Guo C.
    • Food Chem Toxicol. 2020 Nov 30:111892. doi: 10.1016/j.fct.2020.111892. Epub ahead of print.
    • Identification of regulators of poly-ADP-ribose polymerase inhibitor response through complementary CRISPR knockout and activation screens.
    • Clements KE, Schleicher EM, Thakar T, Hale A, Dhoonmoon A, Tolman NJ, Sharma A, Liang X, Imamura Kawasawa Y, Nicolae CM, Wang HG, De S, Moldovan GL.
    • Nat Commun. 2020 Nov 30;11(1):6118. doi: 10.1038/s41467-020-19961-w.
    • Identification of 2-substituted pyrrolo[1,2-b]pyridazine derivatives as new PARP-1 inhibitors.
    • Xiang HY, Chen JY, Huan XJ, Chen Y, Gao ZB, Ding J, Miao ZH, Yang CH.
    • Bioorg Med Chem Lett. 2020 Nov 24:127710. doi: 10.1016/j.bmcl.2020.127710. Epub ahead of print.
    • PARPs, PAR and NAD Metabolism and Their Inhibitors in Cancer.
    • Curtin N, Bai P.
    • Cancers (Basel). 2020 Nov 24;12(12):3494. doi: 10.3390/cancers12123494.
    • Olaparib Monotherapy as Primary Treatment in Unselected Triple Negative Breast Cancer.
    • Eikesdal HP, Yndestad S, Elzawahry A, Llop-Guevara A, Gilje B, Blix ES, Espelid H, Lundgren S, Geisler J, Vagstad G, Venizelos A, Minsaas L, Leirvaag B, Gudlaugsson EG, Vintermyr OK, Aase HS, Aas T, Balmaña J, Serra V, Janssen EAM, Knappskog S, Lønning PE.
    • Ann Oncol. 2020 Nov 23:S0923-7534(20)43164-3. doi: 10.1016/j.annonc.2020.11.009. Epub ahead of print.
    • Nanoparticle Formulations of Poly (ADP-ribose) Polymerase Inhibitors for Cancer Therapy.
    • Singh B, Yang S, Krishna A, Sridhar S.
    • Front Chem. 2020 Nov 23;8:594619. doi: 10.3389/fchem.2020.594619.
    • Therapeutic Potential of PARP Inhibitors in the Treatment of Metastatic Castration-Resistant Prostate Cancer.
    • Jang A, Sartor O, Barata PC, Paller CJ.
    • Cancers (Basel). 2020 Nov 21;12(11):3467. doi: 10.3390/cancers12113467.
    • Olaparib in BRCA+ Pancreatic Cancer: Cost-effectiveness Analyzed.
    • Nelson R.
    • Medscape. Medical News. 2020 Nov 19.

    Related:

    Original research:

    Cost-Effectiveness of Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.

    • Frequency and prognostic value of mutations associated with the homologous recombination DNA repair pathway in a large pan cancer cohort.
    • Principe DR, Narbutis M, Koch R, Rana A.
    • Sci Rep. 2020 Nov 19;10(1):20223. doi: 10.1038/s41598-020-76975-6.
    • Beware Liquid Biopsies to Guide PARP Blockade.
    • [No author given]
    • Cancer Discov. 2020 Nov 18. doi: 10.1158/2159-8290.CD-NB2020-105. Epub ahead of print.
    • Research news
    • Myriad Genetics Expands MyChoice CDx Access Through Partnerships in Europe, China.
    • [No author given]
    • Precision Oncology News. 2020 Nov 16.
    • Olaparib is effective for recurrent urothelial carcinoma with BRCA2 pathogenic germline mutation: first report on olaparib response in recurrent UC.
    • Yang H, Liu Z, Wang Y, Li J, Li R, Wang Q, Hu C, Jiang H, Wu H, Song L, Bai Y.
    • Ther Adv Med Oncol. 2020 Nov 11;12:1758835920970845. doi: 10.1177/1758835920970845.
    • Predictive and Prognostic Value of DNA Damage Response Associated Kinases in Solid Tumors.
    • Gachechiladze M, Skarda J, Bouchalova K, Soltermann A, Joerger M.
    • Front Oncol. 2020 Nov 3;10:581217. doi: 10.3389/fonc.2020.581217.
    • Cost-Effectiveness of Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.
    • Wu B, Shi L.
    • J Natl Compr Canc Netw. 2020 Nov 2;18(11):1528-1536. doi: 10.6004/jnccn.2020.7587.

    Related:

    Press: Olaparib in BRCA+ Pancreatic Cancer: Cost-effectiveness Analyzed. (Medscape)

    Research news: Lynparza Cost-Effectiveness Analysis IDs Pancreatic Cancer Subgroups That Derive Most Benefit. (Precision Oncology News)

    • BRCA1 Mutations in Cancer: Coordinating Deficiencies in Homologous Recombination with Tumorigenesis.
    • Krais JJ, Johnson N.
    • Cancer Res. 2020 Nov 1;80(21):4601-4609. doi: 10.1158/0008-5472.CAN-20-1830. Epub 2020 Aug 3.
    • Molecular characteristics of BRCA1/2 and PALB2 mutations in pancreatic ductal adenocarcinoma.
    • Seeber A, Zimmer K, Kocher F, Puccini A, Xiu J, Nabhan C, Elliott A, Goldberg RM, Grothey A, Shields AF, Battaglin F, El-Deiry WS, Philip PA, Marshall JL, Hall M, Korn WM, Lenz HJ, Wolf D, Feistritzer C, Spizzo G.
    • ESMO Open. 2020 Nov;5(6):e000942. doi: 10.1136/esmoopen-2020-000942.
    • PARP Inhibitor in Advanced Endometrial Carcinoma Beyond BRCA and Related Genetic Mutations.
    • Alexandre J, Ray-Coquard I, Joly F.
    • JCO Precis Oncol. 2020 Nov;4:1025-1026. doi: 10.1200/PO.20.00177.
    • Identification of colorectal cancers with defective DNA damage repair by immunohistochemical profiling of mismatch repair proteins, CDX2 and BRCA1.
    • Rajarajan S, C E A, Jose B, Correa M, Sengupta S, Prabhu JS.
    • Mol Clin Oncol. 2020 Nov;13(5):57. doi: 10.3892/mco.2020.2128. Epub 2020 Sep 1.
    • RAD51-Mediated DNA Homologous Recombination Is Independent of PTEN Mutational Status.
    • Sinha A, Saleh A, Endersby R, Yuan SH, Chokshi CR, Brown KR, Kuzio B, Kauppinen T, Singh SK, Baker SJ, McKinnon PJ, Katyal S.
    • Cancers (Basel). 2020 Oct 29;12(11):3178. doi: 10.3390/cancers12113178.
    • Olaparib Synergizes the Anticancer Activity of Daunorubicin via Interaction with AKR1C3.
    • Tavares TS, Hofman J, Lekešová A, Želazková J, Wsól V.
    • Cancers (Basel). 2020 Oct 26;12(11):3127. doi: 10.3390/cancers12113127.
    • An evaluation of olaparib for the treatment of pancreatic cancer.
    • Vaishampayan UN.
    • Expert Opin Pharmacother. 2020 Oct 23. doi: 10.1080/14656566.2020.1837113. Epub ahead of print.
    • Review
    • Ideaya Biosciences, Broad Institute Partner on Synthetic Lethality-Based Cancer Drug Discovery.
    • [No author given]
    • GenomeWeb. Technology. Gene Silencing/Gene Editing. 2020 Oct 22.
    • PARP Inhibitors in Cancer Diagnosis and Therapy.
    • Chan CY, Tan KV, Cornelissen B.
    • Clin Cancer Res. 2020 Oct 20:clincanres.2766.2020. doi: 10.1158/1078-0432.CCR-20-2766. Epub ahead of print.
    • Review
    • Poly(ADP-Ribose) Polymerase Inhibitors in Prostate Cancer: Molecular Mechanisms, and Preclinical and Clinical Data.
    • Sigorski D, Izycka-Swieszewska E, Bodnar L.
    • Target Oncol. 2020 Oct 12. doi: 10.1007/s11523-020-00756-4. Epub ahead of print.
    • Newly diagnosed ovarian cancer: Which first-line treatment?
    • Lorusso D, Ceni V, Daniele G, Salutari V, Pietragalla A, Muratore M, Nero C, Ciccarone F, Scambia G.
    • Cancer Treat Rev. 2020 Oct 9;91:102111. doi: 10.1016/j.ctrv.2020.102111. Epub ahead of print.
    • Review
    • Targeting SMYD3 to Sensitize Homologous Recombination-Proficient Tumors to PARP-Mediated Synthetic Lethality.
    • Sanese P, Fasano C, Buscemi G, Bottino C, Corbetta S, Fabini E, Silvestri V, Valentini V, Disciglio V, Forte G, Lepore Signorile M, De Marco K, Bertora S, Grossi V, Guven U, Porta N, Di Maio V, Manoni E, Giannelli G, Bartolini M, Del Rio A, Caretti G, Ottini L, Simone C.
    • iScience. 2020 Oct 7;23(10):101604. doi: 10.1016/j.isci.2020.101604.
    • Genetic biomarkers to guide poly (ADP-ribose) polymerase inhibitor precision treatment of prostate cancer.
    • Varnai R, Sipeky C.
    • Pharmacogenomics. 2020 Oct 6. doi: 10.2217/pgs-2020-0019. Epub ahead of print.
    • The DNA damaging revolution.
    • Cetin B, Wabl CA, Gumusay O.
    • Crit Rev Oncol Hematol. 2020 Oct 3;156:103117. doi: 10.1016/j.critrevonc.2020.103117. Epub ahead of print.
    • Review
    • BRCA2 Reversion Mutation Identified by Liquid Biopsy After Durable Response to FOLFIRINOX in BRCA2-Associated Pancreatic Cancer.
    • Kondo T, Kanai M, Matsubara J, Quy PN, Fukuyama K, Yamamoto Y, Yamada T, Nishigaki M, Minamiguchi S, Takeda M, Nishio K, Matsumoto S, Muto M.
    • Pancreas. 2020 Oct 2. doi: 10.1097/MPA.0000000000001672. Epub ahead of print.
    • Efficacy of PARP Inhibition in Metastatic Castration-resistant Prostate Cancer is Very Different with Non-BRCA DNA Repair Alterations: Reconstructing Prespecified Endpoints for Cohort B from the Phase 3 PROfound Trial of Olaparib.
    • Stopsack KH.
    • Eur Urol. 2020 Oct 1:S0302-2838(20)30716-8. doi: 10.1016/j.eururo.2020.09.024. Epub ahead of print.

    Related:

    Letter:

    Efficacy of PARP Inhibition in Metastatic Castration-resistant Prostate Cancer is Very Different with Non-BRCA DNA Repair Alterations: Reconstructing Prespecified Endpoints for Cohort B from the Phase 3 PROfound Trial of Olaparib. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.09.024.

    Letter:

    Efficacy of PARP Inhibition in Metastatic Castration-resistant Prostate Cancer is Very Different with Non-BRCA DNA Repair Alterations: Reconstructing Prespecified Endpoints for Cohort B from the Phase 3 PROfound Trial of Olaparib. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.09.024 .

    • Clinical assays for assessment of homologous recombination DNA repair deficiency.
    • Stover EH, Fuh K, Konstantinopoulos PA, Matulonis UA, Liu JF.
    • Gynecol Oncol. 2020 Oct 1:S0090-8258(20)33922-6. doi: 10.1016/j.ygyno.2020.09.029. Epub ahead of print.
    • Review
    • Bevacizumab as maintenance treatment in BRCA mutated patients with advanced ovarian cancer: A large, retrospective, multicenter case-control study.
    • Lorusso D, Marchetti C, Conte C, Giudice E, Bolomini G, Vertechy L, Ceni V, Ditto A, Ferrandina G, Raspagliesi F, Scambia G, Fagotti A.
    • Gynecol Oncol. 2020 Oct;159(1):95-100. doi: 10.1016/j.ygyno.2020.07.022. Epub 2020 Jul 21.
    • Real world experience of poly (ADP-ribose) polymerase inhibitor use in a community oncology practice.
    • Eakin CM, Ewongwo A, Pendleton L, Monk BJ, Chase DM.
    • Gynecol Oncol. 2020 Oct;159(1):112-117. doi: 10.1016/j.ygyno.2020.07.020. Epub 2020 Aug 15.
    • Exploiting Chromosomal Instability of PTEN-Deficient Triple-Negative Breast Cancer Cell Lines for the Sensitization against PARP1 Inhibition in a Replication-Dependent Manner.
    • Rieckhoff J, Meyer F, Classen S, Zielinski A, Riepen B, Wikman H, Petersen C, Rothkamm K, Borgmann K, Parplys AC.
    • Cancers (Basel). 2020 Sep 29;12(10):2809. doi: 10.3390/cancers12102809.
    • ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer.
    • Miller RE, Leary A, Scott CL, Serra V, Lord CJ, Bowtell D, Chang DK, Garsed DW, Jonkers J, Ledermann JA, Nik-Zainal S, Ray-Coquard I, Shah SP, Matias-Guiu X, Swisher EM, Yates LR.
    • Ann Oncol. 2020 Sep 28:S0923-7534(20)42164-7. doi: 10.1016/j.annonc.2020.08.2102. Epub ahead of print.
    • Who Should Consider BRCA Testing?
    • [No author given]
    • My Gene Counsel. Genetic Journal Blog. 2020 Sep 24.
    • Impact of DNA damage repair defects and aggressive variant features on response to carboplatin-based chemotherapy in metastatic castration-resistant prostate cancer.
    • Slootbeek PHJ, Duizer ML, van der Doelen MJ, Kloots ISH, Kuppen MCP, Westgeest HM, Uyl-de Groot CA, Pamidimarri Naga S, Ligtenberg MJL, van Oort IM, Gerritsen WR, Schalken JA, Kroeze LI, Bloemendal HJ, Mehra N.
    • Int J Cancer. 2020 Sep 23. doi: 10.1002/ijc.33306. Epub ahead of print.
    • Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.
    • Hussain M, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Sartor O, Agarwal N, Olmos D, Thiery-Vuillemin A, Twardowski P, Roubaud G, Özgüroglu M, Kang J, Burgents J, Gresty C, Corcoran C, Adelman CA, de Bono J; PROfound Trial Investigators.
    • N Engl J Med. 2020 Sep 20. doi: 10.1056/NEJMoa2022485. Epub ahead of print.

    Related:

    Press, Conference report: Gene-Specific Exploratory Analysis Sheds Light on Lynparza Benefit in HRR-Mutated Prostate Cancer (Precision Oncology News)

    Press: EMA Committee Recommends Narrower Lynparza Indication for Metastatic Prostate Cancer Than FDA. (Precision Oncology News)

    • Olaparib combined with immunotherapy for treating a patient with liver cancer carrying BRCA2 germline mutation: A case report.
    • Zhao F, Zhou Y, Seesaha PK, Zhang Y, Liu S, Gan X, Hu J, Gu Y, Chen X.
    • Medicine (Baltimore). 2020 Sep 18;99(38):e22312. doi: 10.1097/MD.0000000000022312.
    • Maintenance Therapy for ATM-Deficient Pancreatic Cancer by Multiple DNA Damage Response Interferences after Platinum-Based Chemotherapy.
    • Roger E, Gout J, Arnold F, Beutel AK, Müller M, Abaei A, Barth TFE, Rasche V, Seufferlein T, Perkhofer L, Kleger A.
    • Cells. 2020 Sep 16;9(9):E2110. doi: 10.3390/cells9092110.
    • Functional Characterization of PALB2 Variants of Uncertain Significance: Toward Cancer Risk and Therapy Response Prediction.
    • Boonen RACM, Vreeswijk MPG, van Attikum H.
    • Front Mol Biosci. 2020 Sep 16;7:169. doi: 10.3389/fmolb.2020.00169.
    • Epigenetic based synthetic lethal strategies in human cancers.
    • Gao A, Guo M.
    • Biomark Res. 2020 Sep 15;8:44. doi: 10.1186/s40364-020-00224-1.
    • Nouvelle AMM : olaparib — cancer du pancréas avec mutation germinale de BRCA [New drug approval: Olaparib - pancreatic cancer with BRCA germline mutation].
    • Hilmi M, Neuzillet C.
    • Bull Cancer. 2020 Sep 14:S0007-4551(20)30324-6. French. doi: 10.1016/j.bulcan.2020.06.009. Epub ahead of print.
    • Letter, News, [Article in French]
    • The new world of poly-(ADP)-ribose polymerase inhibitors (PARPi) used in the treatment of gynecological cancers.
    • Chelariu-Raicu A, Zibetti Dal Molin G, Coleman RL.
    • Int J Gynecol Cancer. 2020 Sep 14:ijgc-2020-001789. doi: 10.1136/ijgc-2020-001789. Epub ahead of print.
    • Review
    • Application and reflection of genomic scar assays in evaluating the efficacy of platinum salts and PARP inhibitors in cancer therapy.
    • Gou R, Dong H, Lin B.
    • Life Sci. 2020 Sep 14:118434. doi: 10.1016/j.lfs.2020.118434. Epub ahead of print.
    • What is the role of PARP inhibitors in pancreatic cancer?
    • Halder R, T Shroff R.
    • Expert Rev Anticancer Ther. 2020 Sep 11:1-6. doi: 10.1080/14737140.2020.1816174. Epub ahead of print.
    • PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance.
    • Rose M, Burgess JT, O'Byrne K, Richard DJ, Bolderson E.
    • Front Cell Dev Biol. 2020 Sep 9;8:564601. doi: 10.3389/fcell.2020.564601.
    • Two Steps Forward and One Step Back for Precision in Prostate Cancer Treatment.
    • Schweizer MT, Cheng HH, Nelson PS, Montgomery RB.
    • J Clin Oncol. 2020 Sep 8:JCO2001755. doi: 10.1200/JCO.20.01755. Epub ahead of print.
    • PARP Inhibitors in Metastatic Prostate Cancer: Evidence to Date.
    • Nizialek E, Antonarakis ES.
    • Cancer Manag Res. 2020 Sep 7;12:8105-8114. doi: 10.2147/CMAR.S227033.
    • BRCA Mutations in Prostate Cancer: Prognostic and Predictive Implications.
    • Messina C, Cattrini C, Soldato D, Vallome G, Caffo O, Castro E, Olmos D, Boccardo F, Zanardi E.
    • J Oncol. 2020 Sep 7;2020:4986365. doi: 10.1155/2020/4986365.
    • Novel mutations in BRCA2 intron 11 and overexpression of COX-2 and BIRC3 mediate cellular resistance to PARP inhibitors.
    • Chen HD, Guo N, Song SS, Chen CH, Miao ZH, He JX.
    • Am J Cancer Res. 2020 Sep 1;10(9):2813-2831.
    • Role of Poly (ADP-Ribose) Polymerase inhibitors beyond BReast CAncer Gene-mutated ovarian tumours: definition of homologous recombination deficiency?
    • Gourley C, Miller RE, Hollis RL, Ledermann JA.
    • Curr Opin Oncol. 2020 Sep;32(5):442-450. doi: 10.1097/CCO.0000000000000660.
    • Review
    • Recent advancements in PARP inhibitors-based targeted cancer therapy.
    • Zhou P, Wang J, Mishail D, Wang CY.
    • Precis Clin Med. 2020 Sep;3(3):187-201. doi: 10.1093/pcmedi/pbaa030. Epub 2020 Aug 31.
    • PARP Inhibitors in Biliary Tract Cancer: A New Kid on the Block?
    • Ricci AD, Rizzo A, Bonucci C, Tober N, Palloni A, Mollica V, Maggio I, Deserti M, Tavolari S, Brandi G.
    • Medicines (Basel). 2020 Aug 31;7(9):E54. doi: 10.3390/medicines7090054.
    • Movement of Poly-ADP Ribose (PARP) Inhibition into Frontline Treatment of Ovarian Cancer.
    • Onstad M, Coleman RL, Westin SN.
    • Drugs. 2020 Aug 27. doi: 10.1007/s40265-020-01382-0. Epub ahead of print.
    • Review
    • DNA damage repair as a target in pancreatic cancer: state-of-the-art and future perspectives.
    • Perkhofer L, Gout J, Roger E, Kude de Almeida F, Baptista Simões C, Wiesmüller L, Seufferlein T, Kleger A.
    • Gut. 2020 Aug 27:gutjnl-2019-319984. doi: 10.1136/gutjnl-2019-319984. Epub ahead of print.
    • Exploiting defects in homologous recombination repair for metastatic, castration-resistant prostate cancer.
    • Chau V, Madan RA, Figg WD.
    • Cancer Biol Ther. 2020 Aug 26:1-4. doi: 10.1080/15384047.2020.1809913. Epub ahead of print.
    • Front-Line Maintenance Therapy in Advanced Ovarian Cancer-Current Advances and Perspectives.
    • Reverdy T, Sajous C, Péron J, Glehen O, Bakrin N, Gertych W, Lopez J, You B, Freyer G.
    • Cancers (Basel). 2020 Aug 25;12(9):2414. doi: 10.3390/cancers12092414.
    • BAP1: Not just a BRCA1-associated protein.
    • Louie BH, Kurzrock R.
    • Cancer Treat Rev. 2020 Aug 20;90:102091. doi: 10.1016/j.ctrv.2020.102091. Epub ahead of print.
    • Review
    • Breast cancer (BRCA) gene testing in ovarian cancer.
    • Chelariu-Raicu A, Coleman RL.
    • Chin Clin Oncol. 2020 Aug 19:cco-20-4. doi: 10.21037/cco-20-4. Epub ahead of print.
    • Study: New PARP inhibitor veliparib showed benefit as first-line treatment for ovarian cancer.
    • [No author given]
    • FORCE. XRAYS. 2020 Aug 18.

    Related:

    Original research:

    Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer.

    • When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials.
    • Antonarakis ES, Gomella LG, Petrylak DP.
    • Eur Urol Oncol. 2020 Aug 17:S2588-9311(20)30096-1. doi: 10.1016/j.euo.2020.07.005. Epub ahead of print.
    • A new targeted treatment for patients with a germline BRCA mutation: olaparib in pancreatic cancer.
    • Verdaguer H, Acosta D, Macarulla T.
    • Future Oncol. 2020 Aug 17. doi: 10.2217/fon-2020-0334. Epub ahead of print.
    • Review
    • A Critical Appraisal and Recommendations for Cost-Effectiveness Studies of Poly(ADP-Ribose) Polymerase Inhibitors in Advanced Ovarian Cancer.
    • Gao W, Muston D, Monberg M, McLaurin K, Hettle R, Szamreta E, Swallow E, Zhang S, Kalemaj I, Signorovitch J, McQueen RB.
    • Pharmacoeconomics. 2020 Aug 14. doi: 10.1007/s40273-020-00949-9. Epub ahead of print.
    • Molecular correlates of sensitivity to PARP inhibition beyond homologous recombination deficiency in pre-clinical models of colorectal cancer point to wild-type TP53 activity.
    • Smeby J, Kryeziu K, Berg KCG, Eilertsen IA, Eide PW, Johannessen B, Guren MG, Nesbakken A, Bruun J, Lothe RA, Sveen A.
    • EBioMedicine. 2020 Aug 13;59:102923. doi: 10.1016/j.ebiom.2020.102923. Epub ahead of print.
    • PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline.
    • Tew WP, Lacchetti C, Ellis A, Maxian K, Banerjee S, Bookman M, Jones MB, Lee JM, Lheureux S, Liu JF, Moore KN, Muller C, Rodriguez P, Walsh C, Westin SN, Kohn EC.
    • J Clin Oncol. 2020 Aug 13:JCO2001924. doi: 10.1200/JCO.20.01924. Epub ahead of print.
    • Metastatic Castration-Resistant Prostate Cancer with Neuroendocrine Transformation and BRCA 1 Germ-Line Mutation: A Case Report and Literature Review.
    • Wu Y, Gao Y, Dou X, Yue J.
    • Onco Targets Ther. 2020 Aug 12;13:8049-8054. doi: 10.2147/OTT.S264347.
    • Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment.
    • Fumet JD, Limagne E, Thibaudin M, Truntzer C, Bertaut A, Rederstorff E, Ghiringhelli F.
    • BMC Cancer. 2020 Aug 10;20(1):748. doi: 10.1186/s12885-020-07253-x.
    • Retrospective review of outcomes in patients with DNA-damage repair related pancreatic cancer.
    • Macklin-Mantia SK, Hines SL, Kasi PM.
    • Hered Cancer Clin Pract. 2020 Aug 10;18:17. doi: 10.1186/s13053-020-00148-9.
    • Frontline PARP inhibitor maintenance therapy in ovarian cancer: A Society of Gynecologic Oncology practice statement.
    • Pothuri B, O'Cearbhaill R, Eskander R, Armstrong D.
    • Gynecol Oncol. 2020 Aug 7:S0090-8258(20)33747-1. doi: 10.1016/j.ygyno.2020.07.097. Epub ahead of print.
    • Metastatic Pancreatic Cancer: ASCO Guideline Update.
    • Sohal DPS, Kennedy EB, Cinar P, Conroy T, Copur MS, Crane CH, Garrido-Laguna I, Lau MW, Johnson T, Krishnamurthi S, Moravek C, O'Reilly EM, Philip PA, Pant S, Shah MA, Sahai V, Uronis HE, Zaidi N, Laheru D.
    • J Clin Oncol. 2020 Aug 5:JCO2001364. doi: 10.1200/JCO.20.01364. Epub ahead of print.
    • Niraparib maintenance in frontline management of ovarian cancer: a cost effectiveness analysis.
    • Barrington DA, Tubbs C, Smith HJ, Straughn JM Jr, Senter L, Cohn DE.
    • Int J Gynecol Cancer. 2020 Aug 4:ijgc-2020-001550. doi: 10.1136/ijgc-2020-001550. Epub ahead of print.
    • AMXI-5001, a novel dual parp1/2 and microtubule polymerization inhibitor for the treatment of human cancers.
    • Lemjabbar-Alaoui H, Peto CJ, Yang YW, Jablons DM.
    • Am J Cancer Res. 2020 Aug 1;10(8):2649-2676.
    • Medicare to Cover Myriad Genetics' BRACAnalysis for FDA-Approved CDx Indications.
    • [No author given]
    • GenomeWeb. 2020 Jul 31.
    • Excellent Response to Olaparib in a Patient with Metastatic Pancreatic Adenocarcinoma with Germline BRCA1 Mutation after Progression on FOLFIRINOX: Case Report and Literature Review.
    • Pimenta JR, Ueda SKN, Peixoto RD.
    • Case Rep Oncol. 2020 Jul 29;13(2):904-910. doi: 10.1159/000508533.
    • FEN1 endonuclease as a therapeutic target for human cancers with defects in homologous recombination.
    • Guo E, Ishii Y, Mueller J, Srivatsan A, Gahman T, Putnam CD, Wang JYJ, Kolodner RD.
    • Proc Natl Acad Sci U S A. 2020 Jul 27:202009237. doi: 10.1073/pnas.2009237117. Epub ahead of print.
    • PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies.
    • Lee EK, Matulonis UA.
    • Cancers (Basel). 2020 Jul 25;12(8):2054. doi: 10.3390/cancers12082054.
    • Molecular signatures of BRCAness analysis identifies PARP inhibitor Niraparib as a novel targeted therapeutic strategy for soft tissue Sarcomas.
    • Li H, Tu J, Zhao Z, Chen L, Qu Y, Li H, Yao H, Wang X, Lee DF, Shen J, Wen L, Huang G, Xie X.
    • Theranostics. 2020 Jul 25;10(21):9477-9494. doi: 10.7150/thno.45763.
    • Olaparib for metastatic breast cancer in a patient with a germline PALB2 variant.
    • Kuemmel S, Harrach H, Schmutzler RK, Kostara A, Ziegler-Löhr K, Dyson MH, Chiari O, Reinisch M.
    • NPJ Breast Cancer. 2020 Jul 24;6:31. doi: 10.1038/s41523-020-00174-9.
    • Clinical BRCA1/2 reversion analysis identifies hotspot mutations and predicted neoantigens associated with therapy resistance.
    • Pettitt SJ, Frankum JR, Punta M, Lise S, Alexander J, Chen Y, Yap TA, Haider S, Tutt ANJ, Lord CJ.
    • Cancer Discov. 2020 Jul 22:CD-19-1485. doi: 10.1158/2159-8290.CD-19-1485. Epub ahead of print.
    • PARP Inhibitors in Endometrial Cancer: Current Status and Perspectives.
    • Musacchio L, Caruso G, Pisano C, Cecere SC, Di Napoli M, Attademo L, Tambaro R, Russo D, Califano D, Palaia I, Muzii L, Benedetti Panici P, Pignata S.
    • Cancer Manag Res. 2020 Jul 22;12:6123-6135. doi: 10.2147/CMAR.S221001.
    • PARP inhibitors in castration-resistant prostate cancer.
    • Tripathi A, Balakrishna P, Agarwal N.
    • Cancer Treat Res Commun. 2020 Jul 22;24:100199. doi: 10.1016/j.ctarc.2020.100199. Epub ahead of print.
    • Review
    • Inhibition of c-MET increases the antitumour activity of PARP inhibitors in gastric cancer models.
    • Koustas E, Karamouzis MV, Sarantis P, Schizas D, Papavassiliou AG.
    • J Cell Mol Med. 2020 Jul 20. doi: 10.1111/jcmm.15655. Epub ahead of print.
    • Epidemiology, Staging and Management of Prostate Cancer.
    • Barsouk A, Padala SA, Vakiti A, Mohammed A, Saginala K, Thandra KC, Rawla P, Barsouk A.
    • Med Sci (Basel). 2020 Jul 20;8(3):E28. doi: 10.3390/medsci8030028.
    • Augmentation of the antitumor effects of PARP inhibitors in triple-negative breast cancer via degradation by hydrophobic tagging modulation.
    • Go A, Jang JW, Lee W, Ha JD, Kim HJ, Nam HJ.
    • Eur J Med Chem. 2020 Jul 19;204:112635. doi: 10.1016/j.ejmech.2020.112635. Epub ahead of print.
    • Inactivation of the Prolyl Isomerase Pin1 Sensitizes BRCA1-Proficient Breast Cancer to PARP Inhibition.
    • Luo ML, Zheng F, Chen W, Liang ZM, Chandramouly G, Tan J, Willis NA, Chen CH, Taveira MO, Zhou XZ, Lu KP, Scully R, Wulf GM, Hu H.
    • Cancer Res. 2020 Jul 15;80(14):3033-3045. doi: 10.1158/0008-5472.CAN-19-2739. Epub 2020 Mar 19.

    Related:

    Commentary:

    A Novel Mechanism to Induce BRCAness in Cancer Cells.

    • A Phase I/II Study of Veliparib (ABT-888) in combination with 5-Fluorouracil and Oxaliplatin in Patients with Metastatic Pancreatic Cancer.
    • Pishvaian MJ, Wang H, He AR, Hwang JJ, Smaglo BG, Kim SS, Weinberg BA, Weiner LM, Marshall JL, Brody JR.
    • Clin Cancer Res. 2020 Jul 15:clincanres.1301.2020. doi: 10.1158/1078-0432.CCR-20-1301. Epub ahead of print.
    • The ups and downs of Poly(ADP-ribose) Polymerase-1 inhibitors in cancer therapy-Current progress and future direction.
    • Zhao Y, Zhang LX, Jiang T, Long J, Ma ZY, Lu AP, Cheng Y, Cao DS.
    • Eur J Med Chem. 2020 Jul 15;203:112570. doi: 10.1016/j.ejmech.2020.112570. Epub ahead of print.
    • Review
    • Pharmacologic induction of innate immune signaling directly drives homologous recombination deficiency.
    • McLaughlin LJ, Stojanovic L, Kogan AA, Rutherford JL, Choi EY, Yen RC, Xia L, Zou Y, Lapidus RG, Baylin SB, Topper MJ, Rassool FV.
    • Proc Natl Acad Sci U S A. 2020 Jul 10:202003499. doi: 10.1073/pnas.2003499117. Epub ahead of print.
    • Maintenance therapies in metastatic pancreatic cancer: present and future with a focus on PARP inhibitors.
    • Hammel P, Vitellius C, Boisteau É, Wisniewski M, Colle E, Hilmi M, Dengremont C, Granier S, Turpin A, de Mestier L, Neuzillet C.
    • Ther Adv Med Oncol. 2020 Jul 9;12:1758835920937949. doi: 10.1177/1758835920937949.
    • Synthetic Lethality strategies: Beyond BRCA1/2 mutations in pancreatic cancer.
    • Hu Y, Guo M.
    • Cancer Sci. 2020 Jul 8. doi: 10.1111/cas.14565. Epub ahead of print.
    • PARP Inhibitor Lynparza Receives EU Approval for Germline BRCA-Mutated Pancreatic Cancer.
    • [No author given.]
    • Precision Oncology News. 2020 Jul 8.
    • The efficacy and safety of the addition of poly ADP-ribose polymerase (PARP) inhibitors to therapy for ovarian cancer: a systematic review and meta-analysis.
    • Yang Y, Du N, Xie L, Jiang J, Mo J, Hong J, Mao D, Ng DM, Shi H.
    • World J Surg Oncol. 2020 Jul 4;18(1):151. doi: 10.1186/s12957-020-01931-7.
    • Zebrafish Xenografts Unveil Sensitivity to Olaparib beyond BRCA Status.
    • Varanda AB, Martins-Logrado A, Ferreira MG, Fior R.
    • Cancers (Basel). 2020 Jul 2;12(7):E1769. doi: 10.3390/cancers12071769.
    • The PARP inhibitor, olaparib, depletes the ovarian reserve in mice: implications for fertility preservation.
    • Winship AL, Griffiths M, Lliberos Requesens C, Sarma U, Phillips KA, Hutt KJ.
    • Hum Reprod. 2020 Jun 30:deaa128. doi: 10.1093/humrep/deaa128. Epub ahead of print.
    • Pancreatic cancer.
    • Mizrahi JD, Surana R, Valle JW, Shroff RT.
    • Lancet. 2020 Jun 27;395(10242):2008-2020. doi: 10.1016/S0140-6736(20)30974-0.
    • Review
    • PARP inhibitors for Cancer: Essential Biologic, Diagnostic, and Therapeutic Concepts for Today's Practitioner.
    • Sholl L, Mandelker D, Stockley T.
    • J Mol Diagn. 2020 Jun 20:S1525-1578(20)30359-7. doi: 10.1016/j.jmoldx.2020.06.002. Epub ahead of print.
    • Review
    • PARP inhibitor resistance: the underlying mechanisms and clinical implications.
    • Li H, Liu ZY, Wu N, Chen YC, Cheng Q, Wang J.
    • Mol Cancer. 2020 Jun 20;19(1):107. doi: 10.1186/s12943-020-01227-0.
    • Somatic and Germline BRCA 1 and 2 Mutations in Advanced NSCLC From the SAFIR02-Lung Trial.
    • Remon J, Besse B, Leary A, Bièche I, Job B, Lacroix L, Auguste A, Mauduit M, Audigier-Valette C, Raimbourg J, Madroszyk A, Michels S, Bayar MA, Jimenez M, Soria JC, Rouleau E, Barlesi F.
    • JTO Clin Res Rep. 2020 Jun 11;1(3):100068. doi: 10.1016/j.jtocrr.2020.100068.
    • Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors.
    • Peyraud F, Italiano A.
    • Cancers (Basel). 2020 Jun 9;12(6):E1502. doi: 10.3390/cancers12061502.
    • Germline Testing In Advanced Cancer Can Lead to Targeted Tx.
    • Nelson R.
    • Medscape. Conference News. 2020 Jun 2.
    • Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study.
    • Abida W, Campbell D, Patnaik A, Shapiro JD, Sautois B, Vogelzang NJ, Voog EG, Bryce AH, McDermott R, Ricci F, Rowe J, Zhang J, Piulats JM, Fizazi K, Merseburger AS, Higano CS, Krieger LE, Ryan CJ, Feng FY, Simmons AD, Loehr A, Despain D, Dowson M, Green F, Watkins SP, Golsorkhi T, Chowdhury S.
    • Clin Cancer Res. 2020 Jun 1;26(11):2487-2496. doi: 10.1158/1078-0432.CCR-20-0394. Epub 2020 Feb 21.

    Related:

    Research review:

    Honing in on PARPi Response in Prostate Cancer: from HR Pathway to Gene-by-Gene Granularity.

    • Genetic and epigenetic profiling of BRCA1/2 in ovarian tumors reveals additive diagnostic yield and evidence of a genomic BRCA1/2 DNA methylation signature.
    • Aref-Eshghi E, McGee JD, Pedro VP, Kerkhof J, Stuart A, Ainsworth PJ, Lin H, Volodarsky M, McLachlin CM, Sadikovic B.
    • J Hum Genet. 2020 Jun 1. doi: 10.1038/s10038-020-0780-4. Epub ahead of print.
    • Phase I dose-escalation and expansion study of PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumors.
    • Li H, Liu R, Shao B, Ran R, Song G, Wang K, Shi Y, Liu J, Hu W, Chen F, Liu X, Zhang G, Zhao C, Jia R, Wang Q, Rugo HS, Zhang Y, Li G, Xu J.
    • Chin J Cancer Res. 2020 Jun;32(3):370-382. doi: 10.21147/j.issn.1000-9604.2020.03.08.
    • Molecular profile of BRCA-mutated biliary tract cancers.
    • Spizzo G, Puccini A, Xiu J, Goldberg RM, Grothey A, Shields AF, Arora SP, Khushmann M, Salem ME, Battaglin F, Baca Y, El-Deiry WS, Philip PA, Nassem M, Hall M, Marshall JL, Kocher F, Amann A, Wolf D, Korn WM, Lenz H, Seeber A.
    • ESMO Open. 2020 Jun;5(3):e000682. doi: 10.1136/esmoopen-2020-000682.
    • Germline Results From Tumor-Normal Sequencing Guides Precision Therapy in Advanced Cancer Patients.
    • Ray T.
    • Precision Oncology News. 2020 May 31.

    Related:

    Guidelines:

    Points to consider for reporting of germline variation in patients undergoing tumor testing: a statement of the American College of Medical Genetics and Genomics (ACMG).

    • Q&A: ACMG Work Group Hoping to Spark Discussion on Reporting Germline Findings From Tumor Testing.
    • Ray T.
    • Precision Oncology News. 2020 May 21.
    • News

    Related:

    Guidelines:

    Points to consider for reporting of germline variation in patients undergoing tumor testing: a statement of the American College of Medical Genetics and Genomics (ACMG).

    • FDA Approves Lynparza With Myriad, Foundation Med CDx Tests in HRR-Mutated Prostate Cancer
    • [No author given]
    • GenomeWeb. 2020 May 20.
    • Biomarker-Guided Development of DNA Repair Inhibitors.
    • Cleary JM, Aguirre AJ, Shapiro GI, D'Andrea AD.
    • Mol Cell. 2020 May 17:S1097-2765(20)30277-X. doi: 10.1016/j.molcel.2020.04.035. Epub ahead of print.
    • Review
    • Poly(ADP-ribose) polymerase inhibitors in prostate and urothelial cancer.
    • Brönimann S, Lemberger U, Bruchbacher A, Shariat SF, Hassler MR.
    • Curr Opin Urol. 2020 May 13. doi: 10.1097/MOU.0000000000000776. Epub ahead of print.
    • Review
    • Integration of multiple biological contexts reveals principles of synthetic lethality that affect reproducibility.
    • Ku AA, Hu HM, Zhao X, Shah KN, Kongara S, Wu D, McCormick F, Balmain A, Bandyopadhyay S.
    • Nat Commun. 2020 May 12;11(1):2375. doi: 10.1038/s41467-020-16078-y.
    • The Impact of Whole Genome Data on Therapeutic Decision-Making in Metastatic Prostate Cancer: A Retrospective Analysis.
    • Crumbaker M, Chan EKF, Gong T, Corcoran N, Jaratlerdsiri W, Lyons RJ, Haynes AM, Kulidjian AA, Kalsbeek AMF, Petersen DC, Stricker PD, Jamieson CAM, Croucher PI, Hovens CM, Joshua AM, Hayes VM.
    • Cancers (Basel). 2020 May 7;12(5):E1178. doi: 10.3390/cancers12051178.
    • Replication Fork Remodeling and Therapy Escape in DNA Damage Response-Deficient Cancers.
    • Liptay M, Barbosa JS, Rottenberg S.
    • Front Oncol. 2020 May 5;10:670. doi: 10.3389/fonc.2020.00670.
    • PARP inhibitors as a new therapeutic option in metastatic prostate cancer: a systematic review.
    • Ratta R, Guida A, Scotté F, Neuzillet Y, Teillet AB, Lebret T, Beuzeboc P.
    • Prostate Cancer Prostatic Dis. 2020 May 4. doi: 10.1038/s41391-020-0233-3. [Epub ahead of print]
    • Review
    • Integrating Genetic and Genomic Testing Into Oncology Practice.
    • Domchek SM, Mardis E, Carlisle JW, Owonikoko TK.
    • Am Soc Clin Oncol Educ Book. 2020 May;40:e259-e263. doi: 10.1200/EDBK_280607.
    • Neoantigen load and HLA-class I expression identify a subgroup of tumors with a T-cell-inflamed phenotype and favorable prognosis in homologous recombination-proficient high-grade serous ovarian carcinoma.
    • Matsushita H, Hasegawa K, Oda K, Yamamoto S, Asada K, Karasaki T, Yabuno A, Nishijima A, Nejo T, Kobayashi Y, Sato S, Ikeda Y, Miyai M, Takahashi Y, Yamaguchi R, Fujiwara K, Aburatani H, Kakimi K.
    • J Immunother Cancer. 2020 May;8(1):e000375. doi: 10.1136/jitc-2019-000375.
    • Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial.
    • Ledermann JA, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp AR, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Banerjee S, García-Donas J, Swisher EM, Cameron T, Maloney L, Goble S, Coleman RL.
    • Lancet Oncol. 2020 May;21(5):710-722. doi: 10.1016/S1470-2045(20)30061-9.

    Related:

    Commentary, Introductory article:

    Expanding use of rucaparib as maintenance therapy in recurrent ovarian cancer: updates from the ARIEL3 trial.

    • GSK Gets Broad Zejula Indication in Ovarian Cancer; FDA Deems Myriad Genetics' Test Complementary
    • [No author given.]
    • GenomeWeb. Business & Policy. 2020 Apr 30.

    Related:

    Original research:

    Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.

    • Pan-Cancer Analysis of BRCA1 and BRCA2 Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of Heterozygosity.
    • Sokol ES, Pavlick D, Khiabanian H, Frampton GM, Ross JS, Gregg JP, Lara PN, Oesterreich S, Agarwal N, Necchi A, Miller VA, Alexander B, Ali SM, Ganesan S, Chung JH.
    • JCO Precis Oncol. 2020;4:442-465. doi: 10.1200/po.19.00345. Epub 2020 Apr 30.
    • FDA approves niraparib for first-line maintenance of advanced ovarian cancer.
    • [No author given.]
    • U.S. Food & Drug Administration. Drug Approvals and Databases. 2020 Apr 29.

    Related:

    Research review: Study: New FDA approval for maintenance therapy in ovarian cancer. (FORCE. XRAYS.)

    • TMB: a promising immune-response biomarker, and potential spearhead in advancing targeted therapy trials.
    • Choucair K, Morand S, Stanbery L, Edelman G, Dworkin L, Nemunaitis J.
    • Cancer Gene Ther. 2020 Apr 28. doi: 10.1038/s41417-020-0174-y. [Epub ahead of print]
    • Review
    • Therapeutic Potential of Combining PARP Inhibitor and Immunotherapy in Solid Tumors.
    • Vikas P, Borcherding N, Chennamadhavuni A, Garje R.
    • Front Oncol. 2020 Apr 28;10:570. doi: 10.3389/fonc.2020.00570.
    • Olaparib for Metastatic Castration-Resistant Prostate Cancer.
    • de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Sartor O, Agarwal N, Olmos D, Thiery-Vuillemin A, Twardowski P, Mehra N, Goessl C, Kang J, Burgents J, Wu W, Kohlmann A, Adelman CA, Hussain M.
    • N Engl J Med. 2020 Apr 28. doi: 10.1056/NEJMoa1911440. [Epub ahead of print]
    • A single nucleotide variant of human PARP1 determines response to PARP inhibitors.
    • Cashman R, Zilberberg A, Priel A, Philip H, Varvak A, Jacob A, Shoval I, Efroni S.
    • NPJ Precis Oncol. 2020 Apr 27;4:10. doi: 10.1038/s41698-020-0113-2. eCollection 2020.
    • Points to consider for reporting of germline variation in patients undergoing tumor testing: a statement of the American College of Medical Genetics and Genomics (ACMG).
    • Li MM, Chao E, Esplin ED, Miller DT, Nathanson KL, Plon SE, Scheuner MT, Stewart DR; ACMG Professional Practice and Guidelines Committee.
    • Genet Med. 2020 Apr 23. doi: 10.1038/s41436-020-0783-8. Epub ahead of print.

    Related:

    News, Interview: Q&A: ACMG Work Group Hoping to Spark Discussion on Reporting Germline Findings From Tumor Testing. (Precision Oncology News)

    • Genomic Landscape of Uterine Sarcomas Defined through Prospective Clinical Sequencing.
    • Hensley ML, Chavan SS, Solit DB, Murali R, Soslow R, Chiang S, Jungbluth AA, Bandlamudi C, Srinivasan P, Tap WD, Rosenbaum E, Taylor BS, Donoghue MTA, Hyman DM.
    • Clin Cancer Res. 2020 Apr 16. pii: clincanres.3959.2019. doi: 10.1158/1078-0432.CCR-19-3959. [Epub ahead of print]
    • Therapeutic Strategies and Biomarkers to Modulate PARP Activity for Targeted Cancer Therapy.
    • Singh N, Pay SL, Bhandare SB, Arimpur U, Motea EA.
    • Cancers (Basel). 2020 Apr 14;12(4). pii: E972. doi: 10.3390/cancers12040972.
    • Characterization of therapy-related acute leukemia in hereditary breast-ovarian carcinoma patients: role of BRCA1 mutation and topoisomerase II-directed therapy.
    • Bagal B, Kumar R, Gaur T, Talreja V, Bonda A, Patkar N, Shetty D, Kowtal P, Subramanian PG, Gupta S, Sarin R, Hasan SK.
    • Med Oncol. 2020 Apr 10;37(5):48. doi: 10.1007/s12032-020-01371-z.
    • Case report
    • Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events.
    • Madariaga A, Bowering V, Ahrari S, Oza AM, Lheureux S.
    • Int J Gynecol Cancer. 2020 Apr 9. pii: ijgc-2020-001288. doi: 10.1136/ijgc-2020-001288. [Epub ahead of print]
    • Recurrent uterine serous carcinoma with a germline pathogenic BRCA2 variant treated using olaparib: A case report.
    • Inoue K, Tsubamoto H, Ueda T, Tajima C, Nakagomi N.
    • Gynecol Oncol Rep. 2020 Apr 5;32:100563. doi: 10.1016/j.gore.2020.100563. eCollection 2020 May.
    • Exploring the Synergy between PARP and CHK1 Inhibition in Matched BRCA2 Mutant and Corrected Cells.
    • Smith HL, Prendergast L, Curtin NJ.
    • Cancers (Basel). 2020 Apr 4;12(4). pii: E878. doi: 10.3390/cancers12040878.
    • CDK9 inhibitor CDKI-73 is synergetic lethal with PARP inhibitor olaparib in BRCA1 wide-type ovarian cancer.
    • Li J, Zhi X, Chen S, Shen X, Chen C, Yuan L, Guo J, Meng D, Chen M, Yao L.
    • Am J Cancer Res. 2020 Apr 1;10(4):1140-1155. eCollection 2020.
    • Class I histone deacetylase inhibition is synthetic lethal with BRCA1 deficiency in breast cancer cells.
    • Zhang B, Lyu J, Yang EJ, Liu Y, Wu C, Pardeshi L, Tan K, Chen Q, Xu X, Deng CX, Shim JS.
    • Acta Pharm Sin B. 2020 Apr;10(4):615-627. doi: 10.1016/j.apsb.2019.08.008. Epub 2019 Sep 5.
    • Synergistic lethality between PARP-trapping and alantolactone-induced oxidative DNA damage in homologous recombination-proficient cancer cells.
    • Wang H, Zhang S, Song L, Qu M, Zou Z.
    • Oncogene. 2020 Apr;39(14):2905-2920. doi: 10.1038/s41388-020-1191-x. Epub 2020 Feb 6.
    • Pharmacological ascorbate induces 'BRCAness' and enhances the effects of Poly(ADP-Ribose) polymerase inhibitors against BRCA1/2 wild-type ovarian cancer.
    • Ma Y, Chen P, Drisko JA, Khabele D, Godwin AK, Chen Q.
    • Oncol Lett. 2020 Apr;19(4):2629-2638. doi: 10.3892/ol.2020.11364. Epub 2020 Jan 31.
    • Metastatic Thymoma Harboring a Deleterious BRCA2 Mutation Derives Durable Clinical Benefit from Olaparib.
    • Principe DR, Kamath SD, Munshi HG, Mohindra NA.
    • Oncologist. 2020 Apr;25(4):301-305. doi: 10.1634/theoncologist.2019-0393. Epub 2019 Nov 1.
    • Pancreatic cancer patients with germline BRCA mutations can benefit from olaparib treatment.
    • Mukherjee S, Asaithamby A.
    • Transl Cancer Res. 2020 Apr;9(4):2154-2156. doi: 10.21037/tcr.2020.03.07.

    Related:

    Original research:

    Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.

    • Synthetic lethality on drug discovery: an update on cancer therapy.
    • Yar MS, Haider K, Gohel V, Siddiqui NA, Kamal A.
    • Expert Opin Drug Discov. 2020 Mar 31:1-10. doi: 10.1080/17460441.2020.1744560. [Epub ahead of print]
    • Review
    • Myriad Genetics Seeks Japan Approval for Advanced Pancreatic, Prostate Cancer Companion Diagnostic.
    • [No author given]
    • GenomeWeb. 2020 Mar 30.
    • Response of Breast Cancer Cells to PARP Inhibitors Is Independent of BRCA Status.
    • Keung MY, Wu Y, Badar F, Vadgama JV.
    • J Clin Med. 2020 Mar 30;9(4). pii: E940. doi: 10.3390/jcm9040940.
    • Efficacy and safety of PARP inhibitors as the maintenance therapy in ovarian cancer: a meta-analysis of nine randomized controlled trials.
    • Shao F, Liu J, Duan Y, Li L, Liu L, Zhang C, He S.
    • Biosci Rep. 2020 Mar 27;40(3). pii: BSR20192226. doi: 10.1042/BSR20192226.
    • Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond.
    • Boussios S, Abson C, Moschetta M, Rassy E, Karathanasi A, Bhat T, Ghumman F, Sheriff M, Pavlidis N.
    • Drugs R D. 2020 Mar 25. doi: 10.1007/s40268-020-00301-8. [Epub ahead of print]
    • A critical evaluation of methods to interpret drug combinations.
    • Twarog NR, Connelly M, Shelat AA.
    • Sci Rep. 2020 Mar 20;10(1):5144. doi: 10.1038/s41598-020-61923-1.
    • [Medical treatment options in BRCA-associated cancers].
    • Kahán Z.
    • Magy Onkol. 2020 Mar 17;64(1):13-24. Epub 2020 Feb 10.
    • Review, [Article in Hungarian]
    • Polyclonal BRCA2 mutations following carboplatin treatment confer resistance to the PARP inhibitor rucaparib in a patient with mCRPC: a case report.
    • Simmons AD, Nguyen M, Pintus E.
    • BMC Cancer. 2020 Mar 14;20(1):215. doi: 10.1186/s12885-020-6657-2.
    • ATM-Deficient Cancers Provide New Opportunities for Precision Oncology.
    • Jette NR, Kumar M, Radhamani S, Arthur G, Goutam S, Yip S, Kolinsky M, Williams GJ, Bose P, Lees-Miller SP.
    • Cancers (Basel). 2020 Mar 14;12(3). pii: E687. doi: 10.3390/cancers12030687.
    • An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers.
    • Przybytkowski E, Davis T, Hosny A, Eismann J, Matulonis UA, Wulf GM, Nabavi S.
    • BMC Cancer. 2020 Mar 12;20(1):197. doi: 10.1186/s12885-020-6605-1.
    • The role of poly(ADP-ribose) polymerase inhibitors in the treatment of cancer and methods to overcome resistance: a review.
    • Patel M, Nowsheen S, Maraboyina S, Xia F.
    • Cell Biosci. 2020 Mar 11;10:35. doi: 10.1186/s13578-020-00390-7. eCollection 2020.
    • ATM Loss Confers Greater Sensitivity to ATR Inhibition than PARP Inhibition in Prostate Cancer.
    • Rafiei S, Fitzpatrick K, Liu D, Cai MY, Elmarakeby HA, Park J, Ricker C, Kochupurakkal BS, Choudhury AD, Hahn WC, Balk SP, Hwang JH, Van Allen EM, Mouw KW.
    • Cancer Res. 2020 Mar 3. pii: canres.3126.2019. doi: 10.1158/0008-5472.CAN-19-3126. [Epub ahead of print]
    • PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications.
    • Zhu H, Wei M, Xu J, Hua J, Liang C, Meng Q, Zhang Y, Liu J, Zhang B, Yu X, Shi S.
    • Mol Cancer. 2020 Mar 2;19(1):49. doi: 10.1186/s12943-020-01167-9.
    • PARP and PARG inhibitors in cancer treatment.
    • Slade D.
    • Genes Dev. 2020 Mar 1;34(5-6):360-394. doi: 10.1101/gad.334516.119. Epub 2020 Feb 6.
    • Complete Response to Chemotherapy in Metastatic Pancreatic Carcinoma Associated with Double Heterozygous Germline Mutation in BRCA2 and CHEK2 Genes - a Case Report.
    • Pazderová N, Urbán V, Makovník M, Macák D, Janega P, Chovanec M, Rejleková K, Mardiak J, Mego M.
    • Klin Onkol. 2020 Spring;33(3):220-225. English. doi: 10.14735/amko2020220.
    • PARP Inhibitors for Ovarian Cancer: Current Indications, Future Combinations, and Novel Assets in Development to Target DNA Damage Repair.
    • Konstantinopoulos PA, Lheureux S, Moore KN.
    • Am Soc Clin Oncol Educ Book. 2020 Mar;40:1-16. doi: 10.1200/EDBK_288015.
    • SGO Special Topic: PARP Inhibitor Maintenance Therapy after Initial Chemotherapy.
    • Armstrong DK, Eskander R, Cearbhaill R, Pothuri B.
    • Gynecologic Oncology. Podcasts. 2020 Mar.
    • Podcast
    • The Development of Rucaparib/Rubraca®: A Story of the Synergy Between Science and Serendipity.
    • Curtin NJ.
    • Cancers (Basel). 2020 Feb 29;12(3). pii: E564. doi: 10.3390/cancers12030564.
    • Molecular Mechanisms of PALB2 Function and Its Role in Breast Cancer Management.
    • Wu S, Zhou J, Zhang K, Chen H, Luo M, Lu Y, Sun Y, Chen Y.
    • Front Oncol. 2020 Feb 28;10:301. doi: 10.3389/fonc.2020.00301. eCollection 2020.
    • Therapeutic opportunities for PLK1 inhibitors: Spotlight on BRCA1-deficiency and triple negative breast cancers.
    • García IA, Garro C, Fernandez E, Soria G.
    • Mutat Res. 2020 Feb 25;821:111693. doi: 10.1016/j.mrfmmm.2020.111693. [Epub ahead of print]
    • Review
    • Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: analysis from the phase 2 TRITON2 study.
    • Abida W, Campbell D, Patnaik A, Shapiro JD, Sautois B, Vogelzang NJ, Voog EG, Bryce AH, McDermott R, Ricci F, Rowe J, Zhang J, Piulats JM, Fizazi K, Merseburger AS, Higano CS, Krieger LE, Ryan CJ, Feng FY, Simmons AD, Loehr A, Despain D, Dowson M, Green F, Watkins SP, Golsorkhi T, Chowdhury S.
    • Clin Cancer Res. 2020 Feb 21. pii: clincanres.0394.2020. doi: 10.1158/1078-0432.CCR-20-0394. [Epub ahead of print]

    Related:

    Research review:

    Honing in on PARPi response in Prostate Cancer: from HR pathway- to gene-by-gene granularity.

    • PARP Inhibitors in Gynecologic Cancers: What Is the Next Big Development?
    • Lightfoot M, Montemorano L, Bixel K.
    • Curr Oncol Rep. 2020 Feb 17;22(3):29. doi: 10.1007/s11912-020-0873-4.
    • Review
    • PARP Inhibitors as Therapeutics: Beyond Modulation of PARylation.
    • Min A, Im SA.
    • Cancers (Basel). 2020 Feb 8;12(2). pii: E394. doi: 10.3390/cancers12020394.
    • Routine plasma-based genotyping to comprehensively detect germline, somatic, and reversion BRCA mutations among patients with advanced solid tumors.
    • Vidula N, Rich TA, Sartor O, Yen J, Hardin A, Nance T, Lilly MB, Nezami MA, Patel SP, Carneiro BA, Fan A, Brufksy AM, Parker BA, Bridges BB, Agarwal N, Maughan BL, Raymond VM, Fairclough SR, Lanman RB, Bardia A, Cristofanilli M.
    • Clin Cancer Res. 2020 Feb 7. pii: clincanres.2933.2019. doi: 10.1158/1078-0432.CCR-19-2933. [Epub ahead of print]
    • Personalized Treatment Approach to Metastatic Castration-Resistant Prostate Cancer with BRCA2 and PTEN Mutations: A Case Report.
    • Julka PK, Verma A, Gupta K.
    • Case Rep Oncol. 2020 Feb 4;13(1):55-61. doi: 10.1159/000505182. eCollection 2020 Jan-Apr.
    • TDP1 and TOP1 Modulation in Olaparib-Resistant Cancer Determines the Efficacy of Subsequent Chemotherapy.
    • Kim JW, Min A, Im SA, Jang H, Kim YJ, Kim HJ, Lee KH, Kim TY, Lee KW, Oh DY, Kim JH, Bang YJ.
    • Cancers (Basel). 2020 Feb 3;12(2). pii: E334. doi: 10.3390/cancers12020334.
    • Specific Toxicity of Maintenance Olaparib Versus Placebo in Advanced Malignancies: A Systematic Review and Meta-analysis.
    • Ricci AD, Rizzo A, Novelli M, Tavolari S, Palloni A, Tober N, Abbati F, Mollica V, DE Lorenzo S, Turchetti D, DI Marco M, Brandi G.
    • Anticancer Res. 2020 Feb;40(2):597-608. doi: 10.21873/anticanres.13989.
    • Review
    • PARP inhibitor-induced torsades de pointes in long QT syndrome: a case report.
    • Segan L, Beekman A, Parfrey S, Perrin M.
    • Eur Heart J Case Rep. 2019 Dec 31;4(1):1-5. doi: 10.1093/ehjcr/ytz230. eCollection 2020 Feb.
    • Treatment of Pediatric Glioblastoma with Combination Olaparib and Temozolomide Demonstrates 2-Year Durable Response.
    • Valiakhmetova A, Gorelyshev S, Konovalov A, Trunin Y, Savateev A, Kram DE, Severson E, Hemmerich A, Edgerly C, Duncan D, Britt N, Huang RSP, Elvin J, Miller V, Ross JS, Gay L, McCorkle J, Rankin A, Erlich RL, Chudnovsky Y, Ramkissoon SH.
    • Oncologist. 2020 Feb;25(2):e198-e202. doi: 10.1634/theoncologist.2019-0603. Epub 2019 Oct 16.
    • PARP inhibitors: a tsunami of indications in different malignancies.
    • Haddad G, Saadé MC, Eid R, Haddad FG, Kourie HR.
    • Pharmacogenomics. 2020 Feb;21(3):221-230. doi: 10.2217/pgs-2019-0113.
    • Review
    • Magnitude of benefit of the addition of poly ADP-ribose polymerase (PARP) inhibitors to therapy for malignant tumor: A meta-analysis.
    • Gu L, Du N, Jin Q, Li S, Xie L, Mo J, Shen Z, Mao D, Ji J, Khadaroo PA, Chen B.
    • Crit Rev Oncol Hematol. 2020 Jan 30;147:102888. doi: 10.1016/j.critrevonc.2020.102888. [Epub ahead of print]
    • Review
    • Design, Synthesis, and In Vitro Evaluation of the Photoactivatable Prodrug of the PARP Inhibitor Talazoparib.
    • Li J, Xiao D, Liu L, Xie F, Li W, Sun W, Yang X, Zhou X.
    • Molecules. 2020 Jan 18;25(2). pii: E407. doi: 10.3390/molecules25020407.
    • Germline and somatic mutations in prostate cancer: focus on defective DNA repair, PARP inhibitors and immunotherapy.
    • Cimadamore A, Lopez-Beltran A, Massari F, Santoni M, Mazzucchelli R, Scarpelli M, Galosi AB, Cheng L, Montironi R.
    • Future Oncol. 2020 Jan 9. doi: 10.2217/fon-2019-0745. [Epub ahead of print]
    • Review, Commentary
    • The metallo-intercalator [Ru(dppz)2(PIP)]2+ renders BRCA wild-type triple-negative breast cancer cells hypersensitive to PARP inhibition.
    • Yusoh NA, Leong SW, Chia SL, Harun SN, Abdul Rahman MB, Vallis KA, Gill MR, Ahmad H.
    • ACS Chem Biol. 2020 Jan 3. doi: 10.1021/acschembio.9b00843. [Epub ahead of print]
    • An exceptional response to olaparib in relapsed and refractory BRCA2 mutated non-small cell lung cancer in hereditary breast-ovarian cancer syndrome.
    • Talreja VT, Noronha V, Joshi A, Patil V, Prabhash K.
    • South Asian J Cancer. 2020 Jan-Mar;9(1):6. doi: 10.4103/sajc.sajc_157_19.
    • FDA Approves First PARP Inhibitor as Frontline Maintenance in Pancreatic Cancer.
    • Kahl KL.
    • Cancernetwork. 2019 Dec 30.
    • FDA Approves Myriad BRACAnalysis CDx for Lynparza in Metastatic Pancreatic Cancer.
    • [No author given]
    • Clinical OMICs. 2019 Dec 30.
    • FDA Approves AstraZeneca's Lynparza, Myriad Genetics' CDx for BRCA-Positive Pancreatic Cancer.
    • [No author given]
    • GenomeWeb. 2019 Dec 30.
    • New Option in Pancreatic Cancer: Olaparib for BRCA Mutations.
    • Chustecka Z.
    • Medscape Oncology. 2019 Dec 30.
    • LYNPARZA® (olaparib) Approved by FDA as First-Line Maintenance Treatment of Germline BRCA-Mutated Metastatic Pancreatic Cancer.
    • [No author given]
    • Merck. News Release. 2019 Dec 30.
    • Role of Olaparib as Maintenance Treatment for Ovarian Cancer: The Evidence to Date.
    • Montemorano L, Lightfoot MD, Bixel K.
    • Onco Targets Ther. 2019 Dec 27;12:11497-11506. doi: 10.2147/OTT.S195552. eCollection 2019.
    • Chemotherapy combined with bevacizumab for the treatment of advanced lung adenocarcinoma cancer harboring EGFR-ANXA2, EGFR-RAD51, ATR and BRCA2 mutations: A case report.
    • Zhong R, Li H1, Liu Y, Zhang S, Liu J, Huang Z, Cheng Y.
    • Thorac Cancer. 2019 Dec 22. doi: 10.1111/1759-7714.13286. [Epub ahead of print]
    • Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
    • González-Martín A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, McCormick C, Lorusso D, Hoskins P, Freyer G, Baumann K, Jardon K, Redondo A, Moore RG, Vulsteke C, O'Cearbhaill RE, Lund B, Backes F, Barretina-Ginesta P, Haggerty AF, Rubio-Pérez MJ, Shahin MS, Mangili G, Bradley WH, Bruchim I, Sun K, Malinowska IA, Li Y, Gupta D, Monk BJ; PRIMA/ENGOT-OV26/GOG-3012 Investigators.
    • N Engl J Med. 2019 Dec 19;381(25):2391-2402. doi: 10.1056/NEJMoa1910962. Epub 2019 Sep 28.

    Related:

    Research news, Commentary:

    Personalized Medicine for Primary Treatment of Serous Ovarian Cancer.

    Research news: Study: Niraparib increases progression-free survival in patients with newly diagnosed ovarian cancer. (FORCE. XRAYS.)

    Press, Conference report: PARP Inhibitors Move Into First-Line for Ovarian Cancer. (Medscape Oncology)

    See PubMed abstract for multiple additional related items.

    • Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer.
    • Coleman RL, Fleming GF, Brady MF, Swisher EM, Steffensen KD, Friedlander M, Okamoto A, Moore KN, Efrat Ben-Baruch N, Werner TL, Cloven NG, Oaknin A, DiSilvestro PA, Morgan MA, Nam JH, Leath CA 3rd, Nicum S, Hagemann AR, Littell RD, Cella D, Baron-Hay S, Garcia-Donas J, Mizuno M, Bell-McGuinn K, Sullivan DM, Bach BA, Bhattacharya S, Ratajczak CK, Ansell PJ, Dinh MH, Aghajanian C, Bookman MA.
    • N Engl J Med. 2019 Dec 19;381(25):2403-2415. doi: 10.1056/NEJMoa1909707. Epub 2019 Sep 28.

    Related:

    Research news, Commentary:

    Personalized Medicine for Primary Treatment of Serous Ovarian Cancer.

    Press, Conference report: PARP Inhibitors Move Into First-Line for Ovarian Cancer. (Medscape Oncology)

    • Personalized Medicine for Primary Treatment of Serous Ovarian Cancer.
    • Longo DL.
    • N Engl J Med. 2019 Dec 19;381(25):2471-2474. doi: 10.1056/NEJMe1914488.
    • Research news, Commentary

    Related:

    Original research:

    Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.

    Original research:

    Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer.

    Original research:

    Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.

    • EGFR amplification induces increased DNA damage response and renders selective sensitivity to Talazoparib (PARP inhibitor) in glioblastoma.
    • Wu S, Gao F, Zheng S, Zhang C, Martinez-Ledesma E, Ezhilarasan R, Ding J, Li X, Feng N, Multani A, Sulman EP, Verhaak RG, de Groot JF, Heffernan TP, Yung WKA, Koul D.
    • Clin Cancer Res. 2019 Dec 18. pii: clincanres.2549.2019. doi: 10.1158/1078-0432.CCR-19-2549. [Epub ahead of print]
    • Discovery of Novel Dual Poly(ADP-ribose)polymerase (PARP) and Phosphoinositide 3-kinase (PI3K) Inhibitors as A Promising Strategy for Cancer Therapy.
    • Wang J, Li H, He G, Chu Z, Peng K, Ge Y, Zhu Q, Xu Y.
    • J Med Chem. 2019 Dec 17. doi: 10.1021/acs.jmedchem.9b00622. [Epub ahead of print]
    • Harnessing DNA Double-Strand Break Repair for Cancer Treatment.
    • Trenner A, Sartori AA.
    • Front Oncol. 2019 Dec 10;9:1388. doi: 10.3389/fonc.2019.01388. eCollection 2019.
    • Crizotinib and PARP inhibitors act synergistically by triggering apoptosis in high-grade serous ovarian cancer.
    • Sahin ID, Jönsson JM, Hedenfalk I.
    • Oncotarget. 2019 Dec 10;10(65):6981-6996. doi: 10.18632/oncotarget.27363. eCollection 2019 Dec 10.
    • Poly(ADP-Ribose) Polymerase Inhibitors in Pancreatic Cancer: A New Treatment Paradigms and Future Implications.
    • Gupta M, Iyer R, Fountzilas C.
    • Cancers (Basel). 2019 Dec 9;11(12). pii: E1980. doi: 10.3390/cancers11121980.
    • Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation.
    • Wattenberg MM, Asch D, Yu S, O'Dwyer PJ, Domchek SM, Nathanson KL, Rosen MA, Beatty GL, Siegelman ES, Reiss KA.
    • Br J Cancer. 2019 Dec 2. doi: 10.1038/s41416-019-0582-7. [Epub ahead of print]

    Related:

    Editorial:

    Genotype–phenotype correlation in BRCA1/2 mutation-associated pancreatic cancer.

    • Genotype-phenotype correlation in BRCA1/2 mutation-associated pancreatic cancer.
    • Lowery MA.
    • Br J Cancer. 2019 Dec 2. doi: 10.1038/s41416-019-0645-9. [Epub ahead of print]
    • Translational Highlights in Breast and Ovarian Cancer 2019 - Immunotherapy, DNA Repair, PI3K Inhibition and CDK4/6 Therapy.
    • Hartkopf AD, Müller V, Wöckel A, Lux MP, Janni W, Ettl J, Belleville E, Schütz F, Fasching PA, Kolberg HC, Welslau M, Overkamp F, Taran FA, Brucker SY, Wallwiener M, Tesch H, Fehm TN, Schneeweiss A, Lüftner D.
    • Geburtshilfe Frauenheilkd. 2019 Dec;79(12):1309-1319. doi: 10.1055/a-1039-4458. Epub 2019 Dec 11.
    • Fluzoparib increases radiation sensitivity of non-small cell lung cancer (NSCLC) cells without BRCA1/2 mutation, a novel PARP1 inhibitor undergoing clinical trials.
    • Luo J, Dai X, Hu H, Chen J, Zhao L, Yang C, Sun J, Zhang L, Wang Q, Xu S, Xu Y, Liu N, Ying G, Wang P.
    • J Cancer Res Clin Oncol. 2019 Nov 30. doi: 10.1007/s00432-019-03097-6. [Epub ahead of print]
    • Response to Olaparib in a Patient with Germline BRCA2 Mutation and Breast Cancer Leptomeningeal Carcinomatosis.
    • Exman P, Mallery RM, Lin NU, Parsons HA.
    • NPJ Breast Cancer. 2019 Nov 29;5:46. doi: 10.1038/s41523-019-0139-1. eCollection 2019.
    • Allele-specific expression mediates primary resistance to poly (ADP-ribose) polymerase inhibitor therapy in a case of BRCA1/2 double-germline mutant gastric cancer.
    • Wen L, Li X, Shi J, Zhang S, Wang R, Yao M, Guo J.
    • J Int Med Res. 2019 Nov 27:300060519886226. doi: 10.1177/0300060519886226. [Epub ahead of print]
    • Non-small cell lung cancer cells with deficiencies in homologous recombination genes are sensitive to PARP inhibitors.
    • Ji W, Weng X, Xu D, Cai S, Ding L.
    • Biochem Biophys Res Commun. 2019 Nov 18. pii: S0006-291X(19)32170-9. doi: 10.1016/j.bbrc.2019.11.050. [Epub ahead of print]
    • Correlation of homologous recombination deficiency induced mutational signatures with sensitivity to PARP inhibitors and cytotoxic agents.
    • Póti Á, Gyergyák H, Németh E, Rusz O, Tóth S, Kovácsházi C, Chen D, Szikriszt B, Spisák S, Takeda S, Szakács G, Szallasi Z, Richardson AL, Szüts D.
    • Genome Biol. 2019 Nov 14;20(1):240. doi: 10.1186/s13059-019-1867-0.
    • Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagy-mediated drug resistance in ovarian cancer cells, xenografts, and patient-derived xenograft models.
    • Santiago-O'Farrill JM, Weroha SJ, Hou X, Oberg AL, Heinzen EP, Maurer MJ, Pang L, Rask P, Amaravadi RK, Becker SE, Romero I, Rubio MJ, Matias-Guiu X, Santacana M, Llombart-Cussac A, Poveda A, Lu Z, Bast RC Jr.
    • Cancer. 2019 Nov 12. doi: 10.1002/cncr.32600. [Epub ahead of print]
    • Advances and perspectives of PARP inhibitors.
    • Yi M, Dong B, Qin S, Chu Q, Wu K, Luo S.
    • Exp Hematol Oncol. 2019 Nov 11;8:29. doi: 10.1186/s40164-019-0154-9. eCollection 2019.
    • A phase I study of intravenous or intraperitoneal platinum based chemotherapy in combination with veliparib and bevacizumab in newly diagnosed ovarian, primary peritoneal and fallopian tube cancer.
    • Moore KN, Miller A, Bell-McGuinn KM, Schilder RJ, Walker JL, O'Cearbhaill RE, Guntupalli SR, Armstrong DK, Hagemann AR, Gray HJ, Duska LR, Mathews CA, Chen A, O'Malley D, Gordon S, Fracasso PM, Aghajanian C.
    • Gynecol Oncol. 2019 Nov 7. pii: S0090-8258(19)31569-0. doi: 10.1016/j.ygyno.2019.10.012. [Epub ahead of print]
    • Study: Niraparib increases progression-free survival in patients with newly diagnosed ovarian cancer.
    • [No author given.]
    • FORCE. XRAYS. 2019 Nov 5.

    Related:

    Original research:

    Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.

    • Metastatic Thymoma Harboring a Deleterious BRCA2 Mutation Derives Durable Clinical Benefit from Olaparib.
    • Principe DR, Kamath SD, Munshi HG, Mohindra NA.
    • Oncologist. 2019 Nov 1. pii: theoncologist.2019-0393. doi: 10.1634/theoncologist.2019-0393. [Epub ahead of print]
    • Case report, Review
    • Women With Synchronous or Metachronous Lung and Ovarian Cancer: A Multi-Institutional Report.
    • Mariniello A, Ghisoni E, Righi L, Catino A, Chiari R, Del Conte A, Barbieri F, Cecere F, Gelibter A, Giajlevra M, Parra HS, Zichi C, DI Maio M, Valabrega G, Novello S.
    • In Vivo. 2019 Nov-Dec;33(6):2021-2026. doi: 10.21873/invivo.11699.
    • Can synthetic lethality approach be used with DNA repair genes for primary and secondary MDS?
    • Lopes Ribeiro Jr H, de Oliveira RTG, de Paula Borges D, Costa MB, Farias IR, Dos Santos AWA, Magalhães SMM, Pinheiro RF.
    • Med Oncol. 2019 Oct 30;36(12):99. doi: 10.1007/s12032-019-1324-7.
    • Olaparib to Change Practice in mCRPC.
    • [No authors listed]
    • Cancer Discov. 2019 Oct 24. doi: 10.1158/2159-8290.CD-NB2019-126. [Epub ahead of print]
    • Research news
    • Choosing wisely: Selecting PARP inhibitor combinations to promote anti-tumor immune responses beyond BRCA mutations.
    • Veneris JT, Matulonis UA, Liu JF, Konstantinopoulos PA.
    • Gynecol Oncol. 2019 Oct 17. pii: S0090-8258(19)31549-5. doi: 10.1016/j.ygyno.2019.09.021. [Epub ahead of print]
    • Review
    • PARP Inhibition in Cancer: An Update on Clinical Development.
    • Sachdev E, Tabatabai R, Roy V, Rimel BJ, Mita MM.
    • Target Oncol. 2019 Oct 17. doi: 10.1007/s11523-019-00680-2. [Epub ahead of print]
    • Review
    • Treatment of Pediatric Glioblastoma with Combination Olaparib and Temozolomide Demonstrates 2-Year Durable Response.
    • Valiakhmetova A, Gorelyshev S, Konovalov A, Trunin Y, Savateev A, Kram DE, Severson E, Hemmerich A, Edgerly C, Duncan D, Britt N, Huang RSP, Elvin J, Miller V, Ross JS, Gay L, McCorkle J, Rankin A, Erlich RL, Chudnovsky Y, Ramkissoon SH.
    • Oncologist. 2019 Oct 16. pii: theoncologist.2019-0603. doi: 10.1634/theoncologist.2019-0603. [Epub ahead of print]
    • Synergistic Effect of a HER2 Targeted Thorium-227 Conjugate in Combination with Olaparib in a BRCA2 Deficient Xenograft Model.
    • Wickstroem K, Karlsson J, Ellingsen C, Cruciani V, Kristian A, Hagemann UB, Bjerke RM, Ryan OB, Linden L, Mumberg D, Brands M, Cuthbertson A.
    • Pharmaceuticals (Basel). 2019 Oct 15;12(4). pii: E155. doi: 10.3390/ph12040155.
    • RAD52 as a Potential Target for Synthetic Lethality-Based Anticancer Therapies.
    • Toma M, Sullivan-Reed K, Śliwiński T, Skorski T.
    • Cancers (Basel). 2019 Oct 14;11(10). pii: E1561. doi: 10.3390/cancers11101561.
    • Patients resistant against PSMA-targeting alpha-radiation therapy often harbor mutations in DNA-repair associated genes.
    • Kratochwil C, Giesel FL, Heussel CP, Kazdal D, Endris V, Nientiedt C, Bruchertseifer F, Kippenberger M, Rathke H, Leichsenring J, Hohenfellner M, Morgenstern A, Haberkorn U, Duensing S, Stenzinger A.
    • J Nucl Med. 2019 Oct 10. pii: jnumed.119.234559. doi: 10.2967/jnumed.119.234559. [Epub ahead of print]
    • Maintenance Olaparib for Metastatic Pancreatic Cancer.
    • Charkes ND.
    • N Engl J Med. 2019 Oct 10;381(15):1491. doi: 10.1056/NEJMc1911185.
    • Letter. Comment

    Related:

    Letter. Comment:

    Maintenance Olaparib for Metastatic Pancreatic Cancer.

    Reply:

    Maintenance Olaparib for Metastatic Pancreatic Cancer. Reply.

    Original research:

    Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.

    • Parp inhibitors as maintenance treatment in platinum sensitive recurrent ovarian cancer: An updated meta-analysis of randomized clinical trials according to BRCA mutational status.
    • Tomao F, Bardhi E, Di Pinto A, Sassu CM, Biagioli E, Petrella MC, Palaia I, Muzii L, Colombo N, Panici PB.
    • Cancer Treat Rev. 2019 Oct 9;80:101909. doi: 10.1016/j.ctrv.2019.101909. [Epub ahead of print]
    • Synergism between ATM and PARP1 inhibition involves DNA damage and abrogating the G2 DNA damage checkpoint.
    • Mak JPY, Ma HT, Poon RYC.
    • Mol Cancer Ther. 2019 Oct 9. pii: molcanther.0474.2019. doi: 10.1158/1535-7163.MCT-19-0474. [Epub ahead of print]
    • ADP-ribosylation Levels and Patterns Correlate with Gene Expression and Clinical Outcomes in Ovarian Cancers.
    • Conrad LB, Lin KY, Nandu T, Gibson BA, Lea JS, Kraus WL.
    • Mol Cancer Ther. 2019 Oct 8. pii: molcanther.0569.2019. doi: 10.1158/1535-7163.MCT-19-0569. [Epub ahead of print]
    • Success for First-Line PARP Inhibition in Ovarian Cancer.
    • [No authors listed]
    • Cancer Discov. 2019 Oct 7. doi: 10.1158/2159-8290.CD-NB2019-121. [Epub ahead of print]
    • News
    • Epigenetic synthetic lethality approaches in cancer therapy.
    • Yang H, Cui W, Wang L.
    • Clin Epigenetics. 2019 Oct 7;11(1):136. doi: 10.1186/s13148-019-0734-x.
    • Towards precision oncology in advanced prostate cancer.
    • Ku SY, Gleave ME, Beltran H.
    • Nat Rev Urol. 2019 Oct 7. doi: 10.1038/s41585-019-0237-8. [Epub ahead of print]
    • Review
    • DNA methyltransferase inhibitors induce a BRCAness phenotype that sensitizes NSCLC to PARP inhibitor and ionizing radiation.
    • Abbotts R, Topper MJ, Biondi C, Fontaine D, Goswami R, Stojanovic L, Choi EY, McLaughlin L, Kogan AA, Xia L, Lapidus R, Mahmood J, Baylin SB, Rassool FV.
    • Proc Natl Acad Sci U S A. 2019 Oct 7. pii: 201903765. doi: 10.1073/pnas.1903765116. [Epub ahead of print]
    • 'Landmark' Trial in Prostate Cancer With Mutations.
    • Davenport L.
    • Medscape Oncology. 2019 Oct 4.
    • Why BRCA mutations are not tumour-agnostic biomarkers for PARP inhibitor therapy.
    • Curtin NJ, Drew Y, Sharma-Saha S.
    • Nat Rev Clin Oncol. 2019 Oct 3. doi: 10.1038/s41571-019-0285-2. [Epub ahead of print]
    • Commentary
    • Amplification of the mutation-carrying BRCA2 allele promotes RAD51 loading and PARP inhibitor resistance in the absence of reversion mutations.
    • Park PH, Yamamoto TM, Li H, Alcivar AL, Xia B, Wang Y, Bernhardy AJ, Turner KM, Kossenkov AV, Watson ZL, Behbakht K, Casadei S, Swisher EM, Mischel PS, Johnson N, Bitler BG.
    • Mol Cancer Ther. 2019 Oct 1. pii: molcanther.0256.2019. doi: 10.1158/1535-7163.MCT-17-0256. [Epub ahead of print]
    • A case report of a dramatic response to olaparib in a patient with metastatic pancreatic cancer harboring a germline BRCA2 mutation.
    • Wang H, Mao C, Li N, Sun L, Zheng Y, Xu N.
    • Medicine (Baltimore). 2019 Oct;98(40):e17443. doi: 10.1097/MD.0000000000017443.
    • PARP inhibition - opportunities in pancreatic cancer.
    • Pant S, Maitra A, Yap TA.
    • Nat Rev Clin Oncol. 2019 Oct;16(10):595-596. doi: 10.1038/s41571-019-0257-6.
    • Commentary

    Related:

    Original research:

    Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.

    • PARP Inhibitors Move Into First-Line for Ovarian Cancer.
    • Chustecka Z.
    • Medscape Oncology. 2019 Sep 29.

    Related:

    Original research:

    Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.

    Original research:

    Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer.

    • Olaparib maintenance monotherapy in platinum-sensitive, relapsed ovarian cancer without germline BRCA mutations: OPINION Phase IIIb study design.
    • Poveda AM, Davidson R, Blakeley C, Milner A.
    • Future Oncol. 2019 Sep 25. doi: 10.2217/fon-2019-0343. [Epub ahead of print]
    • Mechanisms of resistance to PARP inhibitors - an evolving challenge in oncology.
    • Mweempwa A, Wilson MK.
    • Cancer Drug Resist. 2019 Sep 19;2(3):608-617. doi: 10.20517/cdr.2019.50.
    • PARP inhibitors: clinical development, emerging differences, and the current therapeutic issues.
    • Murthy P, Muggia F.
    • Cancer Drug Resist. 2019 Sep 19;2(3):665-679. doi: 10.20517/cdr.2019.002.
    • Premature mitotic entry induced by ATR inhibition potentiates olaparib inhibition-mediated genomic instability, inflammatory signaling and cytotoxicity in BRCA2-deficient cancer cells.
    • Schoonen PM, Kok YP, Wierenga E, Bakker B, Foijer F, Spierings DCJ, A T M van Vugt M.
    • Mol Oncol. 2019 Sep 17. doi: 10.1002/1878-0261.12573. [Epub ahead of print]
    • BRCA2 Deletion Induces Alternative Lengthening of Telomeres in Telomerase Positive Colon Cancer Cells.
    • Luca P, Carmen M, Angela DS, Annamaria B, Erica S.
    • Genes (Basel). 2019 Sep 10;10(9). pii: E697. doi: 10.3390/genes10090697.
    • Genome-scale CRISPR knockout screen identifies TIGAR as a modifier of PARP inhibitor sensitivity.
    • Fang P, De Souza C, Minn K, Chien J.
    • Commun Biol. 2019 Sep 9;2:335. doi: 10.1038/s42003-019-0580-6. eCollection 2019.
    • Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells.
    • Mani C, Jonnalagadda S, Lingareddy J, Awasthi S, Gmeiner WH, Palle K.
    • Breast Cancer Res. 2019 Sep 6;21(1):104. doi: 10.1186/s13058-019-1192-2.
    • Population Pharmacokinetics of Talazoparib in Patients With Advanced Cancer.
    • Yu Y, Durairaj C, Shi H, Wang DD.
    • J Clin Pharmacol. 2019 Sep 6. doi: 10.1002/jcph.1520. [Epub ahead of print]
    • Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening.
    • Kim M, Mun H, Sung CO, Cho EJ, Jeon HJ, Chun SM, Jung DJ, Shin TH, Jeong GS, Kim DK, Choi EK, Jeong SY, Taylor AM, Jain S, Meyerson M, Jang SJ.
    • Nat Commun. 2019 Sep 5;10(1):3991. doi: 10.1038/s41467-019-11867-6.
    • Antitumor efficacy of PARP inhibitors in homologous recombination deficient carcinomas.
    • Yi T, Feng Y, Sundaram R, Tie Y, Zheng H, Qian Y, You D, Yi T, Wang P, Zhao X.
    • Int J Cancer. 2019 Sep 1;145(5):1209-1220. doi: 10.1002/ijc.32143. Epub 2019 Feb 23.
    • [Synthetic Lethality - Its Current Application and Potential in Oncological Treatment.]
    • Bortlíková L, Müller P, Vojtěšek B, Rak V, Svoboda M.
    • Klin Onkol. 2019 Fall;32(Supplementum 3):19-24. doi: 10.14735/amko20193S.
    • A decade of clinical development of PARP inhibitors in perspective.
    • Mateo J, Lord CJ, Serra V, Tutt A, Balmaña J, Castroviejo-Bermejo M, Cruz C, Oaknin A, Kaye SB, de Bono JS.
    • Ann Oncol. 2019 Sep;30(9):1437-1447. doi: 10.1093/annonc/mdz192. Epub 2019 Dec 12.
    • PARP3, a new therapeutic target to alter Rictor/mTORC2 signaling and tumor progression in BRCA1-associated cancers.
    • Beck C, Rodriguez-Vargas JM, Boehler C, Robert I, Heyer V, Hanini N, Gauthier LR, Tissier A, Schreiber V, Elofsson M, Reina San Martin B, Dantzer F.
    • Cell Death Differ. 2019 Sep;26(9):1615-1630. doi: 10.1038/s41418-018-0233-1. Epub 2018 Nov 15.
    • Defining and targeting wild-type BRCA high-grade serous ovarian cancer: DNA repair and cell cycle checkpoints.
    • Ivy SP, Kunos CA, Arnaldez FI, Kohn EC.
    • Expert Opin Investig Drugs. 2019 Aug 26. doi: 10.1080/13543784.2019.1657403. [Epub ahead of print]
    • Case report, Review
    • Should PARP Inhibitors Have Tumor-Agnostic Approval Status?
    • Markman M.
    • Medscape Oncology. 2019 Aug 19.

    Related:

    Original research:

    Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.

    • Discovery of novel functionalized 1,2,4-triazoles as PARP-1 inhibitors in breast cancer: Design, synthesis and antitumor activity evaluation.
    • Boraei ATA, Singh PK, Sechi M, Satta S.
    • Eur J Med Chem. 2019 Aug 14;182:111621. doi: 10.1016/j.ejmech.2019.111621. [Epub ahead of print]
    • PARP Inhibitor Resistance: A Tug-of-War in BRCA-Mutated Cells.
    • Noordermeer SM, van Attikum H.
    • Trends Cell Biol. 2019 Aug 14. pii: S0962-8924(19)30124-2. doi: 10.1016/j.tcb.2019.07.008. [Epub ahead of print]
    • The indenoisoquinoline TOP1 inhibitors selectively target homologous recombination deficient- and Schlafen 11-positive cancer cells and synergize with olaparib.
    • Marzi L, Szabova L, Gordon M, Weaver Ohler Z, Sharan SK, Beshiri ML, Etemadi M, Murai J, Kelly K, Pommier Y.
    • Clin Cancer Res. 2019 Aug 13. pii: clincanres.0419.2019. doi: 10.1158/1078-0432.CCR-19-0419. [Epub ahead of print]
    • The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP inhibition.
    • Parmar K, Kochupurakkal BS, Lazaro JB, Wang ZC, Palakurthi S, Kirschmeier PT, Yang C, Sambel LA, Färkkilä A, Reznichenko E, Reavis HD, Dunn CE, Zou L, Do KT, Konstantinopoulos PA, Matulonis UA, Liu JF, D'Andrea AD, Shapiro GI.
    • Clin Cancer Res. 2019 Aug 13. pii: clincanres.0448.2019. doi: 10.1158/1078-0432.CCR-19-0448. [Epub ahead of print]
    • LMO2 Confers Synthetic Lethality to PARP Inhibition in DLBCL.
    • Parvin S, Ramirez-Labrada A, Aumann S, Lu X, Weich N, Santiago G, Cortizas EM, Sharabi E, Zhang Y, Sanchez-Garcia I, Gentles AJ, Roberts E, Bilbao-Cortes D, Vega F, Chapman JR, Verdun RE, Lossos IS.
    • Cancer Cell. 2019 Aug 12. pii: S1535-6108(19)30334-4. doi: 10.1016/j.ccell.2019.07.007. [Epub ahead of print]
    • Clinical Development of PARP Inhibitors in Treating Metastatic Castration-Resistant Prostate Cancer.
    • Adashek JJ, Jain RK, Zhang J.
    • Cells. 2019 Aug 9;8(8). pii: E860. doi: 10.3390/cells8080860.
    • BRCA2 loss-of-function germline mutations are associated with esophageal squamous cell carcinoma risk in Chinese.
    • Ko JM, Ning L, Zhao XK, Chai AW, Lei LC, Choi SSA, Tao L, Law S, Kwong A, Lee NP, Chan KT, Lo A, Song X, Chen PN, Chang YL, Wang LD, Lung ML.
    • Int J Cancer. 2019 Aug 9. doi: 10.1002/ijc.32619. [Epub ahead of print]
    • Poly-ADP-ribose polymerases (PARPs) as a therapeutic target in the treatment of selected cancers.
    • Przybycinski J, Nalewajska M, Marchelek-Mysliwiec M, Dziedziejko V, Pawlik A.
    • Expert Opin Ther Targets. 2019 Aug 8. doi: 10.1080/14728222.2019.1654458. [Epub ahead of print]
    • Review
    • Homologous recombination DNA repair defects in PALB2-associated breast cancers.
    • Li A, Geyer FC, Blecua P, Lee JY, Selenica P, Brown DN, Pareja F, Lee SSK, Kumar R, Rivera B, Bi R, Piscuoglio S, Wen HY, Lozada JR, Gularte-Mérida R, Cavallone L; kConFab Investigators, Rezoug Z, Nguyen-Dumont T, Peterlongo P, Tondini C, Terkelsen T, Rønlund K, Boonen SE, Mannerma A, Winqvist R, Janatova M, Rajadurai P, Xia B, Norton L, Robson ME, Ng PS, Looi LM, Southey MC, Weigelt B, Soo-Hwang T, Tischkowitz M, Foulkes WD, Reis-Filho JS.
    • NPJ Breast Cancer. 2019 Aug 8;5:23. doi: 10.1038/s41523-019-0115-9. eCollection 2019.
    • MiR223-3p promotes synthetic lethality in BRCA1-deficient cancers.
    • Srinivasan G, Williamson EA, Kong K, Jaiswal AS, Huang G, Kim HS, Schärer O, Zhao W, Burma S, Sung P, Hromas R.
    • Proc Natl Acad Sci U S A. 2019 Aug 8. pii: 201903150. doi: 10.1073/pnas.1903150116. [Epub ahead of print]
    • Myriad to Pursue mCRPC Approval for BRACAnalysis CDx
    • [No author given.]
    • Clinical Omics. 2019 Aug 7.
    • Myriad Genetics Seeking Additional FDA Approval for BRACAnalysis CDx.
    • [No author given]
    • GenomeWeb. 2019 Aug 7.
    • An Analysis of Patients with DNA Repair Pathway Mutations Treated with a PARP Inhibitor.
    • Borazanci E, Korn R, Liang WS, Guarnieri C, Haag S, Snyder C, Hendrickson K, Caldwell L, Von Hoff D, Jameson G.
    • Oncologist. 2019 Aug 7. pii: theoncologist.2018-0905. doi: 10.1634/theoncologist.2018-0905. [Epub ahead of print]
    • Preparation and Comparison of Oral Bioavailability for Different Nano-formulations of Olaparib.
    • Pathade AD, Kommineni N, Bulbake U, Thummar MM, Samanthula G, Khan W.
    • AAPS PharmSciTech. 2019 Aug 6;20(7):276. doi: 10.1208/s12249-019-1468-y.
    • Paradigm Shifting of Systemic Chemotherapy for Unresectable Pancreatic Cancer in Japan.
    • Furuse J.
    • J Clin Med. 2019 Aug 4;8(8). pii: E1170. doi: 10.3390/jcm8081170.
    • Design, synthesis and evaluation of phthalazinone thiohydantoin-based derivative as potent PARP-1 inhibitors.
    • Zhong Y, Meng Y, Xu X, Zhao L, Li Z, You Q, Bian J.
    • Bioorg Chem. 2019 Aug 3;91:103181. doi: 10.1016/j.bioorg.2019.103181. [Epub ahead of print]
    • Bringing Prostate Cancer Germline Genetics into Clinical Practice.
    • Das S, Salami SS, Spratt DE, Kaffenberger SD, Jacobs MF, Morgan TM.
    • J Urol. 2019 Aug;202(2):223-230. doi: 10.1097/JU.0000000000000137. Epub 2019 Jul 8.
    • Cationic liposome codelivering PI3K pathway regulator improves the response of BRCA1-deficient breast cancer cells to PARP1 inhibition.
    • Zhang H, Yu N, Chen Y, Yan K, Wang X.
    • J Cell Biochem. 2019 Aug;120(8):13037-13045. doi: 10.1002/jcb.28574. Epub 2019 Mar 14.
    • Defining and Modulating 'BRCAness'.
    • Byrum AK, Vindigni A, Mosammaparast N.
    • Trends Cell Biol. 2019 Jul 27. pii: S0962-8924(19)30104-7. doi: 10.1016/j.tcb.2019.06.005. [Epub ahead of print]
    • Review
    • PARP Inhibitors in Prostate Cancer-The PreclinicalRationale and Current Clinical Development.
    • Virtanen V, Paunu K, Ahlskog JK, Varnai R, Sipeky C, Sundvall M.
    • Genes (Basel). 2019 Jul 26;10(8). pii: E565. doi: 10.3390/genes10080565.
    • Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.
    • Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, Park JO, Hochhauser D, Arnold D, Oh DY, Reinacher-Schick A, Tortora G, Algül H, O'Reilly EM, McGuinness D, Cui KY, Schlienger K, Locker GY, Kindler HL.
    • N Engl J Med. 2019 Jul 25;381(4):317-327. doi: 10.1056/NEJMoa1903387. Epub 2019 Jun 2.

    Related:

    See PubMed abstract for multiple related items.

    • Emerging Roles of RAD52 in Genome Maintenance.
    • Jalan M, Olsen KS, Powell SN.
    • Cancers (Basel). 2019 Jul 23;11(7). pii: E1038. doi: 10.3390/cancers11071038.
    • Molecular Testing Identifies Determinants of Exceptional Response and Guides Precision Therapy in a Patient with Lethal, Treatment-emergent Neuroendocrine Prostate Cancer.
    • Turina CB, Coleman DJ, Thomas GV, Fung AW, Alumkal JJ.
    • Cureus. 2019 Jul 22;11(7):e5197. doi: 10.7759/cureus.5197.
    • Clinical utility of FoundationOne tissue molecular profiling in men with metastatic prostate cancer.
    • Zhu J, Tucker M, Marin D, Gupta RT, Healy P, Humeniuk M, Jarvis C, Zhang T, McNamara M, George DJ, Wu Y, Lisi S, Armstrong AJ.
    • Urol Oncol. 2019 Jul 18. pii: S1078-1439(19)30244-3. doi: 10.1016/j.urolonc.2019.06.015. [Epub ahead of print]
    • The role of BRCA1/2 in hereditary and familial breast and ovarian cancers.
    • Hawsawi YM, Al-Numair NS, Sobahy TM, Al-Ajmi AM, Al-Harbi RM, Baghdadi MA, Oyouni AA, Alamer OM.
    • Mol Genet Genomic Med. 2019 Jul 17:e879. doi: 10.1002/mgg3.879. [Epub ahead of print]
    • Targeting autophagy potentiates the anti-tumor effect of PARP inhibitor in pediatric chronic myeloid leukemia.
    • Liu Y, Song H, Song H, Feng X, Zhou C, Huo Z.
    • AMB Express. 2019 Jul 15;9(1):108. doi: 10.1186/s13568-019-0836-z.
    • Olaparib in germline-mutated metastatic breast cancer: implications of the OlympiAD trial.
    • Armstrong AC, Clay V.
    • Future Oncol. 2019 Jul 15. doi: 10.2217/fon-2018-0067. [Epub ahead of print]
    • Review
    • Overview: FDA Approval of Olaparib Maintenance for BRCA-Mutated.
    • Saleh N, Copur MS.
    • Oncology (Williston Park). 2019 Jul 15;33(7). pii: 629388.
    • Review
    • Induction of apoptosis and modulation of homologous recombination DNA repair pathway in prostate cancer cells by the combination of AZD2461 and valproic acid.
    • Sargazi S, Saravani R, Zavar Reza J, Jaliani HZ, Mirinejad S, Rezaei Z, Zarei S.
    • EXCLI J. 2019 Jul 8;18:485-498. doi: 10.17179/excli2019-1098. eCollection 2019.
    • PARP-1 inhibitor modulate β-catenin signaling to enhance cisplatin sensitivity in cancer cervix.
    • Mann M, Kumar S, Sharma A, Chauhan SS, Bhatla N, Kumar S, Bakhshi S, Gupta R, Kumar L.
    • Oncotarget. 2019 Jul 2;10(42):4262-4275. doi: 10.18632/oncotarget.27008. eCollection 2019 Jul 2.
    • Chlorambucil targets BRCA1/2-deficient tumours and counteracts PARP inhibitor resistance.
    • Tacconi EM, Badie S, De Gregoriis G, Reisländer T, Lai X, Porru M, Folio C, Moore J, Kopp A, Baguña Torres J, Sneddon D, Green M, Dedic S, Lee JW, Batra AS, Rueda OM, Bruna A, Leonetti C, Caldas C, Cornelissen B, Brino L, Ryan A, Biroccio A, Tarsounas M.
    • EMBO Mol Med. 2019 Jul;11(7):e9982. doi: 10.15252/emmm.201809982. Epub 2019 May 24.
    • BRCA1/2 Functional Loss Defines a Targetable Subset in Leiomyosarcoma.
    • Seligson ND, Kautto EA, Passen EN, Stets C, Toland AE, Millis SZ, Meyer CF, Hays JL, Chen JL.
    • Oncologist. 2019 Jul;24(7):973-979. doi: 10.1634/theoncologist.2018-0448. Epub 2018 Dec 12.
    • PARP inhibitors for BRCA wild type ovarian cancer; gene alterations, homologous recombination deficiency and combination therapy.
    • Matsumoto K, Nishimura M, Onoe T, Sakai H, Urakawa Y, Onda T, Yaegashi N.
    • Jpn J Clin Oncol. 2019 Jun 26. pii: hyz090. doi: 10.1093/jjco/hyz090. [Epub ahead of print]
    • Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-Inhibitors.
    • Criscuolo D, Morra F, Giannella R, Cerrato A, Celetti A.
    • Int J Mol Sci. 2019 Jun 25;20(12). pii: E3100. doi: 10.3390/ijms20123100.
    • High frequency of pathogenic germline variants within homologous recombination repair in patients with advanced cancer.
    • Bertelsen B, Tuxen IV, Yde CW, Gabrielaite M, Torp MH, Kinalis S, Oestrup O, Rohrberg K, Spangaard I, Santoni-Rugiu E, Wadt K, Mau-Sorensen M, Lassen U, Nielsen FC.
    • NPJ Genom Med. 2019 Jun 21;4:13. doi: 10.1038/s41525-019-0087-6. eCollection 2019.
    • A decade of clinical development of PARP inhibitors in perspective.
    • Mateo J, Lord CJ, Serra V, Tutt A, Balmaña J, Castroviejo-Bermejo M, Cruz C, Oaknin A, Kaye SB, de Bono JS.
    • Ann Oncol. 2019 Jun 20. pii: mdz192. doi: 10.1093/annonc/mdz192. [Epub ahead of print]
    • Resolution Bioscience, Janssen Partner to Develop CDx for Niraparib in Prostate Cancer.
    • [No author given]
    • GenomeWeb. 2019 Jun 19.
    • A Mechanistic Approach to understand the Allosteric Reverse Signaling by Selective and Trapping Poly(ADP-ribose) Polymerase 1 (PARP-1) Inhibitors.
    • Kumar C, Lakshmi PTV, Arunachalam A.
    • J Biomol Struct Dyn. 2019 Jun 16:1-12. doi: 10.1080/07391102.2019.1633406. [Epub ahead of print]
    • Loss of ARID1A in Tumor Cells Renders Selective Vulnerability to Combined Ionizing Radiation and PARP Inhibitor Therapy.
    • Park Y, Chui MH, Suryo Rahmanto Y, Yu ZC, Shamanna RA, Bellani MA, Gaillard S, Ayhan A, Viswanathan A, Seidman MM, Franco S, Leung AKL, Bohr VA, Shih IM, Wang TL.
    • Clin Cancer Res. 2019 Jun 13. doi: 10.1158/1078-0432.CCR-18-4222. [Epub ahead of print]
    • Exploiting interconnected synthetic lethal interactions between PARP inhibition and cancer cell reversible senescence.
    • Fleury H, Malaquin N, Tu V, Gilbert S, Martinez A, Olivier MA, Sauriol A, Communal L, Leclerc-Desaulniers K, Carmona E, Provencher D, Mes-Masson AM, Rodier F.
    • Nat Commun. 2019 Jun 11;10(1):2556. doi: 10.1038/s41467-019-10460-1.
    • Efficacy and Safety Exposure-Response Analyses of Olaparib Capsule and Tablet Formulations in Oncology Patients.
    • Zhou D, Li J, Learoyd M, Bui K, Berges A, Milenkova T, Al-Huniti N, Tomkinson H, Xu H.
    • Clin Pharmacol Ther. 2019 Jun;105(6):1492-1500. doi: 10.1002/cpt.1338. Epub 2019 Feb 22.
    • Review
    • PARP Inhibition Increases the Response to Chemotherapy in Uveal Melanoma.
    • de Koning L, Decaudin D, El Botty R, Nicolas A, Carita G, Schuller M, Ouine B, Cartier A, Naguez A, Fleury J, Cooke V, Wylie A, Smith P, Marangoni E, Gentien D, Meseure D, Mariani P, Cassoux N, Piperno-Neumann S, Roman-Roman S, Némati F.
    • Cancers (Basel). 2019 May 29;11(6). pii: E751. doi: 10.3390/cancers11060751.
    • Discovery of naphthacemycins as a novel class of PARP1 inhibitors.
    • Shen W, Lu X, Zhu J, Mu Y, Xu Y, Gao J, Zhang X, Zheng Z.
    • Bioorg Med Chem Lett. 2019 May 28. pii: S0960-894X(19)30361-0. doi: 10.1016/j.bmcl.2019.05.055. [Epub ahead of print]
    • Chlorambucil targets BRCA1/2-deficient tumours and counteracts PARP inhibitor resistance.
    • Tacconi EM, Badie S, De Gregoriis G, Reisländer T, Lai X, Porru M, Folio C, Moore J, Kopp A, Baguña Torres J, Sneddon D, Green M, Dedic S, Lee JW, Batra AS, Rueda OM, Bruna A, Leonetti C, Caldas C, Cornelissen B, Brino L, Ryan A, Biroccio A, Tarsounas M.
    • EMBO Mol Med. 2019 May 24. pii: e9982. doi: 10.15252/emmm.201809982. [Epub ahead of print]
    • Novel poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitor, AZD2461, down-regulates VEGF and induces apoptosis in prostate cancer cells.
    • Sargazi S, Saravani R, Zavar Reza J, Zarei Jaliani H, Galavi H, Liliya Viacheslavovna M, Abtahi NA.
    • Iran Biomed J. 2019 May 18. [Epub ahead of print]
    • Whole-genome sequencing reveals clinically relevant insights into the aetiology of familial breast cancers.
    • Nones K, Johnson J, Newell F, Patch AM, Thorne H, Kazakoff SH, de Luca XM, Parsons MT, Ferguson K, Reid L, Reed AEM, Srihari S, Lakis V, Davidson AL, Mukhopadhyay P, Holmes O, Xu Q, Wood S, Leonard C; Kathleen Cuningham Foundation Consortium for Research into Familial Aspects of Breast Cancer (kConFab); Australian Breast Cancer Tissue Bank (ABCTB); Brisbane Breast Bank (BBB), Beesley J, Harris J, Barnes D, Degasperi A, Ragan MA, Spurdle AB, Khanna KK, Lakhani SR, Pearson JV, Nik-Zainal S, Chenevix-Trench G, Waddell N, Simpson PT.
    • Ann Oncol. 2019 May 15. pii: mdz132. doi: 10.1093/annonc/mdz132. [Epub ahead of print]

    Related:

    Editorial:

    Journey's End: the quest for BRCA-like hereditary breast cancer genes is nearly over.

    • Phosphatase 1 Nuclear Targeting Subunit Mediates Recruitment and Function of Poly (ADP-Ribose) Polymerase 1 in DNA Repair.
    • Wang F, Zhu S, Fisher LA, Wang L, Eurek NJ, Wahl JK 3rd, Lan L, Peng A.
    • Cancer Res. 2019 May 15;79(10):2526-2535. doi: 10.1158/0008-5472.CAN-18-1673. Epub 2019 Feb 7.
    • Commentary
    • [New therapeutic strategies in advanced stage breast and tubo-ovarian cancers].
    • Nikolopoulou A, Galli-Vareia I, Stravodimou A, Sarivalasis A, Zaman K.
    • Rev Med Suisse. 2019 May 15;15(651):1027-1031.
    • Review, [Article in French]
    • Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1/2 and RAD51.
    • Kaplan AR, Gueble SE, Liu Y, Oeck S, Kim H, Yun Z, Glazer PM.
    • Sci Transl Med. 2019 May 15;11(492). pii: eaav4508. doi: 10.1126/scitranslmed.aav4508.

    Related:

    Research news:

    Mechanism of Cediranib/Olaparib Combo Revealed.

    • A Comparison of DNA Mutation and Copy Number Profiles of Primary Breast Cancers and Paired Brain Metastases for Identifying Clinically Relevant Genetic Alterations in Brain Metastases.
    • Tyran M, Carbuccia N, Garnier S, Guille A, Adelaïde J, Finetti P, Toulzian J, Viens P, Tallet A, Goncalves A, Metellus P, Birnbaum D, Chaffanet M, Bertucci F.
    • Cancers (Basel). 2019 May 13;11(5):665. doi: 10.3390/cancers11050665.
    • Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer.
    • Jiang X, Li W, Li X, Bai H, Zhang Z.
    • Cancer Manag Res. 2019 May 10;11:4371-4390. doi: 10.2147/CMAR.S200524. eCollection 2019.
    • Re: Catherine H. Marshall, Alexandra O. Sokolova, Andrea L. McNatty, et al. Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.02.002.
    • Liang J, Beckta JM, Bindra RS.
    • Eur Urol. 2019 May 9. pii: S0302-2838(19)30358-6. doi: 10.1016/j.eururo.2019.04.041. [Epub ahead of print]
    • Letter, Commentary

    Related:

    Original research:

    Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations.

    • The mechanism of cancer cell death by PARP inhibitors goes beyond DNA damage alone.
    • Macciò A, Madeddu C.
    • Int J Cancer. 2019 May 9. doi: 10.1002/ijc.32392. [Epub ahead of print]
    • Letter
    • Alterations in DNA damage repair genes in primary liver cancer.
    • Lin J, Shi J, Guo H, Yang X, Jiang Y, Long J, Bai Y, Wang D, Yang X, Wan X, Zhang L, Pan J, Hu K, Guan M, Huo L, Sang X, Wang K, Zhao H.
    • Clin Cancer Res. 2019 May 8. pii: clincanres.0127.2019. doi: 10.1158/1078-0432.CCR-19-0127. [Epub ahead of print]
    • Design and Synthesis of Poly(ADP-ribose) polymerase Inhibitors: Impact of Adenosine Pocket-Binding Motif Appendage to the 3-Oxo-2,3-dihydrobenzofuran-7-carboxamide on Potency and Selectivity.
    • Velagapudi UK, Langelier MF, Delgado-Martin C, Diolaiti ME, Bakker S, Ashworth A, Patel BA, Shao X, Pascal JM, Talele TT.
    • J Med Chem. 2019 May 1. doi: 10.1021/acs.jmedchem.8b01709. [Epub ahead of print]
    • DNA repair defects in prostate cancer: impact for screening, prognostication and treatment.
    • Warner EW, Yip SM, Chi KN, Wyatt AW.
    • BJU Int. 2019 May;123(5):769-776. doi: 10.1111/bju.14576. Epub 2018 Oct 26.
    • Review
    • Bridging Olaparib Capsule and Tablet Formulations Using Population Pharmacokinetic Meta-analysis in Oncology Patients.
    • Zhou D, Li J, Bui K, Learoyd M, Berges A, Milenkova T, Al-Huniti N, Tomkinson H, Xu H.
    • Clin Pharmacokinet. 2019 May;58(5):615-625. doi: 10.1007/s40262-018-0714-x.
    • BMN 673 (talazoparib): A potent PARP inhibitor for triple negative breast cancer with different genetic profile.
    • Guney Eskiler G, Cecener G, Egeli U, Tunca B.
    • J Biochem Mol Toxicol. 2019 May;33(5):e22286. doi: 10.1002/jbt.22286. Epub 2019 Jan 23.
    • Integrating poly(ADP-ribose) polymerase (PARP) inhibitors in the treatment of early breast cancer.
    • Garber HR, Litton JK.
    • Curr Opin Oncol. 2019 May;31(3):247-255. doi: 10.1097/CCO.0000000000000516.
    • Review
    • Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.
    • Parikh AR, He Y, Hong TS, Corcoran RB, Clark JW, Ryan DP, Zou L, Ting DT, Catenacci DV, Chao J, Fakih M, Klempner SJ, Ross JS, Frampton GM, Miller VA, Ali SM, Schrock AB.
    • Oncologist. 2019 Apr 30. pii: theoncologist.2019-0034. doi: 10.1634/theoncologist.2019-0034. [Epub ahead of print]
    • Reviewing the characteristics of BRCA and PALB2-related cancers in the precision medicine era.
    • Macedo GS, Alemar B, Ashton-Prolla P.
    • Genet Mol Biol. 2019 Apr 29. pii: S1415-47572019005015101. doi: 10.1590/1678-4685-GMB-2018-0104. [Epub ahead of print]
    • DAXX, as a Tumor Suppressor, Impacts DNA Damage Repair and Sensitizes BRCA-Proficient TNBC Cells to PARP Inhibitors.
    • Shi Y, Jin J, Wang X, Ji W, Guan X.
    • Neoplasia. 2019 Apr 24;21(6):533-544. doi: 10.1016/j.neo.2019.04.001. [Epub ahead of print]
    • Phase I/Ib study of olaparib and carboplatin in heavily pretreated recurrent high-grade serous ovarian cancer at low genetic risk.
    • Lampert EJ, Hays JL, Kohn EC, Annunziata CM, Minasian L, Yu M, Gordon N, Sissung TM, Chiou VL, Figg WD, Houston N, Lee JM.
    • Oncotarget. 2019 Apr 23;10(30):2855-2868. doi: 10.18632/oncotarget.26869. eCollection 2019 Apr 23.
    • MUC1-C Integrates Chromatin Remodeling and PARP1 Activity in the DNA Damage Response of Triple-Negative Breast Cancer Cells.
    • Yamamoto M, Jin C, Hata T, Yasumizu Y, Zhang Y, Hong D, Maeda T, Miyo M, Hiraki M, Suzuki Y, Hinohara K, Rajabi H, Kufe D.
    • Cancer Res. 2019 Apr 15;79(8):2031-2041. doi: 10.1158/0008-5472.CAN-18-3259. Epub 2019 Mar 1.
    • Detecting the mutational signature of homologous recombination deficiency in clinical samples.
    • Gulhan DC, Lee JJ, Melloni GEM, Cortés-Ciriano I, Park PJ.
    • Nat Genet. 2019 Apr 15. doi: 10.1038/s41588-019-0390-2. [Epub ahead of print]
    • N6-methylation of adenosine (m6A) of FZD10 mRNA contributes to PARP inhibitor resistance.
    • Fukumoto T, Zhu H, Nacarelli T, Karakashev S, Fatkhutdinov N, Wu S, Liu P, Kossenkov AV, Showe LC, Jean S, Zhang L, Zhang R.
    • Cancer Res. 2019 Apr 9. pii: canres.3592.2018. doi: 10.1158/0008-5472.CAN-18-3592. [Epub ahead of print]
    • Defective homologous recombination DNA repair as therapeutic target in advanced chordoma.
    • Gröschel S, Hübschmann D, Raimondi F, Horak P, Warsow G, Fröhlich M, Klink B, Gieldon L, Hutter B, Kleinheinz K, Bonekamp D, Marschal O, Chudasama P, Mika J, Groth M, Uhrig S, Krämer S, Heining C, Heilig CE, Richter D, Reisinger E, Pfütze K, Eils R, Wolf S, von Kalle C, Brandts C, Scholl C, Weichert W, Richter S, Bauer S, Penzel R, Schröck E, Stenzinger A, Schlenk RF, Brors B, Russell RB, Glimm H, Schlesner M, Fröhling S.
    • Nat Commun. 2019 Apr 9;10(1):1635. doi: 10.1038/s41467-019-09633-9.
    • Myriad Genetics Expands CDx Collaboration with AstraZeneca, Merck & Co.
    • [No author given.]
    • Clinical Omics. 2019 Apr 4.
    • Dissecting PARP inhibitor resistance with functional genomics.
    • Pettitt SJ, Lord CJ.
    • Curr Opin Genet Dev. 2019 Apr 4;54:55-63. doi: 10.1016/j.gde.2019.03.001. [Epub ahead of print]
    • Partnering with PARP inhibitors in acute myeloid leukemia with FLT3-ITD.
    • Dellomo AJ, Baer MR, Rassool FV.
    • Cancer Lett. 2019 Apr 3. pii: S0304-3835(19)30212-5. doi: 10.1016/j.canlet.2019.03.048. [Epub ahead of print]
    • Maintenance Rucaparib Controls Some Pancreatic Cancers.
    • [No authors listed]
    • Cancer Discov. 2019 Apr 2. doi: 10.1158/2159-8290.CD-NB2019-043. [Epub ahead of print]
    • PARP Inhibitors for Maintenance Therapy in Pancreatic Cancer?
    • Castellino AM.
    • Medscape. Medscape Oncology. 2019 Apr 2.

    Related:

    Conference abstract: CT234 - A Phase II, single arm study of maintenance rucaparib in patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic mutation in BRCA1, BRCA2 or PALB2 (AACR Annual Meeting 2019)

    • Response to olaparib in a PALB2 germline mutated prostate cancer and genetic events associated with resistance.
    • Horak P, Weischenfeldt J, von Amsberg G, Beyer B, Schütte A, Uhrig S, Gieldon L, Klink B, Feuerbach L, Hübschmann D, Kreutzfeldt S, Heining C, Maier S, Hutter B, Penzel R, Schlesner M, Eils R, Sauter G, Stenzinger A, Brors B, Schröck E, Glimm H, Fröhling S, Schlomm T.
    • Cold Spring Harb Mol Case Stud. 2019 Apr 1;5(2). pii: a003657. doi: 10.1101/mcs.a003657. Print 2019 Apr.
    • Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.
    • Moore KN, Secord AA, Geller MA, Miller DS, Cloven N, Fleming GF, Wahner Hendrickson AE, Azodi M, DiSilvestro P, Oza AM, Cristea M, Berek JS, Chan JK, Rimel BJ, Matei DE, Li Y, Sun K, Luptakova K, Matulonis UA, Monk BJ.
    • Lancet Oncol. 2019 Apr 1. pii: S1470-2045(19)30029-4. doi: 10.1016/S1470-2045(19)30029-4. [Epub ahead of print]

    Related:

    Commentary:

    Fighting against the challenge of treating patients with late-line ovarian cancer: are we there yet?

    • RAD51D splice variants and cancer-associated mutations reveal XRCC2 interaction to be critical for homologous recombination.
    • Baldock RA, Pressimone CA, Baird JM, Khodakov A, Luong TT, Grundy MK, Smith CM, Karpenshif Y, Bratton-Palmer DS, Prakash R, Jasin M, Garcin EB, Gon S, Modesti M, Bernstein KA.
    • DNA Repair (Amst). 2019 Apr;76:99-107. doi: 10.1016/j.dnarep.2019.02.008. Epub 2019 Feb 23.
    • PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms.
    • Jiang X, Li X, Li W, Bai H, Zhang Z.
    • J Cell Mol Med. 2019 Apr;23(4):2303-2313. doi: 10.1111/jcmm.14133. Epub 2019 Jan 22.
    • Non-NAD-like PARP1 inhibitor enhanced synthetic lethal effect of NAD-like PARP inhibitors against BRCA1-deficient leukemia.
    • Nieborowska-Skorska M, Maifrede S, Ye M, Toma M, Hewlett E, Gordon J, Le BV, Sliwinski T, Zhao H, Piwocka K, Valent P, Tulin AV, Childers W, Skorski T.
    • Leuk Lymphoma. 2019 Apr;60(4):1098-1101. doi: 10.1080/10428194.2018.1520988. Epub 2018 Oct 2.
    • Letter
    • Exploiting DNA repair defects in colorectal cancer.
    • Reilly NM, Novara L, Di Nicolantonio F, Bardelli A.
    • Mol Oncol. 2019 Apr;13(4):681-700. doi: 10.1002/1878-0261.12467. Epub 2019 Mar 2.
    • Targeted blockade of HSP90 impairs DNA-damage response proteins and increases the sensitivity of ovarian carcinoma cells to PARP inhibition.
    • Gabbasov R, Benrubi ID, O'Brien SW, Krais JJ, Johnson N, Litwin S, Connolly DC.
    • Cancer Biol Ther. 2019 Mar 30:1-11. doi: 10.1080/15384047.2019.1595279. [Epub ahead of print]
    • PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers.
    • Keung MYT, Wu Y, Vadgama JV.
    • J Clin Med. 2019 Mar 30;8(4). pii: E435. doi: 10.3390/jcm8040435.
    • Targeting DNA Repair Defects for Precision Medicine in Prostate Cancer.
    • Athie A, Arce-Gallego S, Gonzalez M, Morales-Barrera R, Suarez C, Casals Galobart T, Hernandez Viedma G, Carles J, Mateo J.
    • Curr Oncol Rep. 2019 Mar 27;21(5):42. doi: 10.1007/s11912-019-0790-6.
    • Review
    • Advances in the use of PARP inhibitors for BRCA1/2-associated breast cancer: talazoparib.
    • McCann KE.
    • Future Oncol. 2019 Mar 26. doi: 10.2217/fon-2018-0751. [Epub ahead of print]
    • Review
    • Familial Pancreatic Cancer and Surveillance of High-Risk Individuals.
    • Matsubayashi H, Takaori K, Morizane C, Kiyozumi Y.
    • Gut Liver. 2019 Mar 26. doi: 10.5009/gnl18449. [Epub ahead of print]
    • Aberrations in DNA repair pathways in cancer and therapeutic significances.
    • Motegi A, Masutani M, Yoshioka KI, Bessho T.
    • Semin Cancer Biol. 2019 Mar 25. pii: S1044-579X(18)30089-0. doi: 10.1016/j.semcancer.2019.02.005. [Epub ahead of print]
    • Review
    • Genomic profiling in pancreatic ductal adenocarcinoma and a pathway towards therapy individualization: A scoping review.
    • Singh RR, Goldberg J, Varghese AM, Yu KH, Park W, O'Reilly EM.
    • Cancer Treat Rev. 2019 Mar 22;75:27-38. doi: 10.1016/j.ctrv.2019.03.003. [Epub ahead of print]
    • Review
    • BRCA1 Haploinsufficiency Is Masked by RNF168-Mediated Chromatin Ubiquitylation.
    • Zong D, Adam S, Wang Y, Sasanuma H, Callén E, Murga M, Day A, Kruhlak MJ, Wong N, Munro M, Ray Chaudhuri A, Karim B, Xia B, Takeda S, Johnson N, Durocher D, Nussenzweig A.
    • Mol Cell. 2019 Mar 21;73(6):1267-1281.e7. doi: 10.1016/j.molcel.2018.12.010. Epub 2019 Jan 28.

    Related:

    Research news:

    Context Matters: RNF168 Connects with PALB2 to Rewire Homologous Recombination in BRCA1 Haploinsufficiency.

    • Polo-like Kinase 1 inhibition as a therapeutic approach to selectively target BRCA1-deficient cancer cells by synthetic lethality induction.
    • Carbajosa S, Pansa MF, Paviolo NS, Castellaro AM, Andino DL, Nigra AD, García IA, Racca AC, Rodriguez-Berdini L, Angiolini V, Guantay L, Villafañez F, Federico MB, Rodríguez-Baili MC, Caputto BL, Drewes G, Madauss KP, Gloger I, Fernandez E, Gil GA, Bocco JL, Gottifredi V, Soria G.
    • Clin Cancer Res. 2019 Mar 19. pii: clincanres.3516.2018. doi: 10.1158/1078-0432.CCR-18-3516. [Epub ahead of print]
    • DNA Replication Vulnerabilities Render Ovarian Cancer Cells Sensitive to Poly(ADP-Ribose) Glycohydrolase Inhibitors.
    • Pillay N, Tighe A, Nelson L, Littler S, Coulson-Gilmer C, Bah N, Golder A, Bakker B, Spierings DCJ, James DI, Smith KM, Jordan AM, Morgan RD, Ogilvie DJ, Foijer F, Jackson DA, Taylor SS.
    • Cancer Cell. 2019 Mar 18;35(3):519-533.e8. doi: 10.1016/j.ccell.2019.02.004.
    • TWiST Strengthens PARP Inhibitor Role in Ovarian Cancer.
    • Harrison P.
    • Medscape Oncology. Conference News. 2019 Mar 18.
    • The deubiquitylating enzyme USP15 regulates homologous recombination repair and cancer cell response to PARP inhibitors.
    • Peng Y, Liao Q, Tan W, Peng C, Hu Z, Chen Y, Li Z, Li J, Zhen B, Zhu W, Li X, Yao Y, Song Q, Liu C, Qi X, He F, Pei H.
    • Nat Commun. 2019 Mar 15;10(1):1224. doi: 10.1038/s41467-019-09232-8.

    Related:

    Press: New Biomarker Could Expand Effective PARP Inhibitor Treatment Options. (Clinical OMICs)

    • Nitric oxide-donor/PARP-inhibitor combination: A new approach for sensitization to ionizing radiation.
    • Wilson A, Menon V, Khan Z, Alam A, Litovchick L, Yakovlev V.
    • Redox Biol. 2019 Mar 15;24:101169. doi: 10.1016/j.redox.2019.101169. [Epub ahead of print]
    • The Effect of Green and Black Tea Polyphenols on BRCA2 Deficient Chinese Hamster Cells by Synthetic Lethality through PARP Inhibition.
    • Alqahtani S, Welton K, Gius JP, Elmegerhi S, Kato TA.
    • Int J Mol Sci. 2019 Mar 14;20(6). pii: E1274. doi: 10.3390/ijms20061274.
    • Exploring the Frequency of Homologous Recombination DNA Repair Dysfunction in Multiple Cancer Types.
    • Gentles L, Goranov B, Matheson E, Herriott A, Kaufmann A, Hall S, Mukhopadhyay A, Drew Y, Curtin NJ, O'Donnell RL.
    • Cancers (Basel). 2019 Mar 13;11(3). pii: E354. doi: 10.3390/cancers11030354.
    • Beyond DNA repair: the novel immunological potential of PARP inhibitors.
    • Chabanon RM, Soria JC, Lord CJ, Postel-Vinay S.
    • Mol Cell Oncol. 2019 Mar 13;6(2):1585170. doi: 10.1080/23723556.2019.1585170. eCollection 2019.
    • Quantitative Characterization of Olaparib in Nanodelivery System and Target Cell Compartments by LC-MS/MS.
    • Ottria R, Ravelli A, Miceli M, Casati S, Orioli M, Ciuffreda P.
    • Molecules. 2019 Mar 11;24(5). pii: E989. doi: 10.3390/molecules24050989.
    • Prospect for Application of PARP Inhibitor in Patients with HER2 Negative Breast Cancer.
    • Shao N, Shi Y, Yu L, Ye R, Shan Z, Zhang Z, Zhang Y, Lin Y.
    • Int J Biol Sci. 2019 Mar 10;15(5):962-972. doi: 10.7150/ijbs.30721. eCollection 2019.
    • Genetic Screens Reveal FEN1 and APEX2 as BRCA2 Synthetic Lethal Targets.
    • Mengwasser KE, Adeyemi RO, Leng Y, Choi MY, Clairmont C, D'Andrea AD, Elledge SJ.
    • Mol Cell. 2019 Mar 7;73(5):885-899.e6. doi: 10.1016/j.molcel.2018.12.008. Epub 2019 Jan 24.
    • Synergism of PARP inhibitor fluzoparib (HS10160) and MET inhibitor HS10241 in breast and ovarian cancer cells.
    • Han Y, Chen MK, Wang HL, Hsu JL, Li CW, Chu YY, Liu CX, Nie L, Chan LC, Yam C, Wang SC, He GJ, Hortobagyi GN, Tan XD, Hung MC.
    • Am J Cancer Res. 2019 Mar 1;9(3):608-618. eCollection 2019.
    • Rad51/BRCA2 disruptors inhibit homologous recombination and synergize with olaparib in pancreatic cancer cells.
    • Roberti M, Schipani F, Bagnolini G, Milano D, Giacomini E, Falchi F, Balboni A, Manerba M, Farabegoli F, De Franco F, Robertson J, Minucci S, Pallavicini I, Di Stefano G, Girotto S, Pellicciari R, Cavalli A.
    • Eur J Med Chem. 2019 Mar 1;165:80-92. doi: 10.1016/j.ejmech.2019.01.008. Epub 2019 Jan 10.
    • Medicinal chemistry approaches of poly ADP-Ribose polymerase 1 (PARP1) inhibitors as anticancer agents - A recent update.
    • Jain PG, Patel BD.
    • Eur J Med Chem. 2019 Mar 1;165:198-215. doi: 10.1016/j.ejmech.2019.01.024. Epub 2019 Jan 12.
    • Review
    • PARP inhibitors synergize with gemcitabine by potentiating DNA damage in non-small-cell lung cancer.
    • Jiang Y, Dai H, Li Y, Yin J, Guo S, Lin SY, McGrail DJ.
    • Int J Cancer. 2019 Mar 1;144(5):1092-1103. doi: 10.1002/ijc.31770. Epub 2018 Sep 24.
    • Pharmacologic characterization of fluzoparib, a novel poly(ADP-ribose) polymerase inhibitor undergoing clinical trials.
    • Wang L, Yang C, Xie C, Jiang J, Gao M, Fu L, Li Y, Bao X, Fu H, Lou L.
    • Cancer Sci. 2019 Mar;110(3):1064-1075. doi: 10.1111/cas.13947. Epub 2019 Feb 19.
    • E-cadherin-deficient cells have synthetic lethal vulnerabilities in plasma membrane organisation, dynamics and function.
    • Godwin TD, Kelly ST, Brew TP, Bougen-Zhukov NM, Single AB, Chen A, Stylianou CE, Harris LD, Currie SK, Telford BJ, Beetham HG, Evans GB, Black MA, Guilford PJ.
    • Gastric Cancer. 2019 Mar;22(2):273-286. doi: 10.1007/s10120-018-0859-1. Epub 2018 Jul 31.
    • PARP inhibitors in older patients with ovarian and breast cancer: Young International Society of Geriatric Oncology review paper.
    • Liposits G, Loh KP, Soto-Perez-de-Celis E, Dumas L, Battisti NML, Kadambi S, Baldini C, Banerjee S, Lichtman SM.
    • J Geriatr Oncol. 2019 Mar;10(2):337-345. doi: 10.1016/j.jgo.2018.10.008. Epub 2018 Oct 14.
    • Review
    • Durable response by olaparib for a Japanese patient with primary peritoneal cancer with multiple brain metastases: A case report.
    • Sakamoto I, Hirotsu Y, Nakagomi H, Ikegami A, Teramoto K, Omata M.
    • J Obstet Gynaecol Res. 2019 Mar;45(3):743-747. doi: 10.1111/jog.13851. Epub 2018 Nov 22.
    • Case report
    • Ex vivo treatment of prostate tumor tissue recapitulates in vivo therapy response.
    • Zhang W, van Weerden WM, de Ridder CMA, Erkens-Schulze S, Schönfeld E, Meijer TG, Kanaar R, van Gent DC, Nonnekens J.
    • Prostate. 2019 Mar;79(4):390-402. doi: 10.1002/pros.23745. Epub 2018 Dec 5.
    • The Tumor Suppressor PALB2: Inside Out.
    • Ducy M, Sesma-Sanz L, Guitton-Sert L, Lashgari A, Gao Y, Brahiti N, Rodrigue A, Margaillan G, Caron MC, Côté J, Simard J, Masson JY.
    • Trends Biochem Sci. 2019 Mar;44(3):226-240. doi: 10.1016/j.tibs.2018.10.008. Epub 2019 Jan 10.
    • Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations.
    • Marshall CH, Sokolova AO, McNatty AL, Cheng HH, Eisenberger MA, Bryce AH, Schweizer MT, Antonarakis ES.
    • Eur Urol. 2019 Feb 20. pii: S0302-2838(19)30110-1. doi: 10.1016/j.eururo.2019.02.002. [Epub ahead of print]
    • BET proteins regulate homologous recombination-mediated DNA repair: BRCAness and implications for cancer therapy.
    • Mio C, Gerratana L, Bolis M, Caponnetto F, Zanello A, Barbina M, Di Loreto C, Garattini E, Damante G, Puglisi F.
    • Int J Cancer. 2019 Feb 15;144(4):755-766. doi: 10.1002/ijc.31898. Epub 2018 Dec 4.
    • Women's cancers: how the discovery of BRCA genes is driving current concepts of cancer biology and therapeutics.
    • Murthy P, Muggia F.
    • Ecancermedicalscience. 2019 Feb 14;13:904. doi: 10.3332/ecancer.2019.904. eCollection 2019.
    • PARP Inhibitors: Extending Benefit Beyond BRCA Mutant Cancers.
    • Pilie P, Gay CM, Byers LA, O'Connor MJ, Yap TA.
    • Clin Cancer Res. 2019 Feb 13. pii: clincanres.0968.2018. doi: 10.1158/1078-0432.CCR-18-0968. [Epub ahead of print]
    • Review
    • Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models.
    • Wang Z, Sun K, Xiao Y, Feng B, Mikule K, Ma X, Feng N, Vellano CP, Federico L, Marszalek JR, Mills GB, Hanke J, Ramaswamy S, Wang J.
    • Sci Rep. 2019 Feb 12;9(1):1853. doi: 10.1038/s41598-019-38534-6.
    • NADP+ is an endogenous PARP inhibitor in DNA damage response and tumor suppression.
    • Bian C, Zhang C, Luo T, Vyas A, Chen SH, Liu C, Kassab MA, Yang Y, Kong M, Yu X.
    • Nat Commun. 2019 Feb 11;10(1):693. doi: 10.1038/s41467-019-08530-5.
    • Evaluation of site-specific homologous recombination activity of BRCA1 by direct quantitation of gene editing efficiency.
    • Yoshino Y, Endo S, Chen Z, Qi H, Watanabe G, Chiba N.
    • Sci Rep. 2019 Feb 7;9(1):1644. doi: 10.1038/s41598-018-38311-x.
    • Loss of NFBD1/MDC1 disrupts homologous recombination repair and sensitizes nasopharyngeal carcinoma cells to PARP inhibitors.
    • Wang Z, Zuo W, Zeng Q, Qian Y, Li Y, Liu C, Wang J, Zhong S, Bu Y, Hu G.
    • J Biomed Sci. 2019 Feb 4;26(1):14. doi: 10.1186/s12929-019-0507-z.
    • Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas.
    • de Jonge MM, Auguste A, van Wijk LM, Schouten PC, Meijers M, Ter Haar NT, Smit VTHBM, Nout RA, Glaire MA, Church DN, Vrieling H, Job B, Boursin Y, de Kroon CD, Rouleau E, Leary A, Vreeswijk MPG, Bosse T.
    • Clin Cancer Res. 2019 Feb 1;25(3):1087-1097. doi: 10.1158/1078-0432.CCR-18-1443. Epub 2018 Nov 9.
    • Exaggeration of PFS by blinded, independent, central review (BICR).
    • Stone A, Gebski V, Davidson R, Bloomfield R, Bartlett JW, Sabin A.
    • Ann Oncol. 2019 Feb;30(2):332-338. doi: 10.1093/annonc/mdy514. Epub 2019 Dec 24.
    • A PALB2 truncating mutation: Implication in cancer prevention and therapy of Hereditary Breast and Ovarian Cancer.
    • Velázquez C, Esteban-Cardeñosa EM, Lastra E, Abella LE, de la Cruz V, Lobatón CD, Durán M, Infante M.
    • Breast. 2019 Feb;43:91-96. doi: 10.1016/j.breast.2018.11.010. Epub 2018 Nov 29.
    • Update in the use and evaluation of poly (ADP-ribose) polymerase inhibitors in epithelial ovarian cancer: current and pending clinical research.
    • Washington C, Gunderson CC, Moore KN.
    • Curr Opin Obstet Gynecol. 2019 Feb;31(1):4-11. doi: 10.1097/GCO.0000000000000507.
    • Review
    • PARP1 Trapping by PARP Inhibitors Drives Cytotoxicity in Both Cancer Cells and Healthy Bone Marrow.
    • Hopkins TA, Ainsworth WB, Ellis PA, Donawho CK, DiGiammarino EL, Panchal SC, Abraham VC, Algire MA, Shi Y, Olson AM, Johnson EF, Wilsbacher JL, Maag D.
    • Mol Cancer Res. 2019 Feb;17(2):409-419. doi: 10.1158/1541-7786.MCR-18-0138. Epub 2018 Nov 14.
    • State-of-the-art strategies for targeting the DNA damage response in cancer.
    • Pilié PG, Tang C, Mills GB, Yap TA.
    • Nat Rev Clin Oncol. 2019 Feb;16(2):81-104. doi: 10.1038/s41571-018-0114-z.
    • Review
    • CHK2-mediated regulation of PARP1 in oxidative DNA damage response.
    • Hsu PC, Gopinath RK, Hsueh YA, Shieh SY.
    • Oncogene. 2019 Feb;38(8):1166-1182. doi: 10.1038/s41388-018-0506-7. Epub 2018 Sep 25.
    • Olaparib: A tale of two dosage forms.
    • Christ TN.
    • Semin Oncol. 2019 Feb;46(1):100-101. doi: 10.1053/j.seminoncol.2018.11.003. Epub 2018 Dec 19.
    • Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro.
    • Borchert S, Wessolly M, Schmeller J, Mairinger E, Kollmeier J, Hager T, Mairinger T, Herold T, Christoph DC, Walter RFH, Eberhardt WEE, Plönes T, Wohlschlaeger J, Aigner C, Schmid KW, Mairinger FD.
    • BMC Cancer. 2019 Jan 30;19(1):108. doi: 10.1186/s12885-019-5314-0.
    • BRCA1 promoter methylation is linked to defective homologous recombination repair and elevated miR-155 to disrupt myeloid differentiation in myeloid malignancies.
    • Poh W, Dilley RL, Moliterno A, Maciejewski JP, Pratz KW, McDevitt MA, Herman JG.
    • Clin Cancer Res. 2019 Jan 28. pii: clincanres.0179.2018. doi: 10.1158/1078-0432.CCR-18-0179. [Epub ahead of print]
    • The F-Box Domain-Dependent Activity of EMI1 Regulates PARPi Sensitivity in Triple-Negative Breast Cancers.
    • Marzio A, Puccini J, Kwon Y, Maverakis NK, Arbini A, Sung P, Bar-Sagi D, Pagano M.
    • Mol Cell. 2019 Jan 17;73(2):224-237.e6. doi: 10.1016/j.molcel.2018.11.003. Epub 2018 Dec 13.
    • PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness.
    • Shen J, Zhao W, Ju Z, Wang L, Peng Y, Labrie M, Yap TA, Mills GB, Peng G.
    • Cancer Res. 2019 Jan 15;79(2):311-319. doi: 10.1158/0008-5472.CAN-18-1003. Epub 2018 Nov 27.
    • GEICO1601-ROLANDO: a multicentric single arm Phase II clinical trial to evaluate the combination of olaparib and pegylated liposomal doxorubicin for platinum-resistant ovarian cancer.
    • Perez-Fidalgo JA, Iglesias M, Bohn U, Calvo E, Garcia Y, Guerra E, Manso L, Santaballa A, Gonzalez-Martin A.
    • Future Sci OA. 2019 Jan 10;5(2):FSO370. doi: 10.4155/fsoa-2018-0107. eCollection 2019 Feb.
    • ATM orchestrates the DNA-damage response to counter toxic non-homologous end-joining at broken replication forks.
    • Balmus G, Pilger D, Coates J, Demir M, Sczaniecka-Clift M, Barros AC, Woods M, Fu B, Yang F, Chen E, Ostermaier M, Stankovic T, Ponstingl H, Herzog M, Yusa K, Martinez FM, Durant ST, Galanty Y, Beli P, Adams DJ, Bradley A, Metzakopian E, Forment JV, Jackson SP.
    • Nat Commun. 2019 Jan 8;10(1):87. doi: 10.1038/s41467-018-07729-2.
    • Splicing modulator FR901464 is a potential agent for colorectal cancer in combination therapy.
    • Yamano T, Kubo S, Yano A, Kominato T, Tanaka S, Ikeda M, Tomita N.
    • Oncotarget. 2019 Jan 8;10(3):352-367. doi: 10.18632/oncotarget.26564. eCollection 2019 Jan 8.
    • The DNA Damaging Revolution: PARP Inhibitors and Beyond.
    • Yap TA, Plummer R, Azad NS, Helleday T.
    • Am Soc Clin Oncol Educ Book. 2019 Jan;(39):185-195. doi: 10.1200/EDBK_238473.
    • Targeting homologous repair deficiency in breast and ovarian cancers: Biological pathways, preclinical and clinical data.
    • Chartron E, Theillet C, Guiu S, Jacot W.
    • Crit Rev Oncol Hematol. 2019 Jan;133:58-73. doi: 10.1016/j.critrevonc.2018.10.012. Epub 2018 Nov 5.
    • Targeted and immuno-biology driven treatment strategies for triple-negative breast cancer: current knowledge and future perspectives.
    • Fremd C, Jaeger D, Schneeweiss A.
    • Expert Rev Anticancer Ther. 2019 Jan;19(1):29-42. doi: 10.1080/14737140.2019.1537785. Epub 2018 Oct 29.
    • Review
    • Cyclin D1 silencing impairs DNA double strand break repair, sensitizes BRCA1 wildtype ovarian cancer cells to olaparib.
    • Zhong Q, Hu Z, Li Q, Yi T, Li J, Yang H.
    • Gynecol Oncol. 2019 Jan;152(1):157-165. doi: 10.1016/j.ygyno.2018.10.027. Epub 2018 Nov 7.
    • Exploring and comparing adverse events between PARP inhibitors.
    • LaFargue CJ, Dal Molin GZ, Sood AK, Coleman RL.
    • Lancet Oncol. 2019 Jan;20(1):e15-e28. doi: 10.1016/S1470-2045(18)30786-1.
    • Review
    • Repurposing of mTOR Complex Inhibitors Attenuates MCL-1 and Sensitizes to PARP Inhibition.
    • Mattoo AR, Joun A, Jessup JM.
    • Mol Cancer Res. 2019 Jan;17(1):42-53. doi: 10.1158/1541-7786.MCR-18-0650. Epub 2018 Sep 10.
    • Improved Therapeutic Window in BRCA-mutant Tumors with Antibody-linked Pyrrolobenzodiazepine Dimers with and without PARP Inhibition.
    • Zhong H, Chen C, Tammali R, Breen S, Zhang J, Fazenbaker C, Kennedy M, Conway J, Higgs BW, Holoweckyj N, Raja R, Harper J, Pierce AJ, Herbst R, Tice DA.
    • Mol Cancer Ther. 2019 Jan;18(1):89-99. doi: 10.1158/1535-7163.MCT-18-0314. Epub 2018 Oct 23.
    • PARP inhibitor re‑sensitizes Adriamycin resistant leukemia cells through DNA damage and apoptosis.
    • Wu J, Xiao S, Yuan M, Li Q, Xiao G, Wu W, Ouyang Y, Huang L, Yao C.
    • Mol Med Rep. 2019 Jan;19(1):75-84. doi: 10.3892/mmr.2018.9628. Epub 2018 Nov 6.
    • Poly (ADP-Ribose) Polymerases (PARPs) and PARP Inhibitor-Targeted Therapeutics.
    • Li N, Wang Y, Deng W, Lin SH.
    • Anticancer Agents Med Chem. 2019;19(2):206-212. doi: 10.2174/1871520618666181109164645.
    • Review

Continue to Older References